0001104659-14-080372.txt : 20141113 0001104659-14-080372.hdr.sgml : 20141113 20141113160342 ACCESSION NUMBER: 0001104659-14-080372 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141113 DATE AS OF CHANGE: 20141113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 141218390 BUSINESS ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 10-Q 1 a14-19656_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36046

AxoGen, Inc.

(Exact name of registrant as specified in its charter)

Minnesota		41-1301878
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

13631 Progress Blvd., Suite 400, Alachua, FL		32615
(Address of principal executive offices)		(Zip Code)

386-462-6800

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o

Non-Accelerated filer o (Do not check if a smaller reporting company)		Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO x

As of November 13, 2014 the registrant had 19,487,530 shares of common stock outstanding.

Table of Contents

Table of Contents

Part I - Financial Information

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19

Item 4.	Controls and Procedures	19

Part II - Other Information

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	20

Item 4.	Mine Safety Disclosures	20

Item 5.	Other Information	20

Item 6.	Exhibits	21

	Signature Page	22

Table of Contents

Forward-Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission (including this Form 10-Q), in press releases, and in other communications to shareholders or the investment community, the Company may provide forward-looking statements concerning possible or anticipated future results of operations or business developments. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential, regulatory environment, sales and marketing strategies, liquidity, capital resources or operating performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this Form 10-Q should be evaluated together with the many uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Table of Contents

PART 1 — FINANCIAL INFORMATION

ITEM 1 — CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AxoGen, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2014 (unaudited)			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	11,802,608		$	20,069,750
Accounts receivable, net of allowance for doubtful accounts of approximately $69,000 and $59,000, respectively	2,743,041			1,893,699
Inventory	3,346,115			3,398,438
Prepaid expenses and other	100,923			296,719
Total current assets	17,992,687			25,658,606
Property and equipment, net	613,174			381,689
Intangible assets	576,382			570,396
Deferred financing costs	914,931			1,073,579
	$	20,097,174		$	27,684,270
Liabilities and Shareholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses	$	2,020,091		$	2,083,942
Current Deferred Revenue	14,118			14,118
Total current liabilities	2,034,209			2,098,060
Note Payable — Revenue Interest Purchase Agreement	28,173,877			25,363,695
Long Term Deferred Revenue	75,168			85,882
Total liabilities	30,283,254			27,547,637
Commitments and contingencies
Shareholders’ equity (deficit):
Common stock, $.01 par value; 50,000,000 shares authorized; 17,466,381 and 17,339,561 shares issued and outstanding	174,664			173,395
Additional paid-in capital	73,264,241			72,369,016
Accumulated deficit	(83,624,985		)	(72,405,778		)
Total shareholders’ equity (deficit)	(10,186,080		)	136,633
	$	20,097,174		$	27,684,270

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended						Nine Months Ended
	September 30, 2014			September 30, 2013			September 30, 2014			September 30, 2013
Revenues	$	4,671,340		$	2,957,462		$	12,023,789		$	7,962,683
Cost of goods sold	896,178			650,212			2,485,299			1,843,748
Gross profit	3,775,162			2,307,250			9,538,490			6,118,935
Costs and expenses:
Sales and marketing	3,250,977			2,757,241			9,326,596			7,177,170
Research and development	681,230			593,643			2,049,603			1,498,904
General and administrative	1,645,859			1,233,360			5,254,082			4,237,738
Total costs and expenses	5,578,066			4,584,244			16,630,281			12,913,812
Loss from operations	(1,802,904		)	(2,276,994		)	(7,091,791		)	(6,794,877		)
Other income (expense):
Interest expense	(1,380,470		)	(1,214,603		)	(3,963,885		)	(3,505,869		)
Interest expense—deferred financing costs	(55,217		)	(61,216		)	(158,648		)	(146,648		)
Other income (expense)	417			32			(4,886		)	(696		)
Total other income (expense)	(1,435,270		)	(1,275,787		)	(4,127,419		)	(3,653,213		)
Net loss	$	(3,238,174	)	$	(3,552,781	)	$	(11,219,210	)	$	(10,448,090	)
Weighted Average Common Shares outstanding — basic and diluted	17,466,097			14,320,113			17,437,373			12,205,863
Loss Per Common share - basic and diluted	$	(0.19	)	$	(0.25	)	$	(0.64	)	$	(0.86	)

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2014			2013
Cash flows from operating activities:
Net loss	$	(11,219,210	)	$	(10,448,090	)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	111,390			60,869
Amortization of intangible assets	33,468			44,176
Amortization of deferred financing costs	158,648			146,648
Share-based compensation	701,697			534,673
Stock grants	60,125			—
Interest added to note	2,810,182			2,752,273
Change in assets and liabilities:
Accounts receivable	(849,342		)	(690,127		)
Inventory	52,323			(308,955		)
Prepaid expenses and other	195,796			9,821
Accounts payable and accrued expenses	(63,848		)	(162,631		)
Deferred revenue	(10,714		)	—
Net cash used for operating activities	(8,019,485		)	(8,061,343		)

Cash flows from investing activities:
Purchase of property and equipment	(342,875		)	(66,564		)
Acquisition of intangible assets	(39,454		)	(50,262		)
Net cash used for investing activities	(382,329		)	(116,826		)

Cash flows from financing activities:
Proceeds from issuance of common stock	—			16,784,203
Proceeds from exercise of stock options	134,672			73,015
Net cash provided by financing activities	134,672			16,857,218

Net increase (decrease) in cash and cash equivalents	(8,267,142		)	8,679,049
Cash and cash equivalents, beginning of year	20,069,750			13,907,401

Cash and cash equivalents, end of period	$	11,802,608		$	22,586,450

Supplemental disclosures of cash flow activity:
Cash paid for interest	$	1,154,738		$	749,857

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of September 30, 2014 and December 31, 2013 and for the three month and nine month periods ended September 30, 2014 and 2013. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2013, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2013. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

2. Organization and Business

Business Summary

The Company is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

3. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenue from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company

Table of Contents

has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $69,000 and $59,000 at September 30, 2014 and December 31, 2013, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

	September 30, 2014		December 31, 2013
	(unaudited)
Finished goods	$	2,116,046	$	2,131,336
Work in process	221,362		235,966
Raw materials	1,008,707		1,031,136
	$	3,346,115	$	3,398,438

Inventories were net of reserve of approximately $383,000 and $383,000 at September 30, 2014 and December 31, 2013, respectively.

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In

Table of Contents

addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2010 through 2013; there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable and accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company’s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:

Nine months ended September 30,	2014 (unaudited)		2013 (unaudited)
Expected term (in years)	4.0		4.0
Expected volatility	79.76	%	83.27	%
Risk free rate	1.23	%	0.71	%
Expected dividends	0.0	%	0.0	%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the nine months ended September 30, 2014 and 2013 as they were deemed insignificant.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported

Table of Contents

amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The core principle of the ASU is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration, or payment, to which the company expects to be entitled in exchange for those goods or services. The ASU may also result in enhanced disclosures about revenue. For public entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Due to the recent date of issuance for this ASU, management is currently evaluating what impact, if any, the pronouncement will have on the Company’s disclosures, its financial position or results from operations.

4. Property and Equipment

Property and equipment consist of the following:

	September 30, 2014			December 31, 2013
	(unaudited)

Furniture and equipment	$	825,690		$	893,973
Leasehold improvements	285,698			53,864
Processing equipment	1,194,712			1,015,388
Less: accumulated depreciation and amortization	(1,692,926		)	(1,581,536		)

Property and equipment	$	613,174		$	381,689

5. Intangible Assets

The Company’s intangible assets consist of the following:

	September 30, 2014			December 31, 2013
	(unaudited)
License agreements	$	838,586		$	816,300
Patents	79,721			62,553
Less: accumulated amortization	(341,925		)	(308,457		)
Intangible assets, net	$	576,382		$	570,396

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of December 31, 2013, the patents were fully amortized, the remaining patents of $79,721 were pending patent costs and were not amortizable. Amortization expense was approximately $11,000 and $15,000 for the three months and was approximately $33,000 and $44,000 for the nine months ended September 30, 2014 and 2013, respectively. As of September 30, 2014, future amortization of license

Table of Contents

agreements is expected to be approximately $15,000 for the remainder of 2014 and $48,000 for 2015 through 2018.

License Agreements

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

· AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

· If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;

· AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

· Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

Royalty fees were approximately $93,000 and $64,000 for the three months and were $238,000 and $169,000 for the nine months ended September 30, 2014 and 2013, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses includes $182,880 and $203,380 for accrued payroll at September 30, 2014 and December 31, 2013, respectively, $512,774 and $417,825 for accrued commissions at September 30, 2014 and December 31, 2013, respectively and $154,252 and $31,176 for accrued bonuses at September 30, 2014 and December 31, 2013, respectively.

7. Notes Payable

Notes Payable consists of the following:

	September 30, 2014 (unaudited)		December 31, 2013

Revenue Interest Purchase Agreement with PDL BioPharma, Inc. (“PDL”) for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues through September 2014; and the greater of (i) 9.95% of product revenue or (ii) specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.	$	28,173,877	$	25,363,695
Long-term Notes Payable	$	28,173,877	$	25,363,695

Table of Contents

Note Payable

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, as defined below, and extinguish AxoGen’s long-term debt obligations there under. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, currently anticipated to be operative, of approximately $1.3 to $2.5 million per quarter which begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), including $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated.

The Company records interest using its best estimate of the effective interest rate. Currently the Company is accruing interest using the specified internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.

Put Option

Under the Royalty Contract, on October 5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen’s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the “Put Price.” The Put Price is equal to the sum of (i) an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of 20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii) any “Delinquent Assigned Interest Payment” (as defined in the Royalty Contract) the Company owed to PDL.

Change of Control; Call Option

In addition, in the event of a “Change of Control” (as defined in the Royalty Contract), the Company must repurchase the assigned Interests from PDL for a repurchase price equal to the “Change of Control Price” on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i) an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii) any “Delinquent Assigned Interest Payment” (as defined in the Royalty Contract) the Company owed to PDL. In addition, at any time after October 5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the Change of Control Price.

Table of Contents

Board Designee

Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of the Company (the “Board”). The PDL designee was elected at the Company’s 2013 Annual Meeting of Shareholders. At each annual meeting thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen’s proxy statement for each annual meeting thereafter, provided that the election of the PDL designee is subject to shareholders’ approval.

Should at any time there become a vacancy on the Board as a result of (i) the resignation, death or removal of the PDL designee or (ii) such PDL designee failing to obtain the requisite approval of the Company’s shareholders at any annual or special meeting of the Company’s shareholders and where no other individual is elected to such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board.

On August 20, 2014, John McLaughlin, the PDL designee who was serving on the Board, delivered to us notice of his resignation as a member of the Board of Directors (the “Board”) of AxoGen, Inc. (the “Company”) effective as of the date of the notice. The Board accepted Mr. McLaughlin’s notice of resignation. The Company notes that Mr. McLaughlin’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Mr. McLaughlin had served as a member of the Board since October 2012. PDL has informed the Company that it does not intend to appoint a replacement for Mr. McLaughlin at this time.

Preemptive Rights

Under the Royalty Contract, PDL has preemptive rights with respect to certain new issuances of AxoGen’s equity securities and securities convertible, exchangeable or exercisable into such equity securities.

Restriction on Dividends

Under the Royalty Contract, during the period from the October 5, 2012 to December 4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to December 4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or acquire any such shares of common or preferred stock of any such entity (collectively, “Restricted Payments”), except that: (i) each subsidiary may make direct or indirect Restricted Payments to the Company; and (ii) the Company and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of the Royalty Contract, “Equity Interests” of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other “equity security” (as such term is defined in Rule 3a11-1under the Securities Exchange Act of 1934, as amended).

Guarantee and Collateral Agreement

In connection with the Royalty Contract, on October 5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) with PDL, pursuant to which (i) AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the “Secured Obligations,” which include the Company’s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii) each of the Company and AC grants to PDL a security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations.

Table of Contents

8. Stock Options

The Company granted 476,250 options to purchase shares of stock pursuant to its 2010 Stock Incentive Plan for the nine months ended September 30, 2014. Stock-based compensation expense was $227,553 and $142,200 for the three months ended September 30, 2014 and 2013, respectively and $701,697 and $534,673 for the nine months ended September 30, 2014 and 2013, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,508,000 at September 30, 2014.

9. Subsequent Events

On November 12, 2014, (the “Signing Date”), AxoGen, Inc. (the “Company” or “AxoGen”), as borrower, and the Company’s wholly owned subsidiary AxoGen Corporation, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, the Company has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. The Company has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three peaks has a first perfected security interest in the assets of the Company.

As of the Signing Date, the Company also entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of the Company’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. The Company has to maintain certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, the Company has the option at any time to prepay the Term Loan in whole or in part, and the Royalty Interest Agreements by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of the Company, sale of the majority of the Company’s assets or a material adverse change to the Company or any portion being prepaid: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) ) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan; or any portion being prepaid (iv) ) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case the Company will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, the Company would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In addition, on the Initial Closing Date, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million in cash (“Three Peaks Equity Sale”) at a public offering price of $2.58 per share. The proceeds from the Initial Term Loan, the Three Peaks Equity Sale and $1.75 million of capital from the Company, were used to fully repay the Royalty Contract with PDL. The Company has no further obligations to PDL under the Royalty Contract.

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary. AxoGen Corporation (“AC”), entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

Subsequent to the closing of the Term Loan, also on the Initial Closing Date, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a public offering price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL dated the Signing Date. The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

Table of Contents

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, all references in this report to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. and its wholly owned subsidiary AxoGen Corporation (“AC”).

OVERVIEW

The Company is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Revenue from the distribution of these products is the main contributor to AxoGen’s total reported sales and has been the key component of its growth to date. AxoGen revenues increased in third quarter 2014 compared to 2013 primarily as a result of the sales strategy to focus on growing sales and increasing product usage in existing accounts. AxoGen has continued to broaden and strengthen its sales and marketing activity with a focus on the execution of its sales operations. This is expected to have a continued positive contribution to its revenue growth in the long term.

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2014 and 2013

Revenues

Revenues for the three months ended September 30, 2014 increased 58.0% to approximately $4,671,000 as compared to approximately $2,957,000 for the three months ended September 30, 2013. Additionally, revenues for the nine months ended September 30, 2014 increased 51.0% to approximately $12,024,000 as compared to approximately $7,963,000 for the nine months ended September 30, 2013. This increase was primarily a result of the sales strategy to focus on growing sales and increasing product usage in existing accounts. In addition, AxoGen recognized approximately $57,000 and $175,000 of grant revenue for the three and nine months ended September 30, 2014, respectively, as compared to no such revenue in the corresponding time period in 2013.

Gross Profit

Gross profit for the three months ended September 30, 2014 increased 63.6% to approximately $3,775,000 as compared to approximately $2,307,000 for the three months ended September 30, 2013. Such increase in aggregate dollars was primarily attributable to the increased revenues in the third quarter of 2014. Gross margin improved to 80.8% for the three months ended September 30, 2014 as compared to 78.0% for the same period in 2013 as a result of price increases in March 2014, manufacturing efficiencies and changes in product mix.

Gross profit for the nine months ended September 30, 2014 increased 55.9% to approximately $9,538,000 as compared to approximately $6,119,000 for the nine months ended September 30, 2013. Such increase in aggregate dollars was primarily attributable to the increased revenues in the first nine months of 2014. Gross margin improved to 79.3% for the nine months ended September 30, 2014 as compared to 76.9% for the same period in 2013 as a result of price increases in March 2014 and changes in product mix.

Costs and Expenses

Total cost and expenses increased 21.7% to approximately $5,578,000 for the three months ended September 30, 2014 as compared to approximately $4,584,000 for the three months ended September 30, 2013. These

Table of Contents

increases were primarily due to increasing sales and marketing activities as revenues increased and increases in compensation as AxoGen hired additional personnel to meet its current and expected growth.

Total cost and expenses increased 28.8% to approximately $16,630,000 for the nine months ended September 30, 2014 as compared to approximately $12,914,000 for the nine months ended September 30, 2013. These increases were primarily due to increasing sales and marketing activities and increases in compensation as AxoGen hired additional personnel to meet its current and expected growth. To a lesser extent, these increases were also attributable to expenses associated with being a public company listed on NASDAQ, facility costs and research and development costs associated with the Company’s preparation for its clinical trial.

Sales and marketing expenses increased 17.9% to approximately $3,251,000 for the three months ended September 30, 2014 as compared to approximately $2,757,000 for the three months ended September 30, 2013. This increase was primarily due to increased expenses related to AxoGen’s direct sales force and independent distributors, sales training and surgeon education. As a percentage of revenues, sales and marketing expenses were 69.6% for the three months ended September 30, 2014 compared to 93.2% for the three months ended September 30, 2013. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Sales and marketing expenses increased 30.0% to approximately $9,327,000 for the nine months ended September 30, 2014 as compared to approximately $7,177,000 for the nine months ended September 30, 2013. This increase was primarily due to expansion of the direct sales force, increased support for both AxoGen’s direct sales force and independent distributors, sales training and surgeon education. As a percentage of revenues, sales and marketing expenses were 77.6% for the nine months ended September 30, 2014 compared to 90.1% for the nine months ended September 30, 2013. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 33.5% to approximately $1,646,000 for the three months ended September 30, 2014 as compared to approximately $1,233,000 for the three months ended September 30, 2013. The increase was primarily a result of increased compensation including non-cash stock option compensation of approximately $84,000 and insurance expenses As a percentage of revenues, general and administrative expenses were 35.2% for the three months ended September 30, 2014 as compared to 41.7% for the three months ended September 30, 2013. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 24.0% to approximately $5,254,000 for the nine months ended September 30, 2014 as compared to approximately $4,238,000 for the nine months ended September 30, 2013. The increase was primarily a result of increased compensation, including non-cash stock option compensation of approximately $167,000 and insurance expenses. As a percentage of revenues, general and administrative expenses were 43.7% for the nine months ended September 30, 2014 as compared to 53.2% for the nine months ended September 30, 2013. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Research and development expenses increased approximately 14.6% to approximately $681,000 in the three months ended September 30, 2014 as compared to approximately $594,000 for the three months ended September 30, 2013. Research and development expenses increased approximately 36.8% to approximately $2,050,000 in the nine months ended September 30, 2014 as compared to approximately $1,499,000 for the nine months ended September 30, 2013. Development includes AxoGen’s product development and clinical efforts substantially focused on its biological license application (“BLA”) for the Avance® Nerve Graft. A substantial portion of the increase in research and development expenses from 2013 to 2014 is related to expenditures for such clinical activity. Although AxoGen’s products are developed for sale in their current use, it does conduct limited research and product development focused on new products and new applications to existing products. AxoGen has become more active in pursuing research grants to support this research. AxoGen’s product pipeline development also contributed to a portion of the research and development expense increase in 2014, with grant revenue partially offsetting a portion of this activity.

Table of Contents

Other Income and Expenses

Interest expense increased 13.6% to approximately $1,380,000 for the three months ended September 30, 2014 as compared to approximately $1,215,000 for the three months ended September 30, 2013. Interest expense increased 13.1% to approximately $3,964,000 for the nine months ended September 30, 2014 as compared to approximately $3,506,000 for the nine months ended September 30, 2013. This increase was due to the increase in the interest related to the Royalty Contract from higher revenues and the interest accrued related to PDL. As a result of the accounting treatment for the PDL transaction, interest expense included approximately $890,000 and $923,000 for the three months ended September 30, 2014 and 2013, respectively, and approximately $2,809,000 and $2,756,000 for the nine months ended September 30, 2014 and 2013, respectively, of non-cash expense that is expected to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. Other than the $2,809,000 and $2,756,000 non-cash expense, the remaining $1,155,000 and $750,000 in interest expense for the nine months ended September 30, 2014 and 2013, respectively, is related to cash paid for interest on the note payable.

Interest expense—deferred financing costs decreased 9.8% to approximately $55,000 for the three months ended September 30, 2014 as compared to approximately $61,000 for the three months ended September 30, 2013. Interest expense—deferred financing costs increased 8.2% to approximately $159,000 for the nine months ended September 30, 2014 as compared to approximately $147,000 for the nine months ended September 30, 2013. This increase is primarily due to higher deferred financing cost amortization associated with the PDL agreement from applying the effective interest rate method.

Income Taxes

The Company had no income tax expenses or income tax benefit for each of the three months and nine months ended September 30, 2014 and 2013 due to incurrence of net operating loss in each of these periods.

Effect of Inflation

Inflation has not had a significant impact on the Company’s operations or cash flow.

Liquidity and Capital Resources

Note Payable

On October 5, 2012, AxoGen entered into the Royalty Contract with PDL. Proceeds from the PDL transaction were used to fully repay a prior credit facility and extinguish AxoGen’s long-term debt obligations thereunder. Pursuant to the Royalty Contract the Company sold to PDL the right to receive specified royalties on the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of the Company’s products Avance® Nerve Graft, AxoGuard® Nerve Protector and AxoGuard® Nerve Connector (the “Acquired Revenues”). The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments currently paid weekly based on a royalty rate of 9.95% of the Company’s Net Revenues (the “Assigned Interests”), subject to certain agreed upon minimum payment requirements which begin in the fourth quarter of 2014 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), including $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to the Interim Royalty Contract. Upon the closing of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. There are no financial covenants or other restrictions on the use of capital by AxoGen as a result of the Royalty Contract, however, PDL has a first perfected security interest in the Assigned Interests.

The Company had no material commitments for capital expenditures at September 30, 2014.

On November 12, 2014, (the “Signing Date”), AxoGen, Inc. (the “Company” or “AxoGen”), as borrower, and the Company’s wholly owned subsidiary AxoGen Corporation, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, the Company has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. The Company has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Twin peaks has a first perfected security interest in the assets of the Company.

Table of Contents

Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. The Company has to maintain certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, the Company has the option at any time to prepay the Term Loan, in whole or in part, and the Revenue Interest Agreements by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of the Company, sale of the majority of the Company’s assets or a material adverse change to the Company: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) ) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) ) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case the Company will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, the Company would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, Axogen Corporation (“AC”), entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

Cash Flow Information

AxoGen had working capital of approximately $15.96 million and a current ratio of 8.85 at September 30, 2014, compared to working capital of $23.56 million and a current ratio of 12.23 at December 31, 2013. The decrease in working capital and the current ratio at September 30, 2014 as compared to December 31, 2013 was primarily due to the use of working capital for operations. The Company believes it has sufficient cash resources to meet its liquidity requirements for at least the next 12 months.

AxoGen’s future capital requirements depend on a number of factors, including, without limitation, revenue increases consistent with its business plan, and pursuant to AxoGen’s licensing agreements in connection with Avance® Nerve Graft, cost of products and acquisition and/or development of new products. AxoGen could face increasing capital needs. Such capital needs could be substantial depending on the extent to which AxoGen is unable to increase revenue.

If AxoGen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional equity would result in dilution to AxoGen’s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain action, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.

During the nine months ended September 30, 2014, the Company had a net decrease in cash and cash equivalents of approximately $8,267,000 as compared to a net increase of cash and cash equivalents of approximately $8,679,000 in the nine months ended September 30, 2013. The Company’s principal sources and uses of funds are explained below:

Cash used in operating activities

The Company used approximately $8,019,000 of cash for operating activities in the nine months ended September 30, 2014, as compared to using approximately $8,061,000 of cash for operating activities in the nine months ended September 30, 2013. This decrease in cash used in operating activities is primarily attributed to the decrease in inventory offset by an increase in our accounts receivable associated with increased revenues.

Table of Contents

Cash used for investing activities

Investing activities for the nine months ended September 30, 2014 used approximately $382,000 of cash as compared to using approximately $117,000 of cash in the nine months ended September 30, 2013. This increase in use is principally attributable to the purchase of certain fixed assets for the expansion of the headquarters office and the opening of the worldwide distribution facility in Burleson, Texas.

Cash provided by financing activities

Financing activities in the nine months ended September 30, 2014 provided approximately $135,000 of cash as compared to providing approximately $16,857,000 of cash in the nine months ended September 30, 2013. The cash provided in 2014 was due to proceeds received from the exercise of stock options where as the cash provide in 2013 was attributable to the underwritten public offering of our common shares completed in September 2013.

Off-Balance Sheet Arrangements

AxoGen does not have any off-balance sheet arrangements.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2014 and concluded that our disclosure controls and procedures were effective.

Changes in Internal Controls Over Financial Reporting

During the nine months ended September 30, 2014, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d—15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

UNITED STATES

PART II —OTHER INFORMATION

ITEM 1 — Legal Proceedings

The Company is not a party to any material litigation as of September 30, 2014.

ITEM 1A — RISK FACTORS

The Company faces a number of risks and uncertainties. In addition to the other information in this report and the Company’s other filings with the Securities and Exchange Commission, readers should consider carefully the risk factors discussed in Part I “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2013. There have been no material changes to these risk factors. If any of these risks actually occur, the Company’s business, results of operations or financial condition could be materially adversely affected.

ITEM 2 — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 — DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5 — OTHER INFORMATION

None.

Table of Contents

ITEM 6 — EXHIBITS

Exhibit Number		Description

3.1		Amended and Restated Articles of Incorporation of AxoGen, Inc. (incorporated by reference to Appendix B to the Proxy Statement/Prospectus included as part of LecTec Corporation’s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)

3.2		AxoGen, Inc. Amended and Restated Bylaws (incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation’s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011).

*10.4.3		Fourth Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of September 8, 2014, by and between AxoGen Corporation and LifeNet Health

31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS†		XBRL Instance Document.

101.SCH†		XBRL Taxonomy Extension Schema Document.

101.CAL†		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF†		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB†		XBRL Extension Labels Linkbase.

101.PRE†		XBRL Taxonomy Extension Presentation Linkbase Document.

† Filed herewith.

†† Furnished herewith.

* Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AXOGEN, INC.


Dated November 13, 2014	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer
	(Principal Executive Officer)

	/s/ Lee R. Johnston, Jr.
	Lee R. Johnston, Jr.
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number		Description

3.1		Amended and Restated Articles of Incorporation of AxoGen, Inc. (incorporated by reference to Appendix B to the Proxy Statement/Prospectus included as part of LecTec Corporation’s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)

3.2		AxoGen, Inc. Amended and Restated Bylaws (incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation’s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011).

*10.4.3		Fourth Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of September 8, 2014, by and between AxoGen Corporation and LifeNet Health

31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS†		XBRL Instance Document.

101.SCH†		XBRL Taxonomy Extension Schema Document.

101.CAL†		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF†		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB†		XBRL Extension Labels Linkbase.

101.PRE†		XBRL Taxonomy Extension Presentation Linkbase Document.

† Filed herewith.

†† Furnished herewith.

* Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.

EX-10.4.3 2 a14-19656_1ex10d4d3.htm EX-10.4.3

Exhibit 10.4.3

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

FOURTH AMENDMENT TO AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENT

THIS FOURTH AMENDMENT (“Fourth Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement dated February 27, 2008 as amended from time to time (the “Agreement”), is effective upon last signature hereto by and between LifeNet Health (“LIFENET Health”) and AxoGen Corporation (“AXOGEN”).

WHEREAS, the parties desire to amend the Agreement under the terms and subject to the conditions set forth below;

In consideration of the mutual promises contained herein, the parties agree to the following:

1. The parties agree that Appendix B to the Agreement is hereby deleted in its entirety and replaced with the attached Appendix B.

IN WITNESS, WHEREOF, the parties execute this Fourth Amendment as of the date of the last party signing hereto:

AXOGEN CORPORATION		LIFENET HEALTH


By:	/s/ Lee R. Johnston, Jr.	By:	/s/ Gordon Berustresser

Name: Lee R. Johnston, Jr.		Name: Gordon Berustresser

Its: Chief Financial Officer		Its: Chief Financial Officer

Date: 9/8/2014		Date: 8/29/2014

AxoGen

APPENDIX B — Revised

FEE SCHEDULE

1) AXOGEN shall pay LIFENET HEALTH a $[***] fee per week for processing in Suite 114;

2) LIFENET HEALTH shall bill AXOGEN at the rate of $[***] per each batch debrided at LIFENET HEALTH; and

3) LIFENET HEALTH shall bill AXOGEN at the rate of $[***] per each [***] at LIFENET HEALTH.

OTHER TERMS:

· There shall be no Minimum Batches/Year and no Maximum Batches/Year;

· Pricing reflected in this Exhibit B shall be increased by 3% on January 1, 2015. The fees for use of Suite 114 may be adjusted thereafter annually beginning January 1, 2016 as mutually agreed upon by the parties, provided, however, that any such adjustment shall not exceed the annual change in the CPI-U of the Bureau of Labor Statistics of the U.S. Department of Labor. AXOGEN will have the right to use Suite 114 of the Ward Court facility for up to three shifts per normal business day.

· Parties may periodically review usage and space needs.

· AXOGEN is to employ processors and assume supervisory and oversight responsibilities for processors who process for AXOGEN in the LIFENET HEALTH facility. LIFENET HEALTH will provide support as described in the Quality Plan.

· In conjunction with LIFENET HEALTH’s need for the use of Suite 118, AXOGEN equipment currently situated in Suite 118 (the “Equipment”) will be stored in such area in 3417 Chandler Creek Road, Virginia Beach, Virginia 23453 (“Location”) as designated by LIFENET HEALTH. Any additional equipment relocated to this location must be pre-approved by LIFENET HEALTH. Any cost or expense associated with equipment being removed from this Location, shall be the sole responsibility of AXOGEN. AxoGen will be responsible for the cost of moving the Equipment from Suite 118 to the particular area in the Location designated by LIFENET HEALTH. After the move of the Equipment, LIFENET HEALTH will have complete control and access to Suite 118. Upon 90 days’ notice from AXOGEN to LIFENET HEALTH, LIFENET HEALTH will make reasonable efforts to provide AXOGEN with space to meet AXOGEN’s forecasted needs, provided, however, such space shall be reasonably equivalent as to functionality as Suite 118. AXOGEN would pay for the cost of moving and calibrating the Equipment so it may be operated in the same manner as is available currently. Rates for such comparable space will be equivalent to the

rates paid by AXOGEN for Suite 114 (or such other space that replaced Suite 114) as of such time.

· AXOGEN agrees to maintain adequate property insurance coverage on all property and/or equipment it stores in 3417 Chandler Creek Road, Virginia Beach, Virginia 23453 to cover the cost of any damage to or replacement of such property and/ or equipment and, upon request, shall submit a Certificate of Insurance to LIFENET HEALTH. Any cost of insurance or deductible shall be the sole responsibility of AXOGEN.

EX-31.1 3 a14-19656_1ex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Karen Zaderej, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2014

	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer

EX-31.2 4 a14-19656_1ex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lee R. Johnston, Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2014

	/s/ Lee R. Johnston, Jr.
	Lee R. Johnston, Jr.
	Chief Financial Officer

EX-32 5 a14-19656_1ex32.htm EX-32

EXHIBIT 32

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)

In connection with the Quarterly Report on Form 10-Q (the “Report”) of AxoGen, Inc. (the “Company”), Karen Zaderej, Chief Executive Officer of the Company and Lee R. Johnston, Jr., Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her/his knowledge that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 13, 2014	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer
	(Principal Executive Officer)

	/s/ Lee R. Johnston, Jr.
	Lee R. Johnston, Jr.
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.PRE 6 axgn-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.INS 7 axgn-20140930.xml XBRL INSTANCE DOCUMENT 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember us-gaap:SubsequentEventMember 2014-11-12 2014-11-12 0000805928 us-gaap:SellingAndMarketingExpenseMember 2014-07-01 2014-09-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-09-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2013-07-01 2013-09-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2013-01-01 2013-09-30 0000805928 us-gaap:LeaseholdImprovementsMember 2014-09-30 0000805928 us-gaap:EquipmentMember 2014-09-30 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2014-09-30 0000805928 us-gaap:LeaseholdImprovementsMember 2013-12-31 0000805928 us-gaap:EquipmentMember 2013-12-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2013-12-31 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2012-08-13 2012-08-14 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2012-08-05 2012-10-05 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2013-12-31 0000805928 us-gaap:PatentsMember 2014-01-01 2014-09-30 0000805928 us-gaap:PatentsMember 2014-09-30 0000805928 us-gaap:LicensingAgreementsMember 2014-09-30 0000805928 us-gaap:PatentsMember 2013-12-31 0000805928 us-gaap:LicensingAgreementsMember 2013-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:SubsequentEventMember 2014-11-12 2014-11-12 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2012-10-04 2012-10-05 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember us-gaap:SubsequentEventMember 2014-11-13 0000805928 axgn:ThreePeaksCapitalMember us-gaap:SubsequentEventMember 2014-11-12 0000805928 axgn:PDLEquitySaleMember us-gaap:SubsequentEventMember 2014-11-12 0000805928 2013-09-30 0000805928 2012-12-31 0000805928 us-gaap:SubsequentEventMember 2014-11-12 0000805928 2014-07-01 2014-09-30 0000805928 2013-07-01 2013-09-30 0000805928 2013-01-01 2013-09-30 0000805928 2013-12-31 0000805928 2014-11-13 0000805928 2014-01-01 2014-09-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember us-gaap:SubsequentEventMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember us-gaap:SubsequentEventMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:SubsequentEventMember 2014-11-12 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000805928 2014-09-30 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000805928 us-gaap:PatentsMember 2013-01-01 2013-12-31 0000805928 us-gaap:LicensingAgreementsMember 2014-01-01 2014-09-30 0000805928 axgn:RevenueInterestPurchaseAgreementMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000805928 axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2014-01-01 2014-09-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember us-gaap:SubsequentEventMember 2014-11-12 2014-11-12 0000805928 axgn:RevenueInterestPurchaseAgreementMember 2014-09-30 0000805928 axgn:AgeOver90DaysMember 2014-09-30 0000805928 axgn:Age61To90DaysMember 2014-09-30 0000805928 axgn:AgeOver90DaysMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000805928 axgn:Age61To90DaysMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000805928 axgn:Age61To90DaysMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000805928 us-gaap:MinimumMember 2014-01-01 2014-09-30 iso4217:USD xbrli:shares xbrli:shares axgn:product iso4217:USD xbrli:pure P60D P90D P61D P90D 0.05 0.20 0.325 0.010 quarterly monthly 7000000 2500000 1300000 1250805 9000000 9000000 6939000 9063000 9232642 6781440 15000 12500 79721 P60D 0 0.0375 0.20 1 0.03 0.01 0.0995 0.0375 0.0480 0.0995 0.03 0.1625 1.35 1.5 1.2 false --12-31 Q3 2014 2014-09-30 10-Q 0000805928 19487530 Yes Smaller Reporting Company AxoGen, Inc.

2083942

2020091

1893699

2743041

31176

154252

417825

512774

1581536

1692926

72369016

73264241

59000

69000

146648

158648

146648

61216

158648

55217

44176

15000

33468

11000

27684270

20097174

25658606

17992687

1750000

13907401

22586450

20069750

11802608

8679049

-8267142

0.01

50000000

17339561

17466381

643382

1375969

17339561

17466381

173395

174664

1750000

3550000

1843748

650212

2485299

896178

12913812

4584244

16630281

5578066

20800000

25000000

0.10

LIBOR

0.0900

P8Y

P10Y

P6Y

1073579

914931

14118

85882

75168

60869

111390

-0.86

-0.25

-0.64

-0.19

203380

182880

1508000

308457

341925

15000

48000

816300

62553

838586

79721

570396

576382

P3Y

P20Y

P17Y

4237738

1233360

5254082

1645859

6118935

2307250

9538490

3775162

-162631

-63848

690127

849342

-10714

308955

-52323

-9821

-195796

3505869

1214603

3963885

1380470

749857

1154738

2131336

2116046

3398438

3346115

<div> <div style="margin-left:0pt;margin-right:0pt;"> Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2014 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2013 </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,116,046  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,131,336  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>221,362  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,966  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,008,707  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,136  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,346,115  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,398,438  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $383,000 and $383,000 at September 30, 2014 and December 31, 2013, respectively.   </div> </div>

1031136

1008707

383000

235966

221362

60125

27547637

30283254

27684270

20097174

2098060

2034209

25363695

28173877

25363695

28173877

16857218

134672

-116826

-382329

-8061343

-8019485

-10448090

-3552781

-11219210

-3238174

-3653213

-1275787

-4127419

-1435270

-6794877

-2276994

-7091791

-1802904

-696

-4886

417

2752273

2810182

50262

39454

66564

342875

296719

100923

16784203

20800000

1750000

19050000

73015

134672

893973

1015388

53864

825690

1194712

285698

381689

613174

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:62.50%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2014 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2013 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.50%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.50%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.38%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>825,690 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.38%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>893,973 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.50%;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,698 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53,864 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,015,388 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.50%;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,692,926 </td> <td valign="bottom" style="width:03.12%;"> ) </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,581,536 </td> <td valign="bottom" style="width:01.26%;"> ) </td> </tr> <tr> <td valign="bottom" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.50%;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>613,174 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>381,689 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

1498904

593643

2049603

681230

-72405778

-83624985

7962683

2957462

12023789

4671340

169000

64000

238000

93000

30000000

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:62.48%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2014 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2013 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.48%;padding:0pt;">   </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.48%;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>838,586 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>816,300 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.48%;padding:0pt;"> Patents </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79,721 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,553 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.48%;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(341,925 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(308,457 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:62.48%;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>576,382 </td> <td valign="bottom" style="width:03.12%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>570,396 </td> <td valign="bottom" style="width:01.26%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2014 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2013 </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,116,046  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,131,336  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>221,362  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,966  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,008,707  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,136  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,346,115  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,398,438  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

7177170

2757241

9326596

3250977

534673

142200

701697

227553

0.000

P4Y

0.8327

0.7976

0.0071

0.0123

476250

<div> <div style="margin-left:0pt;margin-right:0pt;"> Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company’s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Nine months ended September 30, </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 (unaudited) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2013 (unaudited) </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.76  </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83.27  </td> <td valign="bottom" style="width:01.38%;padding:0pt;"> % </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.23  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.71  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0  </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0  </td> <td valign="bottom" style="width:01.38%;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the nine months ended September 30, 2014 and 2013 as they were deemed insignificant.   </div> </div>

2.72

2.58

<div> <div style="margin-left:0pt;margin-right:0pt;"> 3.Summary of Significant Accounting Policies   Revenue Recognition   Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenue from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.   Cash and Cash Equivalents and Concentration   For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.   Accounts Receivable and Concentration of Credit Risk   Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.   We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $69,000 and $59,000 at September 30, 2014 and December 31, 2013, respectively.   Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.   Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2014 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2013 </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,116,046  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,131,336  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>221,362  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,966  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,008,707  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,136  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.10%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,346,115  </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,398,438  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $383,000 and $383,000 at September 30, 2014 and December 31, 2013, respectively.   Income Taxes   The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.   The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2010 through 2013; there currently are no examinations in process.   Fair Value of Financial Instruments   The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable and accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.   Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company’s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Nine months ended September 30, </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 (unaudited) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2013 (unaudited) </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.76  </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83.27  </td> <td valign="bottom" style="width:01.38%;padding:0pt;"> % </td> </tr> <tr> <td valign="top" style="width:59.10%;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.23  </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.71  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="top" style="width:59.10%;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0  </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> % </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0  </td> <td valign="bottom" style="width:01.38%;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the nine months ended September 30, 2014 and 2013 as they were deemed insignificant.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Recent Accounting Pronouncements   On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The core principle of the ASU is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration, or payment, to which the company expects to be entitled in exchange for those goods or services. The ASU may also result in enhanced disclosures about revenue. For public entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Due to the recent date of issuance for this ASU, management is currently evaluating what impact, if any, the pronouncement will have on the Company’s disclosures, its financial position or results from operations. </div> </div>

136633

-10186080

<div> <div style="margin-left:0pt;margin-right:0pt;"> 9. Subsequent Events   On November 12, 2014, (the “Signing Date”), AxoGen, Inc. (the “Company” or “AxoGen”), as borrower, and the Company’s wholly owned subsidiary AxoGen Corporation, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term.  Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, the Company has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions.  The Company has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three peaks has a first perfected security interest in the assets of the Company.   As of the Signing Date, the Company also entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of the Company’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%.  The Company has to maintain certain covenants including those covenants under the Term Loan.   Under the Term Loan Agreement, the Company has the option at any time to prepay the Term Loan in whole or in part, and the Royalty Interest Agreements by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of the Company, sale of the majority of the Company’s assets or a material adverse change to the Company or any portion being prepaid: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) ) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan; or any portion being prepaid (iv) ) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid.  In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement.  In each such case the Company will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, the Company would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.   In addition, on the Initial Closing Date, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million in cash (“Three Peaks Equity Sale”) at a public offering price of $2.58 per share.  The proceeds from the Initial Term Loan, the Three Peaks Equity Sale and $1.75 million of capital from the Company, were used to fully repay the Royalty Contract with PDL.  The Company has no further obligations to PDL under the Royalty Contract.   In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AxoGen Corporation (“AC”), entered into a Security Agreement (“the Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.   Subsequent to the closing of the Term Loan, also on the Initial Closing Date, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a public offering price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL dated the Signing Date. The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.   </div> </div>

12205863

14320113

17437373

17466097

EX-101.SCH 8 axgn-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Intangible Assets (Details 3) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Notes Payable (Details 2) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Notes Payable (Details 3) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 axgn-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 axgn-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 axgn-20140930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of year Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of approximately $54,000 and $59,000, respectively Accounts receivable, net of allowance for doubtful accounts of approximately $69,000 and $59,000, respectively Inventory, Net Inventory Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment Finite-Lived Intangible Assets, Net Intangible assets Intangible assets, net Deferred Finance Costs, Noncurrent, Net Deferred financing costs Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity (Deficit) Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Deferred Revenue, Current Current Deferred Revenue Liabilities, Current Total current liabilities Notes Payable, Noncurrent Total Debt Note Payable - Revenue Interest Purchase Agreement Deferred Revenue, Noncurrent Long Term Deferred Revenue Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity (deficit): Common Stock, Value, Issued Common stock, $.01 par value; 50,000,000 shares authorized; 17,466,381 and 17,339,561 shares issued and outstanding Value of common stock sold Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders' equity (deficit) Liabilities and Equity Total Liabilities and Shareholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Allowance for doubtful accounts reserve balance Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Shares of common stock sold Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenues Revenues Cost of Goods Sold Cost of goods sold Gross Profit Gross profit Costs and Expenses [Abstract] Costs and expenses: Selling and Marketing Expense. Sales and marketing Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense Interest expense Amortization of Financing Costs and Discounts Interest expense-deferred financing costs Other Nonoperating Income (Expense) Other income (expense) Nonoperating Income (Expense) Total other income (expense) Net Income (Loss) Attributable to Parent Net loss Net loss Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Common Shares outstanding - basic and diluted Earnings Per Share, Basic and Diluted Loss Per Common share - basic and diluted (in dollars per share) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation, Depletion and Amortization Depreciation Amortization of Intangible Assets Amortization of intangible assets Amortization of Financing Costs Amortization of deferred financing costs Share-based Compensation Stock-based compensation Share-based compensation Issuance of Stock and Warrants for Services or Claims Stock grants Paid-in-Kind Interest Interest added to note Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used for operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Intangible Assets Acquisition of intangible assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow activity: Interest Paid Cash paid for interest Basis of Presentation Basis of Accounting [Text Block] Basis of Presentation Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Notes Payable Long-term Debt [Text Block] Notes Payable Stock Options Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options Subsequent Events Subsequent Events [Text Block] Subsequent Events Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents and Concentration Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable and Concentration of Credit Risk Inventory, Policy [Policy Text Block] Inventories Income Tax, Policy [Policy Text Block] Income Taxes Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Use of Estimates, Policy [Policy Text Block] Use of Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions for options granted Property, Plant and Equipment [Table Text Block] Summary of Property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Long-term Debt Instruments [Table Text Block] Schedule of notes payable Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Information by age of specific types of trade accounts and notes receivable. Accounts Notes and Loans Receivable Age [Axis] Represents information relating to age of specific types of trade accounts and notes receivable. Accounts Notes And Loans Receivable Age [Domain] Accounts Notes and Loans Receivable Age [Domain] Represents the specific types of trade accounts and notes receivable having age group of 61 to 90 days. Age61 To90 Days [Member] 61 - 90 days Represents the specific types of trade accounts and notes receivable having age of over 90 days. Age Over90 Days [Member] Over 90 days Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Receivable and Concentration of Credit Risk Represents the reserve for accounts deemed uncollectible, expressed as a percentage. Reserve for Accounts Receivable Deemed Uncollectible Percentage Reserve for accounts deemed uncollectible (as a percent) Represents the age of specific types of trade accounts and notes receivable. Allowance for Doubtful Accounts Receivable Age of Accounts Receivable Age of doubtful accounts Represents the valuation allowance for receivables due, that are expected to be uncollectible, expressed as a percentage. Allowance for Doubtful Accounts Receivable Percentage Reserve for doubtful accounts (as a percent) Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Work in Process, Net of Reserves Work in process Inventory, Raw Materials, Net of Reserves Raw materials Inventory Valuation Reserves Inventory valuation reserves Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividends (as a percent) Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment and tangible personal property commonly used in offices. Furniture And Office Equipment [Member] Furniture equipment Leasehold Improvements [Member] Leasehold improvements Equipment [Member] Processing equipment Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Gross Property and equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] License agreements Patents [Member] Patents Finite-Lived Intangible Assets [Line Items] Intangible assets Intangible assets consist of: Finite-Lived Intangible Assets, Gross Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Accumulated Amortization Less: accumulated amortization Finite-Lived Intangible Assets, Remaining Amortization Period Amortization period of intangible assets Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross. Nonamortizable Pending Patent Costs Non-amortizable pending costs Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Future amortization of license and patent agreements Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of 2014 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2018 Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling And Marketing Expense [Member] Selling and marketing expense Notice period for termination of license agreements. Notice Period for Termination of License Agreements License agreements extended period Royalty fees percentage under license agreements. Royalty Fees Percentage under License Agreements Royalty fees range under the license agreements (as a percent) Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements. Minimum Royalty of License Agreement Minimum royalty of agreements The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements. Percentage of Capping Royalties for Multiple Royalty Payments to Licensors Royalty stack cap for royalties paid to more than one licensor for sales of the same product (as a percent) Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement. Milestone Payment Contingent upon Receipt of Grant Milestone fee upon receiving a Phase II Small Business Innovation Research Represents the number of products under development. Number of Products Under Development Number of products under development Royalty Expense Royalty fees included in sales and marketing expense Employee-related Liabilities, Current Accrued payroll Accrued Sales Commission, Current Accrued commissions Accrued Bonuses, Current Accrued Bonuses Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Revenue Interest Purchase Agreement, a funding arrangement whereby the reporting entity received cash, with repayment terms based on a royalty rate subject to agreed upon minimum payments. Revenue Interest Purchase Agreement [Member] Revenue Interest Purchase Agreement Debt Instrument [Line Items] Debt Instrument Long-Term Debt Long-term Debt, Excluding Current Maturities Long-term Notes Payable Represents the royalty as a percentage of net revenue. Royalty Percentage of Net Revenue Royalty percentage on net revenue Description of the frequency of periodic payments (monthly, quarterly, annual) for the period from inception of the loan through September 2014 as specified in the agreement. Debt Instrument Frequency of Periodic Payment Period One Royalty payments, frequency through September 2014 Royalty Percentage Of Product Revenue. Royalty Percentage of Product Revenue Royalty percentage on product revenue Description of the frequency of calculation of the periodic payments (monthly, quarterly, annual) for the period from September 2014 through September 2020 as specified in the agreement. Debt Instrument Frequency of Calculation of Periodic Payments Period Two Royalty payments estimated range calculated from September 2014 through September 2020, frequency Debt Instrument, Face Amount Total debt Face amount Amount of the required periodic payments for principal and interest required under the contract. Debt Instrument Periodic Payment Principal and Interest Varying amount EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#4VKBTTP$``!\5```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;PWK MVBFB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"&((9)X;EC8VO,^Z\63[.T/EW45 M+<"Z4JN,L#@A$:A)%V::^5!^8YO9I!!_Q$F M8E[YZ&D9;J])+%2.1`_KA4U61H0Q59D+'TCI0LF]E,XF(0X[VS6N*(V["AB$ M'DQHGOPAJ#L[P/?9QSA"C36RVKA0Z%DX M_12VC5VSNV/"(+"^A%UG=ZC[VB6&,O#TP+WR#9JZ48(\D$W;>G/P!0``__\# M`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($ M`BB@``(````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ( MNR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[ MUVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+ M\>QRI9$P4P>J/OH\^;*W-$UO>"_F M?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;',@H@0!**```0`````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``"\6,MJPS`0O!?Z#T;W1ME5FSZ(DTLIY-K'!PA;B4TY>GE^N+A168BV+6W3 MM2Y7>Q?4UML[<9IGDYGVI_64(L?-;-5F2N_*LFH['G?IZ/_+]ZMUW7A[KOB=>?: M^,L9^KWSVU`Y%U-1ZS%5,TMP0Y.9R3#@A[IO4BH.*O];H_.LQCQ^:YHA@V/KNHVL$AE@8#3&$(TT. M07;X2I@=OD+LF%';.J9L<$?9');Z\`O;1UHP6"_2MDO0=CFEMF@H\13IA6^E MX=PB.-(Q`&4L+1RH&Q*G!G+#HR;DD$='KQFVOB.*+Y%NC+3E&.@YTID`(X&D MT1"$PZ,FU"`3H!S\YBD])#`<$D@Z'@C&`TG'`\%X,-(F:*`)2GL@M$#IFX(7 M1=+4$.2&I>.!83RP]`C#<(0QTIYCH.>84?,J5-:[\BGZ])7L=`8_W49O%M+Q M,*2#_O'5;O$)``#__P,`4$L#!!0`!@`(````(0#'/&2D(P,``$H*```/```` M>&PO=V]R:V)O;VLN>&ULE%9-<]HP$+UWIO_!XWOC#YS/"61"0Z=<$F9(DZ-& ML05H8DN.)(?07]^U`+.V""47S-K>Y[=OWZY]??-1Y-X[4YI+T?>CD]#WF$AE MQL6\[_]Y_/7CPO>TH2*CN12L[Z^8]F\&W[]=+Z5Z?9'RU0,`H?O^PICR*@AT MNF`%U2>R9`*NS*0JJ(%0S0-=*D8SO6#,%'D0A^%94%`N_#7"E3H&0\YF/&5W M,JT*)LP:1+&<&J"O%[S4_N!ZQG/VM*[(HV5Y3PO@_9'[7DZU&67.S^LY:BB?.EGJ7 M5(?>QS,7F5S6MX*TJR;J`8&EO?3,,[.`ZV$8-N=^,SY?F.U)@`\0OE40GF./ MGK#E;14AT"DR$H:;%1F+M?I<0@MKU<=06>1[ZHK#'S7.HIHX1ODI1<:$9AF! M?UKF/*,@%AG2G(J4(908H<1?0P$"#9D>@K%Z'T%F:H!3@%F/$4X_ M0RI<=M/'4+B8\Y>94=A-W3#59$)7M`:H&YIC@>GU8MF;Q5H1$;O$L+ M3EJCY!CO<,>P\1(\39%CO<-`D-N,4X)-&#DNW-]\\EBWHU48=F+D6-$QP1X$ M;,+(<6&KAWNRL0XQ;%N-,0=`BY+7(A$CQGL6/?3R$(=ER,&PW!L3P(;A.\0'*6(O]Q[2:]K0;>0;%CW+W/;RG1P]L( M@HZ>BV5?GYYW_YQ^?5J'O=7U^WN>GYESN_.]EYW]X_/&'A]>F_=(=R[+W MP,*YV_G'OK]L-YNN.)9UWJV;2WF&;PY-6^<]7+;/F^[2EOE^>*@^;6@0R$V= M5V??6-BV2VPTAT-5E&E3O-3EN3=&VO*4]^!_=ZPNW=5:72PQ5^?MEY?+JFCJ M"YAXJDY5_WTPZGMUL?W\?&[:_.D$NK\1GA=7V\/%C?FZ*MJF:P[]&LQMC*.W MFJ--M`%+CP_["A3HL'MM>=CY'\DVHX&_>7P8`O175;YVUF>O.S:O/[75_I?J M7$*T(4\Z`T]-\T6CG_?Z%CR\N7GZTY"!WUIO7Q[REU/_>_/ZZ-"`B^;?A_VNU[X\[G\FU4`$C@'M/ M9==_JK1)WRM>NKZI_S80&4T9(W0TPL#[\7NZIJ$@0K[#"A^MP+BSE86N;(RL M(4IIWN>/#VWSZD'I@>/=)=>%3+9@^!H>(V8*V'_%"P*EC7S45G:^\CT(10=) M_OHHHH?-5\A+,2+Q+2(#%TFNB,Z"-IM>;\QFB?M(=B5T"8"B219$W);U[]F^ M>J]A[?UUW-C<`-N3'.J.F]P2$KF6WB+(2'9+6$8<.5`XMAR=)093X;XL_1!P ME@J)/(@-`H4U">5(Z)M$^B:1W2,"(+?.^/`WO?(CAY+MDKO.Q0<*A(+E4 MA'%<7//#SA0;Q,B3(8'J<_4G-B`B)OF$)B] MS09HP",9("*S"<*C,`KF"G'$$=@*EB=OH)$\-.GCD3'ZB.0BQ/MYXB*4,8;W M\]1!!!4\"-'ZDSD(A\55L3G4KDB]U2^N4&(:`WMWL$K#Y'!DC$@A5!A(5%^) M@T`4..5S#L8>Q8QT#95D`0U1(6>.&4(CPJ!DIH)Q9>JF8+E,TT(X,M'@,3&, M<7!%PH#:A32(2%R&4B6CZ$:H8T<%$5$1&BMS[4@5\=":]ZY0W14L%VIZ"/@[ M+9=JCN"8SWM]QJCS320E;R+97<05J5N#Y2)-(^%D$RT*,3',-9LL##@N[`0Q ME/";Q25U&19)%H;SSC=$*T.,"$0HYY7"%:K;!$OHL@Y5OXBAE5:ALHM'9A0L M!"5X(W$)22A!TSAU"0(RK"9FU&KW.2N(F(VX4G7+8$F]OU42TV`X.45QCD>& MFS[U5I\Q8;YFJ.K3\>$Q/CP,D?C,L;Z2UA[JRM*MPG)9IK%P9*&!8V*8:ZER M)NAMJ;J,[@-"E-_4M<,)59S,93BFS['#I&"4S%/'%:J;AN5"38OA"$4.QL0P MYCUCQ2BL[KB,$\1`'2N\3:0N0Z"0(TI08Y$A*.`\#*RNUI6J6PA+ZL)9:1H/ M1_*\*0_QCHG3G,!KDX0.;]K1!B9Q&+^#'M9.Y#*5Z&9H9 M1S"<)/T/P<-3;D>D4('%(Q,-3IU7-"_Z`(N!:]/=Z7#M(]7'&NA^3+9PV')[/X7#N.'^ M9GH`SL(N^7/Y:]X^5^?..Y4'&"I8*U@N6W.:9B[ZYC(<)CTU/9R"#1^/<.I9 MPC%.L`;XT#3]]4(?UDSGJ(__````__\#`%!+`P04``8`"````"$`WI'088<" M``!K!P``&0```'AL+W=O1KQ@*A'%+L:_?VT>)A@92XN$YJK@,7[A!C\N/G^: MGY3>FXQSB\"A,#'.K"UGA!B6<4E-H$I>P)U4:4DM+/6.F%)SFE2;9$[ZO5Y$ M)!4%]@XSW<5#I:E@?*W80?+">A/-RF85D:E-@`[XD'?USPE4P).BWDB MH`(7.](\C?%3.%N-,5G,JWS^"'XR-]?(9.KT18ODFR@XA`W'Y`Y@J]3>29\3 M]Q-L)N]V;ZH#^*%1PE-ZR.U/=?K*Q2ZS<-HC*,C5-4M>UMPP"!1L@O[(.3&5 M`P!$BE<9T`@]%Q]GT1BLQ@/(HRVW-B-<%88L8.Q2O[U-\.+A=_`/7E M?C_H3T;A*(*'?>!"/$E5V)I:NIAK=4+0+/!,4U+7>N$,G.]7`B4X[9,35UL` MUD#ZQT5_.IR3(T3&+IKE'4U=L;JCB*X2`EQ7."BY.YP30Z`8W<"-KKY5`4NO M&=YH&OBK-D6-#1[4G-VQO-7LVKYGX6"?A>#`9C^OXJYID-(@&T?2M MPAH=E-B=SHD;=+U&+DNOB=KH:I)6.FC7[G1.W*";-H)9>@T`7/-M\*_:%+7D MX`_9G/K:W+Q M#P``__\#`%!+`P04``8`"````"$`H,M)"G\"```^!@``&0```'AL+W=O=/"E4KKE%H9Z2TRO!2]]4=L0%L=3TG+9X>"PT)=XJ*J2A;A3Q:X5 MG0TF6C3<`K^I96]>W=KB$KN6Z\==?U6HM@>+C6RD??&F&+7%XF';*\>/7V@S/[5A9:&579".Q(`#WO>4[F!)Q6RU)"!RYVI$65XQNZ6*>8K)8^ MGU]2[,W1,S*UVG_2LOPB.P%APS*Y!=@H]>BD#Z5[!<7DK/K>+\`WC4I1\5UC MOZO]9R&WM8753J$AU]>B?+D3IH!`P29B'J-0#0#`+VJEVQD0"'_V_WM9VCK' MR31*9W%"08XVPMA[Z2PQ*G;&JO9W$%$'-9BP@TD"](?O+&)92M/IOUU((/(- MWG'+5TNM]@@V#NZV(%V`L^LL@7S>[@QH7,V-*_*EH#:P&D\K-H^7Y`DB M+`Z:VSDR4CLJ`Y9)9.6#I"ATO" MF01!0NELO.'"%1!.2,^WXBO76]D9U(@*EBJ.9F"@PP40!E;U_B1LE(6#ZQ]K MN*<%'),X`G&EE'T=N"MFN/E7?P```/__`P!02P,$%``&``@````A`"Z$>]9V M!```FA,``!D```!X;"]W;W)K&ULE)A=;Z,X%(;O M5]K_@+AOP)"0#R49-3'='6E66JUV9J$<1)4P!$F3?OO]QQ,$FPZ-M.+ML#C MUWY]CLW!RR_O1>Z\L4IDO%RY9.2[#BM3OL_*X\K]_N_+T\QU1)V4^R3G)5NY M'TRX7]:__[:\\NI5G!BK'5`HQ M.%-BMP+?#_RBB0K7:FPJ(9H\,,A2QGEZ:5@92U%*I8G-8Q?G+*SN*D5 MZ1"Y(JE>+^>GE!=GD-AE>59_-**N4Z2+K\>25\DN!]_O9)RD-^WFHB=?9&G% M!3_4(Y#SY$#[GN?>W`.E]7*?@0.<=J=BAY7[3!8QF;G>>ME,T(^,747G?T>< M^/6/*MM_RTH&LPUQP@CL.']%].L>;T%CK]?ZI8G`WY6S9X?DDM?_\.N?+#N> M:@CW!!RAL<7^@S*1PHR"S"B8H%+*LWU]6KEA-)I, M_9``[NR8J%\RE'2=]")J7OPG(=)*29&@%8$6K0@)1L%L0B:17<63(VH,TJ1. MULN*7QW(&NA3G!/,0;(`Y9LS.8Z[UY]9!8\H\HPJ*W?J.N!"0'S>UL%TOO3> M8$[3EMGTFT-P1E$77J[\=`E:I/X1F#XP-+=%\Q6U]?GD;H-'V$<_JW? MC;P!V@\_:K_;/A%I0Z-])%!%XC[1$5'LA+]B!^&5"^*/T<^TJ=Y(9MQAQNK@ MME:"6HG81"C^8"##PX4P+*'.V$-M\!N)F.Q9"6HE8A.AV(.5U;6'JRR$7>T^[S()SU@+@+D&C>!12'D>K0[`QA MU1GI):AD3!&T$M1*Q"9"\0=[6S>"9G$6Q)4(B9[5H):B=A$*/:P4NF\!LSV M$%;#%\RTK6TC&9,_*T'[1##1$CSN,X^M0'$X_Q6'".L.0W5_W$C&Y-!*4$E$ MS?*%6D!?OK%)07%'8#?I!G#8#M.TTGT^YJ]Y!V]:R&34CM`6D3L5`:=Z((T: MJE=\YW>2=:!762FH;\6)%E,B(:-7*T+O*E@(]7R:VJL^L3SH^#0O2B*+"=5? MI/N3D-&?%:%M5P:5V(BH+K%&&.Y25A3&=S^1C&%X6SM"[4AL1%23,)BNR8$I MBZWTY3G50RHAHULK0HE$HFFS%?DC7RLTXA;XO!O5*Y8,PP,J"PPU;6>Z1PE] MWGFS2VWQVIM*D=6M%*)'((VVUEW3<`I^GA>H5*PG-ZQB2RK+KROI#]=K[ M\C45*:U7*T+A@`,SO/4:CJ;CN?(3/VDU&!Z)_'Q-2//RR$.>"!2L.K(MRW/A MI/R"QQDA[`;WN_>CEN<`/Y2U^QNR@,_W_GV*1S-XW[LW@).1PYE(\^$SL`8'`SX(X`/G->W"^S@?JJV M_A\``/__`P!02P,$%``&``@````A`#C+7&-O`@``:`8``!D```!X;"]W;W)K M&ULE)5;C^(@&(;O-]G_0+B?TJI5QU@G8XR[D^PF MF\T>KI%22RRE`3S,O]\/T*:C[NC9_CWK^7#&"-C:9W32M4\PZ_G%\9!(*FH<"!-]#T,5A6!\H=A6\MH& MB.85M1"_*45C3C3)[L%)JC?;YH$IV0!B)2IA7ST4(\DF+^M::;JJ(.]#,J#L MQ/:#"[P43"NC"AL!CH1`+W-^)(\$2+-I+B`#5W:D>9'AYV0R'V$RF_KZ_!%\ M;SKOR)1J_T6+_)NH.10;VN0:L%)JXZ0ON?L+%I.+U4O?@!\:Y;R@V\K^5/NO M7*Q+"]U.(2&7UR1_77##H*"`B7JI(S%500#PBZ1P.P,*0@_^N1>Y+3/<'T;I M*.XG($C,^Q&X1:##J!/!J.7[*.=!,^AH!JWB302`Z4;POK,39QC8 M'>=QRPW.03/VE4G2.([;^3>^$-K]OD[L?'VUXR1MD<$R3`_]]&#\7TO89O=; M.G''\KS#8?JFY?`CED[QFF0R^O%39<%N$L-73- MOU.]%K5!%2]@A\31",JDPU41!E8U_NRLE(4C[E]+N-$Y'*PX`G&AE#T-W&74 M?B-F_P```/__`P!02P,$%``&``@````A`,&)'S$8!0``AQ<``!D```!X;"]W M;W)K&ULG)A=DZHX$(;OMVK_`\7]B(`@4NJI43[5 MK=K:VH]K!J-2(V`!,\[\^],A@B9X:-V;&6@?WB3])B'T],=7>I0^25$F>3:3 MU<%0ED@6Y]LDV\_D?_[V7BQ9*JLHVT;'/",S^9N4\H_Y[[]-SWGQ7AX(J210 MR,J9?*BJDZTH97P@:50.\A/)X)==7J11!;?%7BE/!8FV]4/I4=&&0U-)HR23 MF8)=/**1[W9)3)P\_DA)5C&1@ARC"OI?'I)3V:BE\2-R:52\?YQ>XCP]@<1; MZ.JLC*?U@GZ-R'G\N9:*@_YV2^2[2;)"&0;?*(. MO.7Y.T7#+0W!PTKG::]VX,]"VI)=]'&L_LK/`4GVAPKL-F!$=&#V]MLA90P9 M!9F!9E"E.#]"!^"OE"9T:D!&HJ_Z_SG95H>9K)L#8SS45<"E-U)67D(E92G^ M**L\_8]!]8A:$>TB8D+O+[]K`\TR5,-\0F7<=(4FX2)C#2S#&)G6^/'.0+8O M0X*+1N=_=$=M1D4O&AUS,-*,L?5`8KHTE)M M*MTXQO+;>O@K"\$[JO)*968RY`S<*6'>?W465MV"5-(F]-%-%[$[1*BB-=% M-)-7\1D"R;E.#)X([A""2'@'X456*+%&B)5BUA>04/,.$#S.H!9GV/$2;AII_A4CYZ*N64YE(N!I9BP!$# MKACPQ(#/`M>=)A`#81.XF?VCD3!U[S'7>53$]L+92& M5^SMXC0G?/<6C('VV@4L#&")$@Y*N"CAH82/$@%*A"BQ0HDU2FSZ",Y..,(\ M82>E9S)L8ZU5VEC8`A:,Z;,3)1R4<%'"0PF?$59]F+!TR["$11%P@&KJ0V&L M(=K&"B76MXV,)V--W,)N?X?CI:&WRXSPO&F'5Z7O21 M.M&,MFEV"F!$C]4.JN&B&AZO,;1&AG#N\U&-`"5"E%BAQ!HE-GT$9R?]7KT] M-?>?X"@MVBF8M6`,L],8F[KH]Y(!?6YB$BXJX?$20WTBK#D?E0A0(D2)%4JL M46+31W!>3@0OZ1>0#A]]_9[2IWA/M;&P-RP8TV/9$B4:Z8[*SSCU&.')LNLR5X,Q5P<@G5FJ-B[:*2_4"]?F*(PZ.N#CB MX8B/(P&.A#BRPI$UCFPN"-L)^3-(@",ACJQP9(TCM-Y( M,W]_1,Q25D]D=:F4%'NR),=C*<7Y!ZT53N",TT;;.N;KB%9$A/A"M:&&U(T[ MJ@V%HFX\5&VHY'3C"\U>W--?:C9\.79Y1[/A`[(;=S4;OB.[<4^SX7,2XDH[ M`"B#GJ(]^2,J]DE62D>R@Z$/![346+!"*KNI\E-=M7O+*RB`UI<'*'@3J'0- M!P#O\KQJ;F@#;0E]_A,``/__`P!02P,$%``&``@````A`,-^'Y].`P``,0L` M`!D```!X;"]W;W)K&ULE);;;J,P$(;O5]IW0-P7 M,(13E*1J4G6WTE9:K?9P[8`)5@$CVVG:M]\Q3@DF$4UODI!\_OW/C#.>Q>UK M75DOA`O*FJ6-',^V2).QG#:[I?WG]\--8EM"XB;'%6O(TGXCPKY=??VR.##^ M+$I"I`4*C5C:I93MW'5%5I(:"X>UI(%?"L9K+.&1[US15_(7.WPG=%=**'<($:G`YOG;/1$99!1D'#]4 M2AFKP`"\6C551P,R@E^[]P/-9;FT@\@)8R]`@%M;(N0#59*VE>V%9/4_#:&C ME!;QCR(!N#_^[CM^$J(P^EC%U8ZZ`.^QQ*L%9P<+3@WL*5JLSB":@[**+(#\ M7(X,0E)K[M2B;BG0`LKQLO*CV<)]@11F1V9]@3&)S04BZA$7_/4F(?2AR6ES M"H8@;*LWA^*3;A?`6C.S`3.ROYDB#&^PT=#;=0E4BY8V[#'PZ/>Q:X^:2;KT MWJ`H]5-_%,;&1,($A<$),5Q"J$.7TQE4\-C=25>[TTS4N8M0@.)Q`H=`D*`H M2?OX#&?P![C>F8)-9WX4]KK:F69@^SZW8VM3A.$M^HPW!7]T[C0SY6V*,+S% MG_&FX''>QA75C*YHXH=1ZIF)W1A`&J1QT`.&,W7K#5K*]%E3L.D,Q:.-UYJ9 MRMH487A+/^--P1]55#-3WJ8(PQN"OGM]XCK:S)P?C6MZA'11X:Z(TJ2O6?=O MV1A$&"2#/FZ:&UT4TU5%NK>;#0Z96Z^/T%3N)A'3GVK85Y\ZI-L[],^^29Q? M$D=HTI_6N8R8_E2OOMZ?[NS#_%TH[K#](Y3.8C2Z0]10I(ZPOD20!_=#>O1,T.(=><)\1QMA5:2`W'A.#-V2ZY%'/TC6=G?_EDD85;J/)8RF!`8# MSP&X8$R^/ZBAJA]V5_\!``#__P,`4$L#!!0`!@`(````(0"PS=H&;P4``%\: M```9````>&PO=V]R:W-H965T%$B>#//../8; M,_OV5>Z]3U8W!:_F?C0(?8]5.5\7U7;N__W7Z].S[S5M5JVS/:_8W/_!&O_; MXN>?9D=>OS<[QEH/(E3-W-^U[6$:!$V^8V76#/B!57!FP^LR:^%CO0V:0\VR MM;BHW`=Q&(Z#,BLJ7T:8UGUB\,VFR!GA^4?)JE8&J=D^:R'_9E<+F2C0/P4[-A?OO6;' MC[_4Q?JWHF)0;>@3=N"-\W=$OZ_Q$%P<7%W]*CKP1^VMV2;[V+=_\N.OK-CN M6FCW"!2AL.GZ!V%-#A6%,`.91L[WD`#\]\H"AP94)/L2K\=BW>[F?C(>C"9A M$@'NO;&F?2TPI._E'TW+RW\E%&%279!8!8%7%22"MSTO3M3%\-I=/!C&H\GS M(RD,511(^A1EU#M*((LB:DRR-EO,:G[T8.""[.:0X6T032'RJ;BR%%VY[U4; M*H1!7C#*W)_X'A2R@2'RN8C3YUGP"6W-%;.\Q:0ZLSHQ6'H,3.0!^-\%3L)0 MOXA>,U%'!""STPH=N]1Z>P"=)"&,DDZI+.4!/97S%XET5[>8N$M&2KK%&''H M-7..HDF"(=5?$L(P^B^*&:MR3\)$SWXI&9L^)T&")NA720CL++OQ%]NM-.N`,OY>+=F,"$:1^I M>)$IVVC:4C(VV4Z".`EZ323A>8!IC1W_'Z5XD:ET;#18,C:E3H(X"2J)QQL, M4Z39X"%4S=Y@O,B4/3%D2\8FVTD0)T&OB20\S_-:@]%^72PL=H4(FPJ-M6$I M&9M")T&)&J$+&(A'P5]##.U-0A,:A]Q`5](7`:M`Z50L"'%'H0J1`L?@(8?#\TC2.X@VHK]`:3JZ#IH3*QI>&,.6[%=N MA+@1JA`I,(V3>#R\LUQ&Z"/Z"Y2NHQ-H3J$BFD.@S;@HQ^I$J/HB)5`Z@]MS M3`35?D`@TA=#]#PSJR$JSUL[Z$2(R,E:)JJ0/@+1,O3OH#0870?-)0(?"UU# MU(D0=Q2JD)/`,3R4W+L'T2GT%RA]Q4E@?`ZJ.NAT)JO(B1`W0A4B!8[3)+TO M$#U!?X'206@>/3*>?I;1#9L1G:<`48K5#P[[0EU1-:GQ0PY'T+I)C8>F1`79)+H1XD:H M%=%5/F1S8NE18!'K'J*O-PD49%7I]CKN*-2*Z"K1G5P,6_OS1HRTWLLD,AV= M@JPJ91P+0MQ1J$+4/(!KR;W5)$9ST5^EM"*7-V4\-&V="&E=SE=NA+@1:D7T M7D(]'U")M/YL=6/$2LC2J%7L1(@;H59$5_F0]<&]:O>(=9J;E8IC*01Q([C? MC]FHQV2YNV7,L7(_7^XUEZS>LA7;[QLOYQ^X5X\.ISO:_8[P$N-VJW%\&4UA M7QB.!]T)V-X_9%OV>U9OBZKQ]FP#(&PO=V]R:W-H965T698!RC&&,!6>;O>X'$4PO]FTJTYL(FV3UTDNK=OGU@2K9`L1&U ML*^>%"/)9L_;1FFZJ<'W*1E0=N'VBQMZ*9A61I4V`CH2&KWU/"53`DR+>2'` M@8L=:5[F^"F9+8>8+.8^GY^"'TWO&9E*'3]I47P1#8>P89O:)6^5`^8.98#T/;O4!W^=ITOJKNC:>Y9,.F?! M>\",QGY38!J[UU?&0>K]\J[HK?RTXP_R`=/)9^DP[O^2#A[:"0&ULE)9=;YLP%(;O)^T_(-^7SP`I"JF:D&Z3-FF: M]G'M@`E6`2/;:=I_OV,<*!]=TMTTP7W]^+SG-796=\]5:3P1+BBK8^28-C)( MG;*,UH<8_?KY<+-$AI"XSG#):A*C%R+0W?KCA]6)\4=1$"(-(-0B1H643619 M(BU(A87)&E+#?W+&*RSAD1\LT7""LW9255JN;0=6A6F--"'B[V&P/*5+"T5&E49?#C7C>%^" M[V=G@=..W3[,\!5-.1,LER;@+%WHW/.M=6L!:;W**#A0;3"/E`%1(9Z5%(5OW1(N>,TA#W#($99XCCFN[2=_S@.L72 M%;4&$RSQ>L79R8!-`VN*!JLMZ$1`[ISI.GJO_[(*'A7D7E%B%"(#7`B(YVGM MN?;*>H*>IF?-9JX))I)M)U$=5-RD&WCE.F/JKE.H^,!2[PNZ-?3U=E)=^4JL MRN_6W>@!8/=^W/&ZV[DBF)26S"43R&ZN&$!&=KS_L:/$L,6&U;N3I3=:LQAH M%A.'5Q7)5<7NDF+D#PH9QJ6VH0>OZ>78U*0801/[E#QW$L)&:R[YO*I(M")H M]_4BA+=MLF]WEQ`CF_"U>MJ?$4WO3&+5FV9;FNJ'O>Y,4AP)GX<*],18D M0T%H.\%M.!;LA@+?6P3AZQ(C;\'8V_LB5).F'E_Y[2&PT1KMT?'MI3WUL-6* M"R$G5QEP?:A*WF9HG_IZT*=G1?B!;$E9"B-E1W7T>Y!!/]K?2O>N.E0FXQLG M@J-N/I[`+=:.6_T$N$4:?"#?,#_06A@ER6$IVPPA%*[O(?T@6=.>Y7LFX?YH MOQ;P3&++^_5WGLKFK:4]=)'L]#WBCJ7Z[+>+OW__GUZ$+[7=EF]SO:R M+I;^1]'Z7U:__[8XRN:EW15%YT&$NEWZNZX[S(.@S7=%E;4S>2AJ^&8CFRKK MX&.S#=I#4V3K_J)J'^`P9$&5E;6O(\R;6V+(S:;,BT>9OU9%W>D@3;'/.M#? M[LI#>XI6Y;>$J[+FY?7PD,OJ`"&>RWW9??1!?:_*Y]^VM6RRYSVL^QW1+#_% M[C],PE=EWLA6;KH9A`NTT.F:XR`.(-)JL2YA!2KM7E-LEOY7-$]QY`>K19^@ M'V5Q;$=_>^U.'O]HRO5?95U`MJ%.J@+/4KXH]-M:_0LN#B97/_45^+OQUL4F M>]UW_\CCGT6YW750[@A6I!8V7W\\%FT.&84P,RTCEWL0`#^]JE2M`1G)WOO? MQW+=[98^8;.(AP0![CT7;?=4JI"^E[^VG:Q^:@@I4><@V`0AH-Y\CV=81"AB MOXX2:$7]`A^S+ELM&GGTH&O@GNTA4SV(YA!9K8Q`?CY?&:A1UWQ5%_67`MU" M.=Y6.%H$;Y#!W"#))XA-I)\0[(P$(.^L$58^UGA=FX)A#;XW:./GL+W\1"-T MA%";2*\1EC2XS^W2%+ST(?8@3=@W3C0B^IPB)$+,0@=)QXB:`S&/PG,42QRL M<"Q.U99>[-I3;=5%CLCX'%[G3R-,%YY3$E)D$^F80"(F+!YB6!)!SECB]=(J MV)9&AI5K:1K1T@BA#"&G,5.;B`4E0X(M:>P>:0IVI#DY232BI:$PC#%QDC8& M<,PXNI`S?H\P!3O"L'W?1"-&&(]CS(2S8](Q@B,6"19>V*O*\D;SY'I!%>R( M;<-]&(%A9Q1H23UM0&0A)?R!B" M<7M[RGK:D>:T>&(8K2U&-"9.+Z86@4).(GXA;<@QB.L%[6E'W;!LO44-H]7! M`(OYM*@VPYF@F`];W=JF2,WJFSNNIVU[($ZS)X:!&7:>TT[QTZN(+<]QB!L- M=FH5HS%E\JB94QY5)B=EMA%!8CITJ2U33>S;LZCG^]C)R-`_1I[E`13,S!X[ M*;H,V-+N\@CU6.9L73ITCI$V]@`<$HI#1WUJPIR2&XN0#5%L>8Y/W%C@J6&X M)IH@RQ`$XD1PIU=3FXD(`ZL=QH$M]"[?0%/C&/6.R>/8%G@$L]&`;V MP#!DAL+U^4VO,Y9`?)>)]+0]!:D[I@UC"73*>Q6QY3DNHC8)^^4Q`^LCPGC, MT*%`N@<-HPL-1L*8D^G4(0BYM$'P74[2T[;54:?_$\-H<9Q@1K&[RU.;P;!_ M0S34PLZBXR77O1A//80Z8RXQC!;X(`C#-!9N&]H0QS2,.!^6:DM40_UF'\': M`L8%'IUE3($U8R2B$,&SIQAFL=XI)I#I`L(8&0:"K<\QD]NFM3I?.Z82.5Z; M&$8?W2X\UMC,YX\U^B6$/J,?LFWQ/6NV9=UZ^V(#FR:<<=#2Z%<0^D,G#_U9 M_%EV\.J@_W,'KXH*.*B',X`W4G:G#^HEQ_GET^I_````__\#`%!+`P04``8` M"````"$`?V6&_:$"``!Z!P``&````'AL+W=OX,J:=$J+SB@FJ`]FR!G9*J00UL%1K MHEO%:.&"1$T&89@207F#O<-4?<1#EB7/V;W,-X(UQILH5E,#_+KBK=Z[B?PC M=H*JYTU[DTO1@L6*U]R\.5.,1#Y]7#=2T54->;]&0YKOO=WBS%[P7$DM2Q.` M'?&@YSE/R(2`TWQ6<,C`EATI5F;X+IHN1YC,9ZX^OSG;ZI-GI"NY_:)X\8TW M#(H-UV0O8"7ELY4^%O8O""9GT0_N`KXK5+"2;FKS0VZ_,KZN#-QV`@G9O*;% MVSW3.104;()!8IUR60,`?"/!;6=`0>BK^]WRPE09CM,@&85Q!'*T8MH\<&N) M4;[11HH_7A3MK+S)8&<2`_UN?Q`,QDF4I/]W(9[()7A/#9W/E-PB:!HX4[?4 MMF`T!6>;60SU>3\S2,G&W-D@%PIJ#;?Q,D\&,_("%XEV^72ON827=8Q=>,G%881!&W>WE/[<[4-#Z M'X>RXA[4L5O\=7I)ZOL12F4_/;"+D@Y<>@V<%??@1MV3%U[BX:+1,$WC<;]J M74D<3Y+T*.G`C:Z!L^(>W+@'YR47X;J2=^'\^/33I:5K]D35FC<:U:R$!@^# M$51?^>'I%T:V;HJLI(&AYQXK>,&O._P(``/__`P!0 M2P,$%``&``@````A`,S;FKRH.@``_+H``!0```!X;"]S:&%R9613=')I;F=S M+GAM;.R=VVX<29*F[Q?8=P@(+$@%)%D\D^JJUH!%23V:J9(T(C6-N0QF!LEL M)3-S,C(EL;$7_1H#[`+U!'N[]WJ4?I+]?C-WCV.25$T/%MCJ07'A!W,[ M_F;N\<,_?+Z99!^+13F>37__:&=K^U%63(>ST7AZ]?M'[\]?;AX_RLIE/AWE MD]FT^/VCVZ)\]`_/_OM_^Z$LEQGO3LO?/[I>+N>_^^Z[3'ER M.5O[V]N%W-_EX^B@;SE;3)>/N[>T\RE;3 M\;^OBE/_:6__Z:-G/Y3C9S\LGSV?#539=7ISCUO9SE[_P\?M MUF$J[XJK<;ECBE-4M\@E-1L7G[)^+ MVW:[Q]O\W_'VP=/=X_:C1)WSVWEW\)WMS7]9^\;;8C&>B:2C['F^[+Q\`M%' M1OB7D_RJW(U%" M5^^*^6RQA".SLV6^7)7MYH__K>C\%KIX.9X4B^R4M5W-%EVBGMWD$S6H1CB= MW[-:FH0PP?;,TM;4J?$2;N[,]W$? M-[9?#]O5W\&_[+5'/YW!3=.R&&7\5GSW/ M-KYMO_R\&"(F.R8)W9[#SN1E21>_:[][FI?7)JM#_5'\^VK\,9_`%)U5GPQ- M`939HA@6-+J8%(-L6BRSV67&SLP^V401]&PT6UTL+U>3+(^OJ,E\OIA]'J-F MBLEMMG'X=("0V,`;!_;W@([+>3%=A]10B?C_&(\&2_'17<'T\;, M\UOMBLT=TB]6C!W)LJ[C-,EW!01>=51$DVBU:;0[?#U;%MG;,(--I-2Z0TDN M"_9UF;U=+8;7>5ED)U>+HA!5VSW\-(-"Y\7B)GO8I.Z8#)KA9KS4(,X/0VP, M],=:0L#VN(^__/+EE_:/IB^N9Y,1YO:Q<0),\6147(Z'X^6W72ER95.ZLMG8 MVM[)YBA31&E5?)\=;(O9C>%+UT/Y:GD]6XS_7(R^SW:.!ON'AX.]XQW;.?ZY MM_=T<'"XDX7&X[+45AICK]=?)Z,1_#&;PN,2B,WQ-!OF\S$\WUX;#+.Z64U, MP805M9OXMMOX:XG0_\Y/%:?:C/L(V7[S@2-M_=[,./SRHN7/$@YK.UG/,&DK)<)N`EE+M;]"' MN?AJK?79>[`+U[5-_59OW0S:"PY*IB/1IZA9S?UJ-AN5&=:TXUC^83$KRPR+ M=#GNZ"&][6HC*L^.N)]A(KW)3;[X`$-VW8EW18D[-73;.D(;3F9F2]IKP-N$ MP-A*#$X^NAE/S3V5$6RW#*JX,[MVNY^TM,O%[":3+?.]:[=Y(P.9C8D>;HKL M25AG5ZTE[1U:M+MI/]]$G3S(YO6/W^[>5VS&O#/7=MO7>"(35M[^_8_%^.I: MKM0)D5-^5>!?N5_HBK@F'MEF=I&7XZ%MQ6@\6?%6NS>C+:Y=[,7$M^_%[`GZ M=S2;3/(%?,8+UK+CN3U(!,U%>XF'M58$K<6EM:AO//8TES^UQF\8_6E5!B.Y MG,FMFV$?\1_DU(F4&;_J;_,,5_)-Y=T%IKJ[[^?%G/[&QGQM&I[<*$+XLSV3 ME([O MXPH6K"2X@L9"-?^DHT!Z[$V[S^=1E!;]GID8_OZ=:??:YI0Q?G5I\=H=G))\ M-W8+G0D[MSWD]C`G0WSGTOR1!VUQ=S%]$VN/TEY,Y6C?M9C%;%@4V`63%%E2 M"UQ8&CR2#'A[*`*#VEO%YV(Q'./,\I;9>Z3";&3[M;0NR/9Q+`ZZN*W%`]4T M^UY$/0/%,`I^I__UK5C,-EWFPOZX(V(S\O0U'&07P"#3J4(25G"+H6J/?\>[ MX`QZ"RX`CVB_=[::SR?F/6#31N`**)*5(F_15Q&FM%342K<=N;!A+9Z3JD$S M6/#0'N1'U+3U2/!7XA+V2;4`K]^5\WP($(8N*HO%Q^+1LYVMWG>S]@CGUX11 M1*\&,'CD%N-SM&05GP>.8ZW`"M%K8M\FJU&186.MDY7"$-8?L*4OOPA+8O'EEPBF6=?@!O'G`![8SR*])K>\ M)E++$(FE>S'P2_RG;WX)_BB>7M<_.,G>EJ8A)I#VM? MYFGZYMS`S\/<"%!>SU831+7(!(6:S,VF?UI-L:4X^#:>^LA71%QTTLL$[+?: MA%6;Y=2_)6N!:EWJ#]CHL5S&A6R),5&:\,ETNH+-'/W*F,9+,-LOOP`9_C-& M1^PE28];=^N,=D-K6PVQW=E7LSD)I_B:3ERLB@N M)X`Z@HCP;RN/8PKOE:686'/.L\M\O-`.)WE61_QS-8'_X[(BVX5VQE M$#G.PP`ARJ6TN>*DBF.+R1B/W@)M*>ZD.6C609??+*[R:72+1-W#1VD9VM;HA46JC:0GC]>8U)4:IY-H'E)48WA:@TR9;%\'HZF\RN;F4@ MYZBJ#)D7`6%]/$11>DXT05.$#9H:(+>`>@:E__4OR+LPX4M`S9D3W,72-L!& MD5[!0(Y60_9:D_B8CR<&907>:DCK`(QXFH^"J.(<,;24C,<)!E(N@'E,'H(4 ME7C_TA6NYEFW_O.6_RG_+(SF]X\.MPX>???LAR'K--UW@]78T2^+EZ@_;W,^ MOJ'7U\6G[-T,#M?3R_Q&#&5=6//OK-?ELR__>^U0.]M_RY'ZS1RSU$[\89%? M`EZ:=$YE/RXO-_G')LF=B;L[&X`=#`4"D=*F_+U\]MO5:#(1 ME9;J,Q&*LMS\N!GZ+>N5OPLZ@FXN-49[=8F39G*[CFU.9[,/V8]C"?FUJ@!" M:%6,7&/*GR2L10U?"!_,/LT6D]$G(GLT-0Y[:"0DBJ;>XK;U9,WZ_8Z]K8=WV(FY8\KP'>X!/K>49#LLCTV@ MBN!*6I%!0Y,J."11MP(7P.TIA+0H:\ZJ`@C]V2VR/<=YR<6QQZ`BR29I;-53NV1"$:NIYYY"5)MY`&7C&4 M#XPKJ;A'FIYI:`]+2QJ8X@)^VLK"8CRZ:?`F;=P7UECI'\ICR.'.R6$#.A&O M"C!8$4DK?DI,J1'SF&,UOF^3RAC*A]`:PC(A`9WK6;W[U*TY*,L0H"YQA3%5 M2QDP);\-*K[S559A^-<@NYY]DB>B/&N["?SR.[V.P`!1B=5Q,7-;=N,E,(*NX@-U"P M7]Z/B)"F1,&#=IL(!!]0VB;MAEZ,/6#BEJP0=:5MT=R90.R#N%7A[P7L%]F' M`"Z$2H&-MK*7!5LX)"-RQ2`,&CG`>;.\'L_G\E"D_&K,Q.+"?@FA,H`F\BT- M[2WOKLX9[&)4GZR<_PA.Q,LB8*P$0LDK00&60'-@OCUX8!R/\XV':H&&U5G8 M&P2`)K9!^U6%9PG@M#]>5'4OI@A.286@RS#5Y#A;<(E\%=I4K:CXQ"T3(Q$/)885F:RWB)'`G2 MX&WLW](XC$5=>%E2B5F[E>$#3\\N"U9FL21OFHD5^$%187:.3HDD,&&2_/.: M]DYZ6KH7.I!Q@IZ+P@L37!>A%=)86L%H1A-GZ,F8;C"'4@;TQ6:X=J2K.F8# M<$X@FBW&Y0>A9D:"/EIT&"38P!*VC/5.7=;07ISZ".\8HDQDU'*;U18Z;N*!5.&1H53D!M'0R%>M\3*TUS2_1+* M,2@%4Q.;U3.4&SH2Z$LZ'T!5M&A4+#2`@/E*)(F'I)S0PTJEB11@(39M-!%K83%:=B,.=J M"3C4$JHPNR%_FYJSJG4[\`E)6J*R\+]<=XU4E(0FPN-SPXU%ETH:SF!6X1@B MI[M%YGS$[9R+VK-5R=+K?495N1C1J2E'7SF099M)_BBE&LD7]DX;ET8S0QFD M['`[&^6WZ&6I2/%.9)F1^$.,73$"FRR1*J5/-'W3A/P9:(CKBJD0PCBH.$Q= MSI6?%;''\I]N!WI7OP=)Y&\TP:0+.%Q1/@W;#XTD[U9MK MB5G<*4.#\3.`VM@'52!0"HGRLE1@;EB:L%35O&9/#KYQE"WJU\.=S:=AQ[6W MNTQ0XE^-JI%2"ZSWMU+.4H4FXBXF!K(%L>1GVSZ3Z1+#:^8^GPRM'LRV>6EU MDC*_CN9BGM!PM;7[@\@-G\S'2_E@V1;$B.8\QNXI/&=(FU1Y*[JI>7'^G[N]3S'$/(ZFT5??6X9#JW;8W-LF*2J?L6'2>-5&L&$U!P)"4PQ9!,1 MH`Q;@R!-5YJ,1/:J$$8])WL&34A0*&ZC830[:&X,'7\2,3&QA%)?O MC$3X"0@QL*B/$XC1K4V[Z=!05X^_+!=]-D'+U;P-TJ>SU=5U_,T(SX:C;4,K M]X^,][#%8PR:QC1.48A2=JCY*A1!=XI8#1"L/74G@VP-;H]T`;#!S9Q*\J7% MJ4O#&%74+`$W;)])_7;QQ+_G'GZS%'A;RP1@`DI5K\C9[OE&`F3VY'"_*)876`\(F_84/\*VB,2\*-<%&,^`&F?NE#DB"T@=B'BI? MZJ@^:%RC3J/M)S:4;_OADY23[]08OE1-Z36+L'+8]HL;[1]V!SL[AX/M_<-N M43R/.&6RM]?SZ(^SQ0>Y9<'.=3K=Y;W#W9XN]PX&3P][.GR7?X*.N!7D)SM5 M>3O4TA\/CK:/NAWRB#GN],UQ;["W?\CJ#KIO\>CI\6!_[[C[J*Y6V7TOCT2C M1N/*GRV;NG>\5QUN2?_X&UI5P=(`<.?YY^YIAG.XK!%L@_Y@3BF6@0-B!``J MH@Z6^6?SJCDWDP7'6TP:T_/X1RQ.%:`5QNQ1NL"N2R_TK;J24P-Y@A%G-'FJ MJF%P.QJ=$#M9Z"0#[PZ`XD*`!12UJ0;P5X.G4D]-5=%,\-5JM94VC*:M^,!0 MLLN5('X99??3""#4%R501#:J.!F-+YF]H(<2G\*=3Y-./ZB#4T;:5$&0.?@* M8^0?JH6F8?&R.NR?#S&G:0U']RH7C5X0#B\"M(#0H0M2Y>B5\0>=BD+K3"VF M4V.E$Y8$EGRCA@A0!S\"[0@A+6B!AB4+19G*D;.:B[ILTR%HREX M8H"YFL>:MXVAO1`,EH,[Q'\!X1.#:&83@FD< M=C9C-4WK0T0D'LX33BJAUZ`SY5P(#AU'N34(OX159&L(NI6],DYCZJ;`H>&Z63>1?X_WTOJP;[`:LY:.L]-U$<&`%.MZ-#9+ M+TI'2=N*+_@KGUB)#':STK"A2=E8O<4J%>I`:X)5?!WVX&0.(J/)-8$+:86 MQ%#FGYE0!T&<3:GXMT.S*G/"=E4P8AU=KYELT^Q,Z%*SLOY(VC@,)=F@&'2Q MW!2^D4'7%2MESCQ@%VL=VF[Q4_]H&$FK"%Z+/@.N]V"+XI+T^UVG.YU7J@5$ M%5"/=+D3X,J78:F&&@&D\@E=I6DKDCJ*M$)PXSYG9$.D`9.Z#HA.&*2SRV8QJH#D2M)F)`OD-`_+FG)"PME*R`=NKD%(!L>]>/?'-P MS83@+;Q@XN;U(+I)8#NTP(V27H>=K!%J]H9D+CML_K[U#]BJVC0G1K":73+G MLDY>'T`G25_0C;1@<>_MTUU*` MP]!6'&VVO)871U3',&+@9>AVFG-C.YH=X-?.\X7!'/."6,W^/97EKDJKYRO\ MH*'\+4$[;)P<54W9"2\_37!<8&_R[%=*5TL8&P,'OG<8J79TQ+J+755@8;._ M)DE2,MMIFCS9R?A2,&G`3P#I&M!1BM5SIN!0OXVXR-H=%F0#T0)-^>>.$$IMLU+ MY263N9/&$!(MX@J!$NI].Y8;4K,=29_0\/W6&;VKIF*%GVYL[+6E)D<("OH9 MF47&(@!OBKFFS-A68@DMS8L9FK1TU>UD:BZC2DS:\1-E)$U;6PH+NVA)LRY[ MPA0I)XD#A9S,M6:4M>C?TTN0#LB)!2F,4=TU;DX'JGK$D1`#?!<_R;C)@0@[ MR5@7/;%P6S,"(FH2(GYU=*/WS$;G',YK\D)??K$,8?GE%W,+OOQR-SSQ(H9? MMB,Z_F@^10>.V-_:[@;9Z>5*FML>P-'3K:,>G.";=KOCO:W='EQ`Z5FR9G"G MF++]TL[6[EYW5MM;1SO=7]-<$VNT>]ON6^(YVQ!41DV;U\0JNN8>+;CX5E8S M61%)II5XX(AZ5ABFKG>C<,$.6L!!R>18@-UC92KM(C:AVEC2A>@$;>E:HMZ[ MQ\[D!+VF+HD7[\1'EINT@I0X153&:15TQ5\-(8A*Q7S(FNF,#J>JG5+&B$39 M\'H3&+\Z21+/S#0-;Y`RU\+F'MKPKL4-L@]AF%8=LNV0$1"-Z(K#J9!.EB.Z M+(GXK/)"CFBJ/6.@$-D&C=\4XQ&5'5/",Q24W.3:/BD3%4N`Z%6:965G,;5K MP9[6T$F)4RYI!1\OS1`9S,U97DPZL@/X0 M@6OK'>>!Y*DR8AVL8_2D="D<:#2>(NN#F$IB^J&@MO>B$7L)Y3+=/QTJ`G0Q MBZ]%XF:WW-38H<*JG`55]&#&'0MCIZF,A0.4RU1:J,,`[\CSL:J3 M6AGH@N(*Q==6G-14>,H^]=>#OIE25G)+"'GL3.GA]0X.O.O)P06K(01%/_+AN*58HI[P_IK!)N9.T"W1M)0'TDB_2HP<J.9DA,VAO,MJ$20HN2< M=QSHEZL%&7VA1=+MJ8.FXEP^^XE(I]`-2PJ/R`[TJ5=;L(J@Q!1W]%26OQ-: M5+O::0XG^!T<-HO@VU@PV)[(DYW!X=/=P=/=P_:3C@-/TX-C_KO7:=I/M':' MX)'QXK03R^BT&O3OW,%6Y[W.IIW#FG7>0X+B2,%`F]YYR/[]!$!J0&VLI.\X M06\)(WHN#/F)C6KNPYUDW]O?@>@'+1(\>[)'?G/_X*C]>XT&OJ+>J^FZDS?O MVO,`83IR,XDCDW;1&0DQF`G@SM'F[K;';UM#HYV=_PU_"#+*/AS M!#->VF2=3N5S>Y<*L9E0^(K30"MZCH$=\9Z M7M^K97[W]QNOWQ."M[SV5EU5(&@S`A>6N0]ZY>G.N%Q;(=0"XFIQL`Q^/5[# MDC:!DXW6BGT71F[M-9BID8W]X[0P?CP08:S0B7\<=US)R(OIVK^.(-6DUD[: MP!I$*C+NN`*$?DOS6WJ6$V_0Z`YA7J#%&[)6G!Z'TPE^#6*,IZO>@;_8^8*7 M^+782F5,Y$2^?_GNI;TOQ=U\]9P$!UN/8XPKARFVYNW\4G6F+"S:_31F65!A+2%=5F?R#2AB+G@$Y"_T M4/.FH-BNOE!\XG5>`;4+/0(AQ"Z$C<;\A&9/+?HUL@GM@]<=)5#]QK^C])D_ MTKY-0PW9/&5E155<(2^("5.HG"41*IK2+IT; MY))88;7Z_4"8KY%+9E/::@6_=YR3+_^G95?Z36[(F."9D]28W9*L),VJDT)- M6_&-%K#W#?#%*`A`SUXF$%LY?C\)5^FHZI`;<=L;SK_SJ+61YK2'I2*"&=LY MOEEQ2BC,BS[(D0URMEVB2@"EZ12G M*9\/8*X:!VEO'&-9GT2O-+FYGUH#STI#@;N0'>/*3P.;+$+A'W-3%U[1;7/2 M:&BPO:VC@V^^;WM0_7Q`]CS,FFQ&4"!,N:Y`[)1$)5T]#,`*B3T([$&-E/1. M1U0]R0Z3L1:V3J&+BN39T&JTP'9V=H11S$<1+:H>X7O'^R/AH/JI'PR1U(;Y M)ZB^UK4P^G5KZ:ZC">]A4.5IQ&B6J>FLX075&69[51UQATQ(7Z4945F(JJ`6 MO/ZZ29LX0($3M2I*NT7AJ,_Y@1L9J,#E!#<7*^JCG5NE9;0N= ME)*-T']W<](^.T\925$+[L:1(`,7U/M0E6H8S+T"94^4Y=E;$D!%]NI59O>, MI\MWJ$F8SCZZ=Y`\!C9D7?/S*!6WI+$"5.*)5J_\-W&$3`@.$ MW9^3N[_AWA$V%SVH`#U>!\15IC"W]MZ/*-_%X5O9ZQD,K0*BV%QC5UB#OUR[ M';7C/KZK*5)W_%LNZ].:QWW8]+B[#KL0$W=/?=?1<.-G7`1>73RO]9+5R=: M4[`N!DFYNM:3=#ML2B`$A(0X78GJJ7ESJ(^1!$U%X*MX.A6^>+KU].`;S5:W M:88YR71YU%G;2H6H;D?D'#`:'K\AU4_&W(:8N@G*"/7O"#?<^&2L%BHOLP.$ MP2%T7`)_KZ0NS(NCS/5HJ:"=K3TI7JXWH])AAH+9.DC_KCFC_3/>W7:]'[W) M`!Y#!CLCZ?ZFZVQB3]\K`":+QC>1+QA1E'3\^("KB#<.!T?`<_O[_MF40_WT M=+"[MSLXW-\UE.'(&%?1NC\+=]/;LZ?AI\-*K>YN@P59OT^YEY[&'=XDO;-S MM#4/B_![C84W6O&_^])*W!H6WNUL.HVYK/P(67S]Y,LS?#YB_WE4>)>O1`ZLM*CAE`\@4=PP^SN MB1"IMI?Q;:SOK[PQ&:S:O0SB8V3"+XD('J?3TP9,MOSO)\9^N[?5F0H14Q!H M_]:N['L;#XWA8'_YA7_5;H:6=)I8R_FGR$ZR9(BTX73(LJUPTNM5J,HA;*!(]#JH-1/#5CUO[2H:]8M+:LZU3?&<<=IJ M(%.`D1M:)--JM641\7^?HM;V6P-;'&%O1UG=RG);<4!54E2!$UX(>/DP+390 M$!P+VF-$8J`>9SX4MT5;&8UDJ`6QT3E=&\-^>#06Y!%G6>5.\*(_HNY8=(\= MI]E:^^TU49;$Q<.UW;ODH@)N'P[^@OHTPQQ]$VVP8Q2-%MA3B(\>]=-`:Q2U M^P5^&C\B#!Z(BL&L2I'9:HAH5Y20J#M6$2!_*58@)#`72V:LGF;>V,&H^Q=J M;'/[.H;F71,KSQ__X^C^=T]65P#F7%9,M@+Z[#;,(X"7F6,RW0_Q-^OGM>*Z M-1-H@@DSB+*C.#V^=NK_-OO/#C.2V\'H.O"; M7@O>(X1>)*2-FR^&7!7';U04B.NAU07WR@<$?39E3\U6[<. M2VCAV2`?(D3PTYK)\W/>CW3#W>!8*H)A8%J7.<$"?LG%*,4-[.+[O; MWYA2>VDWH'#CE40[WGQ5#6[WDU#NJ0,=S-%V*"6_K++7OY,;JRQL.M'+9W?I^Z[H4Z2" M=QB45LJ#:./#'7E4TYAVA:[PE0[VY",EX.!O`BY2);K=I5Y(%&>>2$C_F``` M$!0X=9*JV0&$`@3AQ=0HS``UZD@4+]6\U(M\^F&QFB^')/WLXER?2*V5T@6_F^Y5BB4(5?5$82^D?JOK!;=0&@;KI5\L M"1N=>C5GY[4T"U&5*XH)AAQ"6<8@*F33<(YLAN2>4D;W2Q%SUZH8`]$AN6"3 M;)@$,I+YAR"E=ID%WQ>(AP:25;>[IT)?S22:>RD>0@O"A@"Z"V]J=Z1T":50 M3A(ATCPH7A&5HDX!TS5;SHHZ8:B7&&NAIMAGD^^Y^@S&Z6?Z5]`ZG4YM7'L#I]L\^YO]+GM;"EK>; MRT]<'X-6%+Y_G7.[>4@E94_V@&.^X5J&_W_X'OM?8UVTCJ6P9`E]2UNN&OK: MMM0!9X1UZ>DD,P6XRR@=,'Y`!CBAK1`#,_9PX!KVZPBE5_,^+XS?.^)5H;`\?A?RA?EQW130H!+.P!C-YS.,"%3#EM@9#D$L MZ0TK$7!=>TWVPEY1@2MBXBSD*V(VSZG;`'@BXQ^F%I54=!RM)0+Y;8K")-\^ M$CDH>8$%SW[\S$G68.W/=*PR?)31^CW!4;.J`2\[ MO0E-H15^@,GX@RDI^OKR?-VZ3T]4--&2MWB#XD;_TJRQ$A:B&VB='*1$>8OU ML0\]A%NQ3K9BV3AKR;"/'?/UEC\*$U$TC:JNF7FL_V>2IDLF:5Z6 ME.?=U`"97"(_V^0Q)$YFA_'/_",R=?&T M+<&UAHXRW1]S9$_^29VOC)2`[>&N`G,+-$5^,HYFEL0Y(-L<^539[`W92?.- M.IO"XP!K*P/76)+J3LR#Y::]BU0]8CZ/G1&RP+C6;YTMZP20+I'R"9O(B.:. M,*&XGTW),+YN=L!^X^4`5W!^W!''FE!"^B@@8B:M(Q#-I=XYQ4J/C48J71+; M)6%F9G4AY]&E[BUL]B2>:V@(O"'Y98SF"`Y9?E)0_K4:N@@*1#`%36K3Y9FF M81+4X8%/.1>%L2.NJ1M;Q:>?3%%(DDP#U)A% MC&!75+M/M+)J!/D*4%V7`-=X1H`#Z6'+HT5UU:/(.II+;9TV*:VC)>+B)9[@ M.U55%,0P8%A88P]`6XAQ`K;FA;\'ZP1]\*PF!)U M$FY(=Y]+'`.O<)]JVIF?.`71=$=OGU+$*T#WAC`=U8: M^,-WRV?UYN=,TG`RQ-+7,PF>JB]AQ7=4.E8(^Z?39(<`[ MPG`\<*^KG6+UA=IQ(/AKZ%"SP'`.I_NK&J:TVP'2Y@A_,L8`T*C.FC5]6 M%71'A`Y4UCTR<<+HT\HG#MR%[V3^"QV*'($`M&@MW>8;&L5CHHP1^[>1O:(X M;`]4JFB[MELMQ+:A3M5X3RJU0930H?*C)+`/(88OY=V:J*'-31W_SI$,\\%J MS"%,QH>KIMZ5Q/ZKLW4]=^LMQ](T5R.+FYUC62^I,^VAE* MKK,7KDXJ`"<4/(-NP-TD:74G5ZHBQVOT/`]S]HJL5(;8Q*IJP*YU*-I*JU7; M(&YJL[AS0OBU/;-X`JUYYWP[6+,]:K]J>(!O+KQ9PG9<-HV7,ELF#]]BE:P7;>S`'@CV?VS21F7^YM*[_C\L'7L4:?>P@(G;@3B MS'*\/1Y6=YX?8TH^`46!$/&197[.<$@JJ_=L_9. M]6Q31YK.S/5P,+GM_/47SA]O-=YI5]L_.Z^VW8G&NO>/#E72E>Z`J!OWRH*X M&U3G>MD4XH7M_KNM!(N(1@\J;S54R6;>=RM7_?##@8,]V?F.'^C(N MX$H;TJB_-16UML136)>,M84#A!I!4#>.MG4NU0O6-@[0=X='>ZG_!RW&IM;M MGFC2#D6$W)G34Z).(:XGV>,Z:_DX&0N"`7;)KMG"L[[W0!TG4D*U<6]]:Y?) MTN7RV0LER]J,]NRIKF2,%]"O:?-F2N$U9XFM)([*V``VQ.#^#"!)YN\Y*#BWTYQOB_Q#299H/EYB M%L^V\JW%U@02H+EK#9Q(C))K<.8>]#;W^8\')J6NNUZ/8AT]: M8-B5?,M^>FO#Q.9A#*SY"/14$1)L2,RMGNHZTJX;B>(0P]-!J0@ M=?.1K]8*?W2LV5`"=2'+$&Q%J`@R>K.8##(!?)^T5C*D-MR.`]@\P=_"+'*-%G^%(EB95,,H0&II M&*P.E+PQ5?4JF94JQ@OU-M(C*B#>)O.)S8::?#,@F_.A/F/86HGP3Z]^?/-. M'N'.%FW#]4?F6T91RJ2BT"3[MF_BKDB)4""2!$J*#)C)K5B>[="AB@+B&='* M]!$!R=$J'?>+9E1$5/?N>FMS1@MNPY8$I*.('(:N-D9^1J43?C2Y1,#9%[$/ MG<^N"O%^Y=#%F:<]]!F([:-(V:YV<0N(?\(.3:CF,6H<,E4OQ/ZGE>X,VWT: M?C9VB:4T$0P,P1I!:=^$T03F,U5K:5'VON74FZ<5U7^T>#5X0/'.//$18@=C M)4^Q-+XZKU2:`7!L1/Q85CHHHW--7%^*\75?3GK58B']85@6@GD!*_AW=F", M"DMR)S$R.82ML`O-IC,6=_06'!>E82B8P(B97,]-B[GLV4WTYI]Z8JG7^1)W M!8`B"%/@O8X].K'QU+YN-9K\:FXU]DM'JY("4[/K'KE1T M951-=_%!IE"Z%:C&OJ%64TU-M^#0SCE&C5&W3X&$W+K%1T$4GMQP];%.E$*0 MC;WM)%SXH:DI?\O;IH#-3B>(RG91)U&3*.38F]&JXN`DC7(6),F45X]D]O?.@X54.>_DC_]EIR*<[%&(=I,PM_A@WOL MBQ:]1GV%%)&P91%Z7I6^IM'D[,NBHO*LL$C6NO(JXI9W68AJ*D.5)&N:03K) M$BV'=U)C()=CFJ:2>]`X"5OOZUYMRH'A5/:`AM"'7EH,128(H"+^>)/_B2^Y M"`5T`:]S710Z+!$,A^:I5T>%82!2G9P!5@A<0?90JS4JCD*XRQZ$T*;1)N_=]2#-6 M]23=P?E8KA)\%NFQ.DR9EHAN(C9'IKYBEGM^%$BO?]4L12$);R\=;0DZ`?1M MK2JF9W;]R_#:FJ]:Q<&OIO5=RV`C/K86\?5SDYOA-6BU*R3XT<1/_MD[^%:, M\BX5:>X<;NW^5VQ+\.X,HZ1D,UZZ%:9G1UB5Y*3\#U<+56`\Y2I\''U""7?% MPLA-_%J?E=7IJ=6$A--G"=NM=.)Z$Q6G5SDUFF1#>*T*U>RC'49N>'!ZHA[^+6<)%YA-T)]_6]M`AQIOUQ"A M:E2I$F3LCM7W8(?1/R5+X1(>_&&WM;!U6<@C&Q^MY6$!?A_C-4M3D7,DP`A[K1@(T@O^2*->3/ M=0K@V&(&0UV20YC2``G]CVM,M//=J&U/?6AS-#=VN'XAN1BL8!ABQ=1I(`^0 MM6HCUAT>B:;Q-!Q12XAHFFXDLYS#]Q#DQ^$=M9W M_#^'>G9G*KN>H&J3S*@)8'?[^,NO@C0K/S7X#<-P]B%HIK2E>%+ZT-W7B?7A MOLY[[ZX3:J$8=2EN"`7S$5=JI_7_0UKKX<)[M%L);R,]D$<^4/W`VUC277$+ M=D16X:+V7:`H1/I=DU$TZRYCG:T5C55Z309(MX:S#AVA%/]U54=K9:;70G8- M"2/;9]$!,"]7)?9\#_!L=<,-`^;:V424LJ:P,9S1ESI[&VM3GL2_.M?Y?4TG MY_(;RVX7X=IXV3.NN2`4Q`'N?IJ*CPO8[?)J]K67F;>-S=O>.R"S)^MF6%&J M\:9R='/E-MK]X^W$JP-//)._MNO:JMCT^)9[^NUN7]=/\:^?;:W+J;V!L(OT M[>Z^9N\XN:+;IK[-GKP_>YYM=#;QY['=J-0>XG"'L]_A\ZKM9S][R-S^^0TA MQ[I7R/5;+:W)?OSD2;B46JFZ].UE.QJ0;@3JS/;DRGS0SG>PVW-Y'.[VZOZ^ MHR+X#KS^>,U2Z_/N#'K?7._Y?C:@D-$D?+>F/=5?LSJ/]_U(:OOW]-+'ZNLA3_!P MUO-+\_K_>S8L=5\!XW69O0`&"D>YJT-CM1X#=H'G%[YHV;E7[B4J9*EODZG(L:,+ M*1SIF_-)_69.1]3*3OR*.3Z%#B4H,6/)]O;`[^R3)R-4*^93 M:8AV@SMFMK=6'9P5W%O"6N7:=&XK:H\0PPV[ELSQ;MOH<$'=@_J(MW95"Z52 M4:X2/?GNMT<-ABF+B"G+KU[N-JY=@.7XGPUM@[A47V#@O'^YCL2H=K5:M?![5%C_R/WV.HY< MW2`HZ^SDEI,<#R#^FAL*[YEF<%73Q4;&A_S8N+KJ?CT:W\!-TF52[6V(CP4I MA$N@UC7YT:]N:C]^W?3;[E.JSTGY`)B1Z['"F79O7GJ@1NTG';BE&Z"T7^F? MFBFC!_0VR/J]P>T[K<+=-H/"L*TLW$BTVYXN9R"VLG@10/MAY$040;H'DB^B M%CH_:7FDM2^$NR>X#5FIYD+':I;M"Z)ZM>;C<-'4VIX;4PFB_]#II!/<9,!- MHCEH-UP)!0\%X.GR*D\L]TU9AT72HMJS?)SRW.TGSF/*/;:?1'VJ7'@MR8X% M7/74FP@!:/?P^+C?D(9#Q=Y3^R7,DW^GU6):E#BE&';(7_B%J7]_[QZ-\:_A M(J[^05[WRFDF^_<`8>@XIW9!E2A`17Z7D`]>4:V$J%:'?[=+^6LZ[^:I[AZC M69UVK[?JS6/5N57YP<=NI'!(UI2>Z4M@!J'VX`:JJ.NI,6NSSM^@5*O=9:W\ MX(4`B_)^(T,=")HK5%/=UU_[>0T;[#P2?ZF(J?T`=*C]TTN.\82$0/O1X\-^ MH7P<4O%]P8(59?NM&W:$DL_NW!E%_9CK8]@E610.,X$%7HX_PP$2:(!>.T^< M[73F994U_Y>\:UE!&`:"G^0?"!Z\"X(?(!;TG/X_SLQFW9BDI!Z*B)="2FCS MZ.Y.=B9I?7?%DYK0<>R?RS%HLPDVX>BRU,\Y"MPQ!1N08=TZCT,YZBB32#E# M74]'QKB<1_1_LN1_&$(B/'D92=E8\HSC'=/!.)3V:SGA>NZ-UAR.17 MD,*4]33:*WGY.+_X![6/'5Y4L;V&P7\E-@B,Z$XWZ"H M@\D)8$5.3;,7R,GCJ;=>38RPTV\KV.T>T..[[M!GHBXAE MN[Y8A/[:CMU'UW/C-R9+U_S%U8>G((SL1P^@OO9,>Y')9A]*XGUW$86;,B=30V2"#^IE7G9K MQ<+7B>1.:L'-]2H,B"$`FA%T]1*$7P(+OX-@`//P9S?7FY^TS[8'1WH(;Q%Z M8:3%X&6PCQT);-])?C&W/?["0:SJOG M$=%D-HT1!F=3'X]0FWPPR<:#]3;9/^ZQB=,U:-9U#'^<+F9%O5W2=)7CHL3A M,;IR7Q$]T=/C5+I5]3&!]=W-MJ]\T7[/O3M`(FEG1K[-=<2RPU1KZ9D7>FR@)C5^N/R6R3F+T@V$K^MY^9"\ M;^*@%8[<7,/L(':BP((/6OK^X6T-0]8`)C(8]YWD=PV_?HKLMY[!@E.LP2;T MW"6B>)JS@7(Z4)D/[ZSY'=-+D(FBJ!!J6?/1"83>S29S^4CGDXELH88%+\E" MWP_P)5FH!?_-I7&:=E6F+)"Y/"UV<6+;O1Q-)I-Q;S@>CR=FOV>:C.3'-*+= M8.F\.CC7E493&<$`$$SZX\G0`"!=<\Q4G15!'P",!H/QH#)0@4 M>94@4.15-KZ6F*NP?*LX5PD"15XE"!1Y5=K@,ZW`$^5>)0@4>94@.+=7LVG5 M_.[.8NM#Y9%9]?B8S>1@[O@81DLX]Y6=T.GA[#$Y=G/M.:L89HF1^_2,?^-P M#?\^AG$,9XINKI>N_10&M@=O.UF+[&]-2SB7!J?-IGK\["Y>0!DWU4[P)BI. MI2&O1":.\,V1V1V9`V.83*(DJ?:=I;OUR];ENO?&"M"(W#8;3C@,I+*3=F M!K[8B'6/I0TMRG8V--AC94,+41OYN,F\RPG/EQ.P/.]!LL,W]_/#8("BI&&& M9Z<(IO4)SYXDYT^$R]U^)^R3 M_['*AP&PVG5S_;HB&S!@5PSN4,#]'?@6EI33MTF7GWP`FJL:&96--'N]]M[N MM_ZC$UELJPQ3P8[BTG7Q:<;&*L7G]Y[[%/@.6Z_3$S'?16'L+&*VE8D9F$LMGVJO MJ\:%U%[5I`G\GC5/9D_)S!%\P>929"J-E[79V=JI]AQ&[D\PR<3+VQ:PF.I$ M.EX.&;L+>N1+9*\?G%>8BB:GGEY7U6N]@"1;W]@-1AYA):9"/RSBZUH;Y=+Y M.0++\40T6LXF]8T+\SN1P2]N-T9((PAJ$RC'J8PRY<*Z3U&A#7"B M,LL-LA!]?I_7+$D?%'#["E.;#)#.QLD`X>)H'46S=$VVL4`]. M@NL06FS9NA4^W*1"!V.EP9"&%Z(D=1'.O7?J!F4&B;U3X&X3=J?F\)>$A<8; MVT+$MA_5>8JR(Z5$40BG"BDI0`_UFQ3EE*7VCN)3JJE:\;7@H-K5'J)TEI)8 MHDYK48\JHQS/_]3546&V*+"FZGAZ-.W#2WKGW(80VEU(#YQLF:$5(-D#-^H0 MJ8":DE\X@$^'$$8A4E+L:(1D4,)%&=QGZ9>!L+(P`-PZ"BLG3I2R]C7\5]#- M[$!L<*2$GE#FD(:Z^^R&B(5#9;<@K>ZT*8.BL1C8Z\" MV*\E1_C0*S'(Y\B9@HSGKFE4S)>2(R`V!R'0L\I.M\GNE&FI$Q_O:\\.[#B,WC3(E&/!1!-"?X5DW\!@=#7A)&.)C&/?IMA&3YP)/3T_08QD: M:)V@X>,/9[EMT$#K1`Q?5''\)"+F0[#>YA[B:REVW2(B/KK!B[/D(X=G&&P M@V!*?_6=^SF,F8BI7KS_B'<&A"R&J2.4FX\;N-L<_-6VD3O5?[Z;C2:W=Y9Q M,>[.QA=FWQE<3`:SVXN!.9_=WEJ3KM&=_Q/,`J2HU-P7\JCDUU\B&!S_;C`6S8/YD9T=GDC_:Z^1\```#__P,`4$L# M!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM M;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC M@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C M=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[ M[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYE MEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%T MS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/B MPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[] M_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N# MUO5D"53,+2L?VW9`X8NXS'"LY1 MZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ M2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6 MKZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[- M&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F M<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4. MEJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P M!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_ MS3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A M0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N M'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+ M&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<&ULG-M;<]H^&@;P^YW9[\!P M7[`QAY!)\I\:GX\[.WNX)N`D3`$SV&G:;[^2)9SH-=5CMA=IHOQX$=:#+"OX MX:]?A_W@9W&N=N7Q<6B.C.&@.&[*[>[X^CC\][^\;W?#056OC]OUOCP6C\/? M137\Z^GO?WOX*,\_JK>BJ`>LPK%Z'+[5]>E^/*XV;\5A78W*4W%DOWDISX=U MS7X\OXZKT[E8;YL''?;CB6',QX?U[C@4%>[/?6J4+R^[3>&4F_=#<:Q%D7.Q M7]>L_]7;[E1=JATV?=_M=_;LI.AP<-O?AZ[$\KY_W M['7_,J?KS:5V\T.G_&&W.9=5^5*/6+FQZ&CW-2_'RS&K]/2PW;%7P`_[X%R\ M/`Z_F_?Y9#H[34C\(_S8%N\K-_W]3_+CZ#8O;[5;+AG[!7Q%W:__>T4U88=459F M-)GQ2IMRSSK`O@X..QX-=D36OYK_/W;;^NUQ:,U'LX5AF8P/GHNJ]G:\Y'"P M>:_J\O!?@4Q92A29R"(6Z[W\_60TN9N9L_D-5::R"GO>MBN]NS"_O`Y^!&4? M%K?WP6R/!^O-[;W@1UX/SVP.Q7E6G-7\[ MFO=_'ETVK!Q_Y_IQN!@.V,!5+)(_GZS)]&'\D\5H(XW=-1-5K*Z(N4H<0=C7 MSRR.L*:S)3J_@]3-##A%>,^DS1%4%[$_ZO>D"2N>9+XO,&C9=.&%6UP1`/K49N)R7*A'F.WA_&ZQIJ0_/G7#'FN MH(<)>YBHAXE[F*2'27N8K(?)KYEE.Q9*+MC4?4,NN%9R01M6M,$1#>*\P:/D MT@:/-OB7AL\H=2(0]#!A#Q/U,'$/D_0P:0^3]3"YWBC#R\YF-PPOU\KPTH85 M;7!$PY?AI0T>;?!I0W!I^#K>=VU6:K8V_GM;HLL`6AHUD>^HCJZX5%`X4+A0>%#X4 M`10A%!$4,10)%"D4&12Y3BAO1[:HOB$T7#\.V5FX#81E&>J$9@NC"PT4#A2N M$'?-Q<#$N#/X/[4C'BSB0Q%`$4(1"2&[.FMZ2KH:PR()%"D4&12Y3BBQX;LM M_:_?N":Q,N$$IWE3='AFD3'LM0AM87110<*!PH7"@\*'XH`BA"* M2(CYHID874+#EC6"&!(H4B@R+7"24R)ML#NV&Z:3@-#)CXF`17B&61?:?P"B)')L(DQB3!),4DPR37$C5&?%NI_UF+;YUVYAZR M8+(,(DQ23!),)CXF`2:A)&W*2,@B7"+&),$DQ23#)-<2 M-4%\D^N&!(D],35!9`_)-@72)@@2!U=Q,?$P\3$)))DW2YC%M6NF$%>),(DQ M23!),$XM1-F;N M-W(%X^&B/B8!)B$F$28Q)HDD\AA8H\5TJ?SK'(,4%\W4HM.1V!61A]4PS$[1 M7%M431S?=;QAVA*;E.JT1:Y#;/Z'7Q9+;>(@<7`5%Q,/$Q^3`),0DPB3&),$ MDU02,T'P`0^YE*G*9D$\TV M=9N>S97O"A,'$Q<3#Q,?DP"3$)-($CG7F",RN\:X1())BDF&2:XE:I3X7F4G M2A.V4P"B)/8XU2B1U:=MZC9"990@<7`5%Q,/$Q^3`),0DTB2-DIT>R'&-1), M4DPR3'(M4;/$-R__GRR)34\U2^3M99NZG5&9)4@<7,7%Q,/$QR3`),0DDJ3- M$MFIBG&)!),4DPR37$O4*/%-S4Z4>ISAQ&:H&J7.$EVW8RJC!(EC0N)BXF'B M8Q)@$F(222*C9(Q,]BG-=MG+OB'3>XQ+)IBDF&28Y%JB1(N?VSK1FL*U4_,P M<$XG(OKW M%(F^I(A,52LB>(;42U9'"FV"1%\TQ,-5?*4KUJPYYZA]"7"5$),(DQB3!),4 MDPR37)++(*K'18T0W0WG&P(6O(B;7-D5G]*_JTBD&>,5)@XF+B8>)KXD2_&1 MIM&,;/('N$2(281)C$F"28I)ADDNR>6@+/XT$[%!5F:BGC'B#Z,S$CGN-KO9 M">U28N)@XF+B22(^2V8NU#=6M3\/HYB3 MQ#UIXCZE0W%^+5;%?E\--N4[O]_,8F_,MK6]%^Y[_M:^\J\9Y]7 MYI_;;1_`;ET[K5^+='U^W1VKP;YX84]EC!9L67\6-[^)'^KRU-PU]5S6[*:U MYMLW=I-BP6X\,$8,OY1E??F!/P&_Z:ZY[>KI?P```/__`P!02P,$%``&``@` M```A`*_W\)"3`P``40P``!@```!X;"]W;W)KZ)",EZ$"(_&R*-%PE-6[$/TZ^?]U37RI")%2C)> MT!"]4(EN-A\_K$]U?)D MB%Q.Q..QO$IX7H+$EF5,O52BR,N3U<.^X()L,UCW,YZ2Y*Q='?3D_+`3Y\$ M2[^P@D*VH4Z*;'_0C":*IE`YY.F*;#E_U+<^P*DQ!)$5H(/(O^^KLGT37DIWY)BI[_STF;+]04&D&:1!9V.5OMQ1F4`9(-8HF&G5A&<@ M`9]>SO3S!&DDS\8=2]4A1)/Y:+883S#@WI9*=<^T)/*2HU0\_V,@7$L9D:`6 M@>^3N1Z\7V12B\!W+8*#H4Y\LZHJ87=$D@?#K68%T M:/96PR%:0-U")*$T3YOQVG^"Y"Z<0,G;I^8-(1E!+(PW(B&X8GHK-?-B"&F'6+:Q*V\Q_\C+&<@,MR9 MAD,$JVXJ,;/C1H;H.IO;1-PG6N^6,^B$X(G=#C#7N]XO M&-/OR\%[@H8=8T[@R"#=P+CM/=,#?>2"M^5[O&G8\=;*FHW#()8WIT_B/M** M6%V`X8TV/'$5[;AS&C"J&TRSQ*\PE?WKO'5Q8;';J[@Z"G3:,:L;RY[1, M_`ISR9_>HSO^]*MZ`CE]XZ5D=O:NS\#IR0@;INNS]6">P!J95^V#E]/KQ6S2 MRMAUUCMVQ^<;_LS^;OES6Q?WWP&!TT7Q*TR[!ML?K/,=_C1M/X>!TYX13'6: MZ>8O:(/7">PS+6+\F8'-S!\Y%7L:TRR37L*/>@##D/KF;#-1UJ->&ULE)7;CILP$(;O*_4=+-^'8PA)%++: ML+MMI5:JJAZN'3!@+6!D.YO=M^\8!P*D35,N$FS__OEFQ@R;N]>J1"]42,;K M"+N6@Q&M$YZR.H_PC^]/LR5&4I$Z)26O:83?J,1WV_?O-DT!I6,BXJHF`H!9 MQA+ZP)-#16ME3`0MB0)^6;!&=FY5?/6OHIU5.PV;[8_=06 MX*M`*.[($=[*M43TY88)0>I>/7+B-R3E3'Q3B8^T)_6/+;8C:`!^((MN-X$<$AP:>*1NBCZ"[!NL=RA:K%%T%33; MSDR`]YEM\MQ+Q>*,-B*!#`U)=+9\.$W7B?0FT`T`7'<^1M@9S7R@F2CB:XH1 M(Y@,&:^S:7&$(0'GY`2K"9O1#-F\A3/6Q-KVO`36:$ZAK>?[C;"*)1Y+0 MO=N3JL53UK.O836:+JG]0]M%:+7:X&+1$)DN:II,145. M8UJ6$B7\H#ND!U7J9_OF?>_I]W4ROX.FWK9`NU^`IMJ0G'XA(F>U1"7-P!)* M#C45IBV;@>)-V]KV7$$[;6\+^'I2Z`>.!>*,<]4-=+?IO\?;WP```/__`P!0 M2P,$%``&``@````A`&VA&_ZA`P``8PX``!D```!X;"]W;W)K&ULE)=;CZ(P%,??-]GO0'A?;HJWJ),1Y)+L)IO-7IX1JI(!2F@= M9[[]GE)U;"'4>4$Y_?7?]G]*.2R?WLI">T4-R7&UTFW#TC54I3C+J\-*__,[ M^#;3-4*3*DL*7*&5_HZ(_K3^^F5YQLT+.2)$-5"HR$H_4EHO3).D1U0FQ,`U MJJ!ECYLRH7#;'$Q2-RC)VDYE83J6-3'+)*]TKK!H'M'`^WV>(A^GIQ)5E(LT MJ$@HS)\<\YI M)^E5N[WIR)=YVF""]]0`.9-/M+OFN3DW06F]S')8`;-=:]!^I3_;BWBFF^ME MZ\_?')W)W7^-'/$Y;/+L>UXA,!O2Q!*PP_B%H7'&0M#9[/0.V@3\;+0,[9-3 M07_A<9 M/:[TT<1PI];(!ES;(4*#G$GJ6GHB%)?_.&1?I+B(P'*_2N"I3#VF<$K?:IK,%D"67A=.^/1 MTGP%Z](+L^EA1,+K(28BXG,$KA\#B<16201*(E02D9*(AP@3/+X9#>E[W&@& M,Z/95F+.;^2`)P=\'H#I?%@V'DNF]3&NR`0/,.$#3-3'3,6QXF%&L&_T&?L8 M+-@G!SPYX/,`?^*8XULY$%P#`P:'?8RTMZ,K<\UM?`WT"PLNC$47V#DT@M-L M^*EEG8"[VQFV8XF9V'`&KK?=(^T=3TGX2F*K)`(E$2J)2$G$0X3@-YS.]P_M M8WZS3BL=]O;-2V<\D_SFS&3:'J*VV.CQ1ICD34!*AJ\DMDHB4!*ADHB41#Q$ M"%9/1*N'MS2#98OGHHL;S@RXZ"D)OTLXKO3H;+N,E*V@2SBNE/.PCW'$%45= M1AHI[A*.^Z$B^`UO\<]O;=9)\MV5"P#.#/FN)'PEL>7$Y0&R#$M^C2D50B41 M26-\&-F^D^,A`<%J]A5P5V,]=HJP3K+54KHWG)FUA\AD;EG2UO3NV]UNN\_; M!U*U51*!D@B51*0DH+AG;O3/E'O-BW=>VY:H.2`/%0714GQBA?D(/+I%;]\, MSR-684GQC;W8],4]>P%E`_#FK0/4^'5R0#^2YI!71"O0'H:RC"D<>@W_2N`W M%-=MI;W#%*K[]N\1/N80U!F6`?`>8WJ]80/&ULK)IM;Z-&$,??5^IWL/S^;`/&!I2DBGF66JFJKNUK8I,8Q386D,O=M^\L MNPL[.WNV<[TWQ^7'S+`S^_1G\=UO7X^'R9>R::OZ=#^U9HOII#QMZUUU>KF? M_OTY^>1-)VU7G';%H3Z5]]-O93O][>'77^[>Z^:UW9=E-X$(I_9^NN^Z2S:67TN3W#GN6Z.10=_-B_S]MR4Q:YW.A[F]F*QFA^+ZC3E$8+FEACU M\W.U+:-Z^W8L3QT/TI2'HH/VM_OJW,IHQ^TMX8Y%\_IV_K2MCV<(\50=JNY; M'W0Z.6Z#_.54-\73`?+^:BV+K8S=_T'"'ZMM4[?U#<'/>4)JS/_?G$.GA M;E=!!JSLDZ9\OI\^6D'N+*;SA[N^0/]4Y7NK_'_2[NOWM*EVOU>G$JH-_<1Z MX*FN7YEIOF,(G.?$.^E[X,]FLBN?B[=#]U?]GI75R[Z#[G8A(Y98L/L6E>T6 M*@IA9K;+(FWK`S0`_IT<*S8TH"+%U_[Z7NVZ/?QO-;,]UW)78#]Y*MLNJ5C, MZ63[UG;U\5]A)6+Q*+:(`E<1Q5G-W/7"L5B0"XZ.<(2K<%S/EK:[]JXY+H4C M7(6C-UM;"]]97WX@W.WSA:NAI3>FNQ)!X/JQ5J^%(UP_U&J8K7VKX2I;;<^L MY:+OHPOE]84?7&]JZ)R/CGZP1457/-PU]?L$9C!T?WLNV'I@!1!,CC+^Z&'< M?6_8P7AC01Y9E/LI)`\#JH6Y\N7!6J_OYE]@?&^%S<9@@RU":<$&,PL;Z2#6 M0:*#5`>9#G(%S*$(0R5@B/^$2K`HK!(RAXT$8VEL+6UI(5TB'<0Z2'20ZB#3 M0:X`E#9,T)^0-HMR/X5_+PP`;K.$^@]&2ZT4@\E0"T)B0A)"4D(R0G*5H(K` MRO,3*L*BP*2"IPS9TCG!C2Z69#`92D)(3$A"2$I(1DBN$E026%35DICW(+D8 M,.,^<]GB#2=+&()*+3RM[P=KW3<8#=U'2$Q(0DA* M2$9(KA*4*!._RFYV>9PR8YPH)VKW$1(1$A.2$)(2DA&2JP1E!?OR[5DQ8YP5 M)URK]OMJ*(@U#--($#1#[17NXG@PDEV"Y09$X/=OMJ^;FI84F!+,72U`T)$R!,6!!>ECPL[5B_">54D4LHB$0OU MY<%>6-J&%8\&,I5$HC%,*M$0QL&5S48#&2:7J`^#2\(4C#+*E9(8J@`Z?2@# MESZP)\FG;"R!^!L$$UVA1*O!*A+(@?UA7,!M;0&/1RL9/J&Q4FDU/C&C*$>. M.'LF9'XH>ZZ`4/8"P>@;\_(6N'-"BUO9XU"))(+JC8Z.YA@+J^6Z'SV>X[F> M-J42&6B,G4IT,7:FQ;96SD)[?"X#\?=,5>HR5?)C->2B"=60(QOM#IZEUU!8 M+95!Q9%K]=59^VM;_#X M8B)('U_PSONA]88+*50F@?!0TU\%+&Z%AAI'#NQYXU#SM!1CX0A6,L5$QD+C M:*TM8.GHJ(;7K++12H;/KX7'166"Z_\6E8LV5%2.7-8YPXNGY^ICCUOQOA8O MEL(1%-/H2.>OL.+SUUVO'$_KL(2=R,#.HL1.!7(OQLZDE8R]<'QM;+C7[^J)]Q#DRC:#FP7?/*>./*!K6?([7]G%QKO^X70U^S2F`_?Q17 MN/TFM;/B+C7[^*,QQ#IIRN=)N*E!L(CU" MBB**8HH2BE**,HIRA'!^3"9H8\QVV5O31U=VKC?0L!LDB#+1?>T5);0'JV$C MIRBF**$HI2BC*$<(5X,I"*4:5WJ;ZPV4LI`@XTE-:!,44113E%"44I11E".$ M\H-3LP_DUUOCS5J@Y7C&%%(44113E%"44I11Q+[>]\MQWPB>'_\:SS^0'LOF MI0S+PZ&=;.LW]J7=84=I`^8_`]C8=L#V0!ATY,X:[O0OY.2.!W<\HX\/=WS3 M'6C;4!!Y/]AA73$&?C0/(&_K@,'J$;Z8,WRP"^9AFX&\#''P.'&AI+ M"!4T%A#J9RI?SJIG:A"8EHO^#:+A/Y'A?W3B`.2I[N"7+?U9 MR!Y^RE3"^?:";4K/==W)/^#1\^''40__`0``__\#`%!+`P04``8`"````"$` MY[$=OPX'``!:'```&````'AL+W=O1]+R))&P'%CB$6B!HDC;:YJB+,*2*)!TG+Q]9T_D[@ZCV$9N MPOCCS,^=V=G=(77W^=OY-/M:M5W=7#86F2^M674IFWU]>=I8_WQ)/JVM6=<7 MEWUQ:B[5QOI>==;G^]]_NWMMVN?N6%7]#!0NW<8Z]OTU7"RZ\EB=BV[>7*L+ MW#DT[;GHX<_V:=%=VZK8,Z?S:6$OE_[B7-07BRN$[5LTFL.A+JNH*5_.U:7G M(FUU*GH8?W>LKYU4.Y=OD3L7[?/+]5/9G*\@\5B?ZOX[$[5FYS+,GRY-6SR> M(.YOQ"U*JIMN#B&A@X?Y[5'4E9!1DYK9'E]5<05(G"5(YB[MK=:,Y$;3X='L*'#53BNYVO/<_WU"M`-1U\XPE4X MDG>/>B4TX#J,VEY[Q/-IZ#<>#@N/C1JNPZC?%&X@'.'ZWE$O^*2S&HJ*OKB_ M:YO7&2Q,F-[N6M!E3D+0E<7#AS^4TX^J"%376 MH^($HE*G;VU,WV`T3!\B,2()(BDB&2*Y2K1`:4^KG&:WZY0:ZX%RHDX?(A$B M,2()(BDB&2*Y2K2HX%Q^>U346(^*$X=UD>QWO^F-=/F\;V%+@2)F8:@<: M$=&>4!$]*4P73BPE*Q(I:9&(2GV]MY?$.+#BT4"&DD@TRJ02#3*.OGBRT4#* MY!(Q&3TEM(-1JEQ)R406H!D=TL!;'SB3Y%.V1"#^8D!+82>1/UA%`CEP/HP; MN&WL`/%H)>43K)5*J_&)&4:YYJA'3QN9#T7/.R`M>H[LL5W;$8%<)7J.O+%4 M8F&EH`0[IM@JPRC7'/50:8ORH5!Y;Z.%*A`LM'$*_4"OPQUM5V"A\-=5T8,+ M!(4R.CI+W3$6CNZ*+92U[?F!89)@[52BF]J9H1TXPMD1S],F`7&D6>SY!`2N"MB MO"+%P@UL9%0)5DI'*_8&NB20("//V6@CE7)-2<\/[:B,_-@^_8SRGL.'MV5: MKCBBWUF40C*"WA%AI1821Y[N:*R&6#B"E8PQ$8ANJ\H3C>))1T?5RM/G,!NM MI'S^,WD]J[1],[)*/':D_^3\XGV?EDG1"JZ'4'>$(VT/X\@;,QD+*P4EV#'% M5AE&N>:HATI[.C-4^$#VKOKA?:$6-4=&_1CMVHX(JS'J2"*X,Y8!WLRYHQNP M%>D3AZR,2DFDT*B=2G13.Q-60MM9$W]M'$*Y%&+:>CIIFVBFDU<.:P:_--0%C?4LA;W[67"K/5N5R!W[.EV M&$48Q1@E&*4891C1C^!T[^>#X/'QC]K\@^2Y:I^J774Z=;.R>:$?K!UZ)`R8 M?TW?DB"DF8*MQ[QC+^6'=N,.?(%_8">'P;?P99ZUUR:W06CJ"4X(7XWPDQ]< MT&>MARGDAO!-!3MLO1`^04QP/X27^`F^"N&==X*O0WAKQ#PB7DC/3'P'SLB0 MGH'X3D1\\)EZ.AP+X#-U)R(K\)D:&>R,L`L:GY@'<&$)NZ M$Q$;?*;F"IIO\)FZ$Q$7?*:F!=HK\)FZLPW"[>2@=T&XF[P1!2&\+T^E>0E/ MGXH_"4+Z[HA=TB"$-^8)3I8P7.:Q&`H/?MFY%D_5GT7[5%^ZV:DZP$):LL.U MY;\-\3]ZL54^-CW\ML-VS2/\AE?!&^"2GD^'INGE'_#HQ?"KX/W_````__\# M`%!+`P04``8`"````"$`4(TG:T8.``!=30``&````'AL+W=OZ2._/?HXO;ERC^[5Y\&.]VV^VKQ^' MXZOKX6#]NMH^;%Z_?AS^ZS?]R^UPL#\L7Q^6S]O7]R/-"?NZ^C_=MN MO7QHG5Z>1]7U]7STLMR\#D.$Q>Z<&-O'Q\UJW6Q7WU_6KX<09+=^7A[H^/=/ MF[=]BO:R.B?%?-JO==K]]/%Q1N%$X4,SY;G0WHDB?/CQL*`-?]L%N_?AQ^'F\ MC3A[9`_]ZL?^ZS_P_V3]N?9K=Y^-OF=4W5IG[R/?!EN_WF3=V#1^0\ M`F_=]L`_=H.']>/R^_/AG]N?=KWY^G2@[IY11CZQQ<,?S7J_HHI2F*MJYB.M MML]T`/3OX&7CAP959/E[^_ES\W!X^CB3,9D/OJSW![WQ(8>#U??] M8?ORGV`TCJ%"D"H&H<]"D"..D^A(G]&QJJYNQM=WDQOZ]B..T^A(G\EQ>C6> M7L_]41_QH]8V7?I,?M=]ND<IDX0>P M#]M(H"30$A@)K`0N`R,J0E<)&M?_ATKX*+X2*8?[!/K25"+M9)%<&@F4!%H" M(X&5P&6`I4VS4J8]H06JO+2D_O9.M(@<[>]@,Z5R=X-"#(FZ,^E2!Z*`:"`& MB`7B)RPK*B=?C\K+PQSRJ0*8V.K/OFHOLZHZ[[ M@"@@&H@!8H&XG+!$O;[-3E['QZDWYHD&DG/W7$0+71Z27UR'Y&8IK>B+WNK MY-@@4H@T(H/((G(,\92]!#D_Y2!86,H!L2X%U(P!*40:D4%D$3F&>'Y>8F3Y M^8D[N?579)>*"2\CQ,R-2$S=.]G=P3&K4-,[IA&@$&E$!I%%Y!CBY?#R(BO' MB1D)64C?WC<[L*FBH?X!&QW@;EU:"50J01&406D6.(YR?$V(G\4'!544KQL[/< MP>JM^B[M'!-2:*41&406D6.(I^SUTOE=&M05Z]*`6)<":BI`"I%&9!!91(XA MGI^7/5E^[Y_`03^QU*.DHKZC92%N85=RS\I+>2^\>D7:(%*(-"*#R")R#/%J M7*3%*M1B$67)U(@:1`J11F00642.(9Z?5SU9;Y^8P$$CL2X-B#:STSRLJXC" MC:WV%D-"M'1E'2]VNU1OE6+IA/I8)B$>2VROV-XJQ7()M;%X%;PVRJK@Q_QX MUFX&'9XVJV_W6P^*V_43N@\3[LY406"QX@3$BA-1GU`3'2<^U(]/U;6\IZ-Z M@Y2+3J@/8Q+JPH@3H^T-4AB74*$D7B"52W)BC`1EQ3$`V\WG$BKEQ5LF+382(N>'2RZL.;A(Z&M\F*AQ<*VR6K<(,]O]\W M\3+N/>.H=125]+%(3K+3QT0,\SHZTAFNKV1PG-#RG%52J`P5'*L5R+!8?;51TCF?E M$BNLBHYDE5+4&,OT5GDL,:MM;Y5B.1:+E\M+/SFD+BU7D(_Y*D7K;SNZ^GSJ MA/*A%*UH&<]J`Y,R6O'2BSFO,;Q)Z&AXFZQ8^*DX")>LVJ/G%?3B4E8P.]_] MMGW[L_,=2:5TPO,KM1QRH%KK:)4)H`:10J01&406D6.(YRVT[?$SV00%;$24 M3-;[4['8UKU5<-(H5((S*(+"+'$$_Y(@'K5TC9I0%E_5='JPPUB!0BC<@@ MLH@<0SP_+S:SH7RB2X,T9=,^('Z'9RI.<+5?"ZDPV69P@T@ATH@,(HO(,<13 M]A+R_)2#X&0I!Y3U7ST!U"!2B#0B@\@B<@SQ_&A9R_/S:GQ&9_`+GQ69^##B MC!B0F+X@(#JK?OH"4C%\5D2-R""RB!Q#K!93(42/#^_6FJ<[.0 MUB?H[8!\<7NE/967+]&1K/H)W#DFI-!*(S*(+"+'$*_&15IKBEHKHBR9&E&# M2"'2B`PBB\@QQ/.[2&M-46M%Y,=3UJ7BPK+NK5+_-8@4(HW((+*('$,\Y8NT MUA2U5D2L2U%KH95"I!$91!:18XCGYX5-MB;["7Q[]YZG::9!(N4Z,R(Q@\6U M?]U;]=V-<@NM-"*#R")R#+%RS"Z26ZTUEUL1Y=V-J$&D$&E$!I%%Y!CB^0FY M=?Q\Y(68.`5'Y/?[LADL-C;J9-7O3CPDUR9$F>E^E2@Q\A8[Z+$?#''G:0F)E:9_H:E1;LX#\ M=5J?Q$QL,M71*M\^3(XTB3-'L4FBT%&?Y6B8(\_>*R.QF,7;.">R#Y(J7[MF M`?&]YIG<%DA6V09A0B1"LNS%R%71RC_&F5F)JQ-=CB4$KSD5B]?(BZ-WU2BH M*E:CB'A'2X4V"U9LA$1$\RO+7N@`E1Q/U*@82\PU?/(I1TLX#$ M.((%,UKEXR@B2J^OT5Q,/Q7#GQI'Y\0RIV+Q&EVD!6>H!2-B9\I@E:$&K10B MC<@@LH@<0SP_+]+$/'G?8\:S(/?8Q`F("Z.Y6"'KZ,C*T3FF4XL9X&_<92#BA+IIX!:A`I1!J10601.898?O.+A%]KS85?1/S2 M9B[/%[U5ZK\&D4*D$1E$%I%CB*=\D1:08 MXBE[Y7/VFCP/.BE?DR/*!F.-J$&D$&E$!I%%Y!CB^7G5DN7G99B_XKOP/M`\ MB!^6>$!B^@I=74?'K#P-(H5((S*(+"+'$*_%17*+WI(A+]PCHLV]-'!K1`TB MA4@C,H@L(O_VCG8WNSV(D%]X&T=X6<++>O=U7:^?G_>#U?:[?]/&S92V"SH< M7@-R/Y_3>T#:$-!RD]X0`BW7U-)>M$.+?ZM(>^T.+16U5+Y>T#*AEG;'&5JF MU-*J>&B944N[>,J6Z>W"[]`5OF=Z1RUWI989Y4/;/`6?&=6`9&VIA;Z'%%ZI MA;Z'M%&A94HUH#LZI1:J09@:D`_5@);1D@_5()Q`P(?Z-(Q-:*%\:'^V$&U" M/O1@0*F%?.C^>:F%:D`[&J46J@'=ARVT3*G68<,'CHW&#MW/*_A45!VZYBNU M4'7"LVDR6D75H<=K2CZ4*3W#6VB94#1ZWJ740M'HL9!"RYBJ0S]'*K50=>B' M/*46J@[]J*704E%UPK4]Y$/5H9]&E'QH5-&/"@HM8_*AB]E2"_G0KT)++53K ML+K+(QA3=>BGA24?J@[]`J_40K6FWZX56LBEZ$$.17LJ<['*5.1BC:G$Q0J/ MJ<+T$^?2$8T7][09B"VT`[OP&Y/8HJC%[SQB"^VF+OS6(K;0BY<^E_B][ZR" M_;WOWA*GCBK-B<_3Q6`7W_N5I,#I46[ZAE(1Z2GBA7]&&&/1,\$+_Q`P MMC03*DG8OA4#B![V7/A'.4L^%?F4DJ0G'LFGU')/1WU?/&IZ9'Y1%UL::O'/ MQ1>.H+JEEE(-Z*'YA7]`''WHV7FJ02D:/3U.+:W/J"L"O=SJ;?EU_??E[NOF M=3]X7C_2*?FZ?2Q^%UZ/%?XXQ,<%OVP/]%HKNBZF-QS1:\S6]*`WO6=I.'C< M;@_I#SJH4?=BM$__!0``__\#`%!+`P04``8`"````"$`S05ZI=@"``!_"``` M&````'AL+W=O@R'*@J9B7N5K1O16D^B1>9^$L!*;%/)?@`--. MM"A2NF3)'8MIN)B[!/V68F,.?A-3J^:Y*+@J]K^T-MO@A95A:V^Q(V[Y8J[5AD#1@*3I.)8@2X#XM"%P@M@E@E-Z30FLU<`N/"]8 M-)N'SY"YK,?<>0P\]Y@=(@31G3*HC5=&,"IC:G$I=SYP*!.?EIF\1P;!*87G M?O%'!CUF>H"9GE8&R'B#"(8]^+^T!XV0AJ(:+XU@)[U+;A^!8[+/`XM.N[QZ MCQ2"AU)]Q%7ZH#R@RL9;0/"0MX\CT,/Q;:A8T<,3_=!JEP?C&^PZ9VQY&:^ MD4$R"`U-34[O$73W@?*91M6WA\F^83@"4'.WA*\TW^Y].VR$+L4G4=>&9&J- MK3R&!K>+[JZ9I9O_-CY-ECWQ[@NT_XZ7XAO7I6P-J44!G%%P#9G2_@+Q`ZLZ M6!5<`LI"XW<_*[CH!32Y*`!PH93=#O"*VOUU6/P%``#__P,`4$L#!!0`!@`( M````(0#4,!+-DP(``.`&```8````>&PO=V]R:W-H965T&UL ME%7;;IPP$'VOU'^P_!X,>P]:-MIME#92*U55+\]>8\!:C)'MS29_WQD@A'17 M*7D!>S@^9V8\,ZQO'G5)'J1URE0)C8*0$ED)DZHJ3^BOGW=7*TJ7"&E)\!0N806WM MCO65,+H&BKTJE7]J2"G1(K[/*V/YOH2X'Z,9%\_:,7BMAC3.9#X".M8Z> MQWS-KADP;=:I@@@P[<3*+*';*-ZM*-NLF_S\5O+D!FOB"G/Z;%7Z5542D@W7 MA!>P-^:`T/L437"8G9V^:R[@NR6IS/BQ]#_,Z8M4>>'AMN<0$,85IT^WT@E( M*-`$DSDR"5."`_`D6F%E0$+X8_,^J=07L+H.5O/Y;+%:`LU>.G^GD),2<73> MZ#\=JN-J628="[P[ENDBF"_#:02B_R%AK4=-@+?<\\W:FA.!H@%)5W,LP2@& MXLL102B(W2(XH4M*P%<'M_"PB<+%FCU`ZD2'V;48>+Y@>@0#T5X9U,8K(QB5 M,;?HRJXU#&4FEV6F[Y%!<$+A^>+\68`M9C;`S"XK`V1\@`B&.WA;N@6-D(9Z M&"^-X$:Z3VYG@3X9Y&%Y.Z00_%JJLT1-_PW+`ZIL&`*VW'0&CKU=H7CJ MM4!G&59*%*XNQX+C>G0S(/BU5&>9O,323I2VX;2TN?PDR](188XX+2;00KVU M'V3;YOR_]EF\;08?P.W>8NT_?ZK/W(MJN:BY;GZZ)[XE+V>RKRW'K__W7XRKUO:XO+OOBW%S$ MUO\N.O_3_<\_W;TV[=?N)$3O@85+M_5/?7_=!$%7GD1==.OF*B[PRZ%IZZ*' MC^TQZ*ZM*/;#1?4Y8(3PH"ZJBX\6-NT2&\WA4)7B^+M3 M=>UNUNIRB;FZ:+\^7U=E4U_!Q%-UKOKO@U'?J\O-E^.E:8NG,_C]C49%>;,] M?)B8KZNR;;KFT*_!7("@4Y^S(`O`TOW=O@(/9-B]5ARV_@/=[$+J!_=W0X#^ MJ<1K9_SM=:?F]9>VVO]6701$&_(D,_#4-%^E],M>?@47!Y.K'X<,_-%Z>W$H MGL_]G\WKKZ(ZGGI(=PP>2<I*E@9$I/@V M_/]:[?O3U@_Y.DY(2$'N/8FN?ZRD2=\KG[N^J?]%T>#1:(0I(R'0J]_94B,! M`@W^?2[ZXOZN;5X]*!JX97I)6MG_@>.-%! M>E[N4W(7O$!$2R7)IQ)J*W8WA4P$T(V(X+>)^';,;R12+$ED#B1:CE^`[1&- M.?>=*KA<@@0,M)I!CR;-PXU6:1#261(8D8)(E] MXQPEZ9#+%:6,9HPZ*=W9&A)%*C!$!& M3]P(SBDL1&XCSJ-)L1W!-'0BB!(^1)!2&AJA&;*_,P69&#%X_FL2=0HL(6 MISQR^2Q!Q$V!!9C9@/-QDV('3/N-8"A!L(10GCDMLS,%,00VT15A@5$H?#-T M\V2#VD%S[IPK#;)Q`DO%#NI."=[N$QM.3F$CK^_`X+=[8DB1G[8>SDL%Z.AZ/=FL&ZRS"M%#5OAP8[8E9B1T_.Z^5X.-W-Z+E# M(J>HP>BMTB@+HTGT+`G/(/^Z0&P\.;&7XTFU77FA'N\J>JA!O)B%3->\BITI M6(4DS6)=G#:J3R]RBZ*3*G[G-J;H)52F@6I;JV5/DY&D[#2)>H#?BAA4%Q MVD/KC8YGVK`*'VK>#H[BFY-8>.Q#6V-0V[V;.;G+E495%LR5-''#9TLXC[DV M8M-]:&VPZ=K(G%OG2G.CRZ)8WQIC9RMBPKBN$!M.COC%8X_A0C`GBSLWECX\GYO1P/I[U5>'K<8^$QU,P5WJS$QI,3W,!;-OR8 MO,HI0'?X*I!$CNLUL3F=_+.2<[I',264NW]'U'I%/=KK05"F: MBB0D5%>SS?B_%@F;+A)*W$VL1"I2;T*:NP;J,4X8U2FQ.9U5LC"6TY4"3WOV MHVC.K)T"30%+91).4Y/R)".1SHD-ZFR5A:#3[4*)`Y$S'=@X<#[H#B1+=IAA))<)C#TKC*'&?V.0Q MH[2#DB3*H(W&"D<\/$7$4[9:M$>Q$^=SYY7-LSPA9'`@,'X[GEX^,'EBY7R? MPZGF<`08C#_`H>*U.(K?B_9873KO+`Y@DJP3F#\M'DOBA[ZY#F=[3TT/QXG# MGR&PO=V]R:W-H965TTT[;_?,4Y(H%F7WB0X M/'YYSK%C%MN=)"-BDF7H`1;S*9BV:3XE\_[Z\2C+1A3?/RUV4CWIDG.#(*'1*2Z-:>>^K[.2UTQ[LN4-W"FDJIF!H=KXNE6R=R4Z:8QEXT#2@!'*VY-O?"1F*4;;61 M]1\'D7V4"PGW(13L]_=#+TPB$L7_3_&=45?@'3-LN5!RAV#3P#-UR^P6)'-( MMI51Z,_YRJ`D.^?&3NJF`JUA-9Z7810M_&=H8;9G;L\P0V)UAHA[Q`>_7A)* M_[BDG03%8-1+$C+I\[M";ATS.6%&Q.H]8N`(#SIU?+^!%DXQ9!_=PMG(S3&) M:R\A<3`Y=J>S7PT)2B@]$@,W*/!R-PN/W"@=N3DF=FXAH7$X!%8#@$:S^!]F ML/TO-[/PV.R8ZU;4,N;/3#8QLNT-D+0V<>=UE":\X#B=,X`%<2&D. M`WLZ]R_-Y5\```#__P,`4$L#!!0`!@`(````(0`<61^7E`(``/P&```9```` M>&PO=V]R:W-H965TOG5*R1!5]0?AR?,X]]]J7]?63:LBC,%;J M-J=)-*%$M%P7LJUR^OO7W=4G2JQC;<$:W8JJ`8B<;Z9X]*26*9_=5 MJPW;->#[*9DS_L+M%V?T2G*CK2Y=!'1Q2/3<!)_R'B-3 M?Z5]E<*T"5=:"5.)SZ)I+.%ZCY-D"I>TC_9#;NOW_Q^?9UL__.+^`PR?CE7B M.S.5;"UI1`F4DV@%M3=A?(6%TQVD"2-(.Q@[_K6&OXR`>SK!1I5:NY<%#LC^ MO[7Y!P``__\#`%!+`P04``8`"````"$`\MR]&I\"```Z!P``&0```'AL+W=O MN;9UV2)VF=,E5"PV!" MB:R$2565)_37S_NK:TJ;CQ_6!V,?72&E)\!0N806WM$82"V"V"$[JD!'QU<`M/FRB*UNP)4B/"7L$`]%>&=3&*R,8E3&WZ,IM:QC*O#AR)C-]CPR"$PK/WOG+`%O, M;("9O1X@0,8'B&`LBP'MI70+&B$-135>&L&-=)_.Y?H+&>U$OWGSG!@CVX'!)]+=9;+:%;O MX47P.6]GB5ZRU,ZJMI6UM+G\),O2$6'V.(VH_(;7/^7_LLWC:CD_4? M8'35/)??N,U5Y4@I,Z".W_>IN_````__\#`%!+`P04``8`"````"$`8NM[E.:)^/7?L=?0]8_7\N+ M\4+JIJ#5QK0G4],@54X/177:F/_\BGXL3:-IL^J076A%-N8;:;&< MZ=2SRJRH3*[@U_=HT..QR$E`\^>25"T7JB?>M$3:/,_?14T3I[O(#O5]O-\D&[^X#DRR*O:4./[03D+#Y0 M['EEK2Q0VJX/!3A@:3=J\%8?VO#$==[*PIZO9`E0>2=-& M!9,TC?RY:6GY'P^R>RDNXO0B\.Q%9MYDOIC.;.CS7A&W%X%G+V)/EO.YZRW9 M2#[I';[M+,"S;[B:N,Y\L>QZ_Z3AHF\(SY$>/_=N\3QVTQ)D;;9=U_1FP%J' M3#77C.TMDZKKVV7F`EY'W, M#L=H$?LA@DT[DPUT$.H@TD&L@T0'J00L2(+(!*R&;\@$4V&9&#SL!B"E1DW, M?H@8F@0Z"'40Z2#60:*#5`**[=FWV&8J&Q/^B@5@KY:JSQV/<2'_(LA50_8B M1.0"D1"1")$8D0215"9*1F!'?\-"8"JPJ:`7X=9Q'=7OC@=]FA(1(E*"2(A( MA$B,2()(*A,E)7!6R2D9/ZV'PX`%=\Z'$>\X<;M[I=O9>T0"1$)$(D1B1!)$ M4IDHKKRON&+!JBM.9MV%QUWUA-\VW0G6$]A\8A78CJ>N@E`$#0F+D%`L8F2A MA2J4B*!!*)6%%.]P5M\_HRQ8]>./P^F-K:9@_%]\-H(Z01BYCN M3IG:,\VQ^'[02&4-Q3$K(=%--V&7=7LN\J<=A1F"LVED;<_``;_GF(::"$[D M1/1$2D1/Y*/`=K33,11!@Y,("<6<>(ZX71)$4KF5XA]N]P_\CUB&0FCPS-JI MGCEQWB^Y?4]<,;"`$^]]RX>(1*A5C&(21%*YE6+0AFH4.?2@LOO*#'VJB2OW131$/4N']\EGPP- M57EM'Z5#%*_>Y;+(9O62OF^^FE1><_$7BVXG[3K9C>E!UB37VA&Q[Z,<:6'U M:"[[&4DJ[]&#AR2/DLJC)/GX+OED&+TJCY(JRZM+E55C>E+G[X?1+WK]Z#"2 M=J;-:SHEK1RY_-V)74'[/DI"`48A1A%&,48)1JF"5-^LZ))\?W[RL.)).WIZ MY'KBI-EC%&`48A1A%&.48,1>D-FX^""X/_["R]^L2E*?R)Y<+HV1TV?V,NO8 M<)H*+-ZT'[J#7.,[]@;.W.G<\:&&'^$S'TI9S!]<_P$&BK_8N3X4>B-\[D.I M-,)MZ!FF=.P;Z'NTC]CSH1C!+>*%GW37AF8N7OIPE>'XU//A0L,\6/EPGV`> MKWRX,3#?>?YN3&?O^?LQ'G@^5&58)UCX4+:,\*4/%SCFD>?#-0[<$H;AUXQK M=B)_9O6IJ!KC0HZP0*;=UJ_Y[R'\0]L?`8^TA=\QNM/@#+];$=C24W:E'2EM MAP^L`_%+V/9_````__\#`%!+`P04``8`"````"$`LV+YL,0%``"U%0``&0`` M`'AL+W=O8;DD!QJ-K]\;:_& M%]0/37?;FO9J;1KH5G?'YG;>FG]^SCY%IC&,U>U87;L;VIK?T&#^LOOYI\UK MUS\/%X1&`QANP]:\C.,]MJRAOJ"V&E;='=W@S:GKVVJ$G_W9&NX]JHZ34GNU MG/4ZL-JJN9F$(>[?P]&=3DV-DJY^:=%M)"0]NE8CV#] M>$+#F#68TS3JEV'LVK^)E$VY"(M#6>#)6(*5'ZY=^P,D'B6!)R-9>8X?1A/) M&ZN#G9,/\*2*T2KR?2^(0H#>4`RH(CRIHOUAJT/*`4]N]1R_-Q:'"IRLAB>W M^EWN/E!%>'[4:HOL_I1,2356NTW?O1I0H;"]P[W"]6['P,NRB)C/\^K?T@KR M"9,\8I:M"9&`A!F@%K[L'/=A8WV!_*VIS%Z7L66)`Y/`R8II$Q5(52!3@5P% M"A4H!<""(/!(0`K_@$A@%AP)YL.>`4)H%+>9!%-)5"!5@4P%XC5FV)OSE"6"'H>SGGLAX$'\NY,DB!R["8Z$AJ89D&I)K2*$AI8A($8$V M]`,2`;-`4<$JW%O'6\O^[HG0FR'A(CPD&I)J2*8AN884&E**B!02Z*9B2);/ M&-8,L/#D.;-X3Q#/Y55QT)!$0U(-R30DUY!"0TH1D;R"[O]^K["P[!5!W.F8 MGOK5@2+DB)PZ&$6@^'@6V$X@9T'*A5C`,HTHYS(BD5)A!1=B1*5()/D.O5KT MG?3]%3XVQTM3/^\[L!COI.MC#CDD!!%#0A$A)!3!-'!,K&VE!Z3\ M/7,BTSAR+D,Y7#FB!7_/.$J10PH$GH>U`W`*Q(+O,-0PY[&>[#Q%R+"%=_]` MD8#G?4(0%PI-R(=(MC[E0LSZ3"/*J$8;SZ5."CD4$\NTI,N%#Z"A**:4&"9Y" M;+69)Y^E*I3LY1`XHQ# MI00HT:%4AS(=RG6HT*%2@F2_\6@G^/WVV0;W%II_=#:%J0=V/XAM#Q1R]^!$/U%WLOA@E[`?=CF%$7@-4 MBVN400RCCJZ11#&,%3J>1S$,#CJ>V.L8GR+Z&S@UXF+Q36+;H+,40NB5H+/T M9A_$^R5[#T%\6,*3((9Q6;A3!(+C&A^"I MZT;V`R_`+UQW_P```/__`P!02P,$%``&``@````A`";;RW`."P``6CH``!D` M``!X;"]W;W)K&ULK)M=;^.Z$8;O"_0_&+X_<239 M3FPD.=A(_`):H"A.VVNOHR3&QE9@>S=[_GV'(B5Q^/(D=K`WZ\W#X4@S0U*O M*.GF]Y_;E]&/>G_8-+O;<79Q.1[5NW7SL-D]W8[_\X?\[7H\.AQ7NX?52[.K M;\=_UH?Q[W=__]O-6[/_=GBNZ^.(/.P.M^/GX_%U.9DFS>UWSS\8[.K*=M4)UN!KTWS MS9J:!XNH\P1ZR[8"_]J/'NK'U?>7X[^;-UUOGIZ/5.X9160#6S[\6=6'-664 MW%SD,^MIW;S0"="_H^W&#@W*R.IG^_NV>3@^T_^*B^O9;#J_OB(W7^O#46ZL MS_%H_?UP;+;_\U;>E_.2>R_TZ[T4\XO9U661T4%/=5)X)_3KG>19<"KO''[J M>]*O[SF]F.:SJ^OV\.]TI)-KHY_W'4\]Y)7O2;_G'9(F7GO(1=_Q@T-.7,7: M`5"MCJN[FWWS-J)9124YO*[L',V6Y*VKO`NW'PM_-11H#%@G7ZR7VS&%044^ MT/C]<9Z-IE(K>I,\%$`%$`E%`-!`3$I816@!^04:L%[L.!M'BG'!&[Z:D M-^E3`D0`D4`4$`W$A(2EA):X,"7IZT*W&%CC-O+NC.\=F=(0["N?+191[7NC MKEL%1`"10!00#<2$A`5*:_CI@5IC'J@CTZ*?_B60"H@`(H$H(!J("0F+BA;F MTZ.RQCPJ1RBJH7PDT*+R]49]^8`((!*(`J*!F)"P0*T@#:YF[X]3:\P#=20L M'Y`*B``B@2@@&H@)"8N*KLNG1V6->52.%*T$;*^KI2=9/TPK3]@,S>>\Q*(W MZDHLP9'J;8:QDN57W)'NC3I')G3$8L](S)X>?&O-H_&EF=,[="'JCGB?.<12XM$02]59A=,^RR-5)P:KSKWLT.!+>33/ M^Y/0B`SKR#-AU4LZ$XG@Z7:AC][)'A:]0_F@TI5'\R%M`I'$C@JM M-"+#.O)0K2Z)0YW3C=!91;=.HGG@$J8#XM%Y=$L[)@5 MT?(ONHYT#0K<1U)7=E:#>W62>]UUY.ZCV64Z*W>W&XK[S$H;R.J9277RB`[2 M#?7[UNWM>$Z+5!!UM':4WBH/AY?S-0OC22356SY4K8R*DSH;UJ<_FM>_6I_"*>K$&$NK0U.WUV!O!4N['4$#,T`5 M(H%((E*(-"+#$(_;"JT@[@^6(&L=S46'II39H*ZS>"[V5MUXJS)``I%$I!!I M1(8A'K*57*>'[`0:*VFHV9P*R0!5B`0BB4@ATH@,0SP^*[Z"^-I+;39MQ_*Y M>R%.Q['@>VD7UCN25V766PWU!B302B)2B#0BPQ#/AQ5D03X^&.).OK&0'0JU M=`:H0B00240*D49D&&+QT06.Q6?K75S;W4V_0WGRUE?KB4]OCZ(;ID@$EX-5 M7VY$`I%$I!!I1(8AG@XK_TXN=^[$8EANC\)R(ZH0"402D4*D$1F&>'R1?GQ_ M..>9J3:HIOCI[%$W?>+MJL.H*6R$2B"0B MA4@C,@SQ7%AQ%.3B@UH[*<6FKU=7@[0M[5)H!=>`*D0"D42D$&E$AB$>GY4] MI\?G1!*+SR$^?;/H'J;,>ZNAI(`$6DE$"I%&9!CB(9\EN.AF%D8QJ*O26[&2 M@I5`*XE((=*(#$,\/JML@I+:Z3LO/J.W16+E[V13HK2R^U_4=63KZCMT( M$&@E$2E$&I%AB*?C++V5H][R*+@_*A%5B`0BB4@ATH@,0RP^VFMBY7Y_A6JM MN:;R*)K!T:UP.5AU]:L0"402D4*D$1F&>,AG::H"-95'P?@L$56(!"*)2"'2 MB`Q#/+Y(4WWR`ER@V/*(`@^G;[0O40Y60ZV=KR!C`JTD(H5((S(,\5Q8812L M9A\,;R>CPA6K`&55(JH0"402D4*D$1F&>'P)L?6YVZ4"]99'4;GC3;3!:BBW M\\7*#4AB1X5((S(,\72!6=>(JH0"402D4*D$1F&>'Q6]03#^;-3 MVXDG-LX=BFH=[WP5O=50:T`"K20BA4@C,@SQ7)PEQ`H48AZQ6H/JJM!*()*( M%"*-R##$XXN$V`=+%XJMPJ'HRAQO;@U60TG[CAT2:"41*40:D6&(AWR6V"I0 M;'G$2NJL`E2AE4`D$2E$&I%AB,4WC<26G;[YS#[L.//FN'7$=9A'T02.][8& MJZZT%2*!2")2B#0BPQ#/QEDZS+Z+$^W6>Q24MD14(1*()"*%2",R#/'X(AWV M_@2V+^'$\3D43>!X;\MW)*NAI'W'#@FTDH@4(HW(,,1#/DMNV;$:AXQRRUL% M5:X0"402D4*D$1F&>'P)N95][FF$?<84!]]KI%!>Q_M;OB.=9%?<"I%`)!$I M1!J188CGXRR]1??`$+)#03"EMPI0A4@@DH@4(HW(,,3CL^(FT%L?3&$GA4)9 M-76(3^$\WM\:K(:2]AT[)-!*(E*(-"+#$`_Y+%DU15GE45"_$E&%2""2B!0B MC<@PQ..+9-4G)?04]99'%'@P??-XL$E&%2""2B!0BC@/K05D6JA7--- M?*J%2G6J@/;6JG6BC7M!V<:"DHU[1K MFFJA7--^8ZJ%[;=RB2$LE1TR3(S6K]:>879S0D M1\S=UQ^7\^)[U79U<]T:9+DV%M6U;/;U];@U_OJ6?/&-1=<7UWUQ;J[5UOA9 M=<;7^U]_N7MIVJ?N5%7]`A2NW=8X]?TM6*VZ\E1=BF[9W*HKW#DT[:7HX6=[ M7'6WMBKV@]/EO#+7:W=U*>JKP12"]BT:S>%0EU74E,^7ZMHSD;8Z%SV,OSO5 MMTZH70>*S/=?]S$#46ES+(C]>F+1[/$/ET!Y^ M(/E+7;9-UQSZ)/5=7?Y@1X5),Q.0BQ7=\#](JCRQWARAW)NT?M<0VXCJ,V M?8JLC4@$U`P'4R%[_>FY=VMOD/YEMQFAVV( M:A$*"UJK5#;20:R#1`>I#C(=Y!)801+&3$`)?T(FJ`K-A(AA)X"4&BUL82%< M(AW$.DATD.H@TT$N`25LZU/"IBJP@$@%0%Q7C7/';&S(_U@EMFH2CB9C+A") M$4D021')$,EEHF0$EJ%/*`2J`I,*GC)&:UJ^&N^.&;V:DM%D3`DB,2()(BDB M&2*Y3)24P((FIV1^BQ&+`34>(A7=-OL3W7YM&M@O#!39]ZT!>L[6_6IAIH21N24<"*E MA!,J`]O$FFAK0#S>%T$D2",=;;B&I+12(P^04(IMYD>EB&2RUY*S+#1 M?RAFZJ?&S(@Y[7U,T]Y8 M&T^;*;D0&K35'(+VQW)(';4<,F3*NR'QM#A#PJVDVN'((6RU\"$[^FR93,;I M@H72R8HN&8[EN]JZDTT60B=7=-3DT';J(\L&87T8]`7B*3N!E`+S4'/,')4" M8\@QA^00LK$]8NKE-=J(YR7\>9)2RI%06A-(D);G;+(12KFBI.:'=E=:?DR7 M?HB^8W^AS9->2`QIA:0%'7)'4RXDYNC`99K%^FR(N2-8B1@3,0BH3V/*.1(*HR((V?* M9(Q1@AU3;)5AE"N.:JBT:]-#A:.%=]4/U=`6(H:T^M$:LI`>HX"C4C\S)F5O1EFI$LLXFF5DF#M5*!7M3-NQ;4MG[B^M@GE0FAX6VHZ:2.HIY-5 MSM#O?6MND*C9?D_J>0AK)Y4R8DCN[;F5A"*,8HP2C%*,,HQR!:EQT[Y/BOOU MG@Z.ZU#!,&1//5S(K204811CE&"48I1A1(\1Z;C8$UE\[%B0'>5^9FT`$<\GD<^F'2R:WQ'SRGGN!G`H<&,O17`MS/F#W;P``/%-W9V M`%^6,]P)X-MLAA,71C0D'`W5$V>JVIV(F$$,VQ%6@[TMH'L7OA,1"WSF0H'E M''SF[L"""#YST<"*!SYS=W((9RXOD1]`JX_'E?H!-/.81YL`.F?,TTT`O3'F M$2$PUKE7"]T0C'7NSLX-=G-C#=T@G..1&\#GZ\RSO0`^Y#!/W``^YS!/W0"^ M7F>X%\#''/#5^,+A#/M6'*O?B_987[O%N3I`P:^'3;!EI^#L1\^7M,>FA]/K M874[P5\K*O@P6]-]Y-`TO?A!'S#^_>/^7P```/__`P!02P,$%``&``@````A M`"WD#WF3$```N%L``!D```!X;"]W;W)K&ULK)S; M;B.Y$8;O`^0=#-VO[6Z=;&%F%E(W3T`"!,$FN=;(LBV,;1F29F?W[5-LDDT6 M?XX.3F[6.Q^+U:PBF_R;5/>G7_]X?;GZ?;W;;[9OGP?5]>W@:OVVVCYLWIX^ M#_[UF_SE;G"U/RS?'I8OV[?UY\&?Z_W@UR]__GVX(@]O^\^# MY\/A?79SLU\]KU^7^^OM^_J-2AZWN]?E@?ZY>[K9O^_6RX>NTNO+37U[.[EY M76[>!L[#;'>.C^WCXV:U;K>K[Z_KMX-SLEN_+`_4_OWSYGT?O+VNSG'WNMQ] M^_[^RVK[^DXNOFY>-H<_.Z>#J]?5S#R];7?+KR\4]Q_5:+D*OKM_@/O7S6JW MW6\?#]?D[L8U%&.^O[F_(4]?/CUL*`*;]JO=^O'S8%[-S/1^@?V_6 M/_;)_U_MG[<_U&[S\+?-VYJR3?UD>^#K=OO-FIH'BZCR#=2670_\8W?UL'Y< M?G\Y_'/[0Z\W3\\'ZNXQ160#FSW\V:[W*\HHN;FNQ];3:OM"#:#_7KUN[-"@ MC"S_Z/[^V#PE7;CT M-]2[C>$>J3CQ%>EOJ'C6!:>^'OWU]2;7]=VX&I]J*=V@74OI;[C@>2V]]Q7I M;ZAX-*4A#X3-*[_#YFP7FPF0@R+`)+49&$'BU"ES8'(@M1)-(TM]5->)A+9S-B-+=#XK,I.E-^M"!""`2B`*B@9B4 ML`30[)(GP,ZM%]X!U@O=0W25/MJJFF0I<49'4]*;]"D!(H!((`J(!F)2PE)" MX:6CQPI$1N?]Y+IK>*%1K@0@@$H@"HH&8E+!`::(_/U!KS`-U M9#3L[_8&2`M$`)%`%!`-Q*2$147S]4=^U0`00"40!T4!,2E@2K/9-%K;C8]@:\T`=&4UBUP)I@0@@$H@"HH&8 ME+"H:(E.H_K@W'AC(Y.5KU)W]%`!!`)1`'10$Q*6$HJ6JW2 MG!SOZY0-H?=\]'?^(I) MAEI$`I%$I!!I1(8AG@ZK79)TG!CA3NFPD!U*@FFL4J$Y($$M(H%((E*(-"+# M$(_/"I'SXW.RA=S%X>R53#);5X!:1`*11*00:42&(1Z?U1])?!^$6.Q>&]'\E70W;"7T5K&[`8D*D$2D$&E$AB&>#BM=DG2< M&.%.Z+"0O?:),UY3`6H1"402D4*D$1F&6'QU)L!L=T]I?_'BQ;ISQ+691WRQ MKFL^YS71JN]M1`*11*00:42&(9Z-B[19C=K,HV1E;A"UB`0BB4@ATH@,0SR^ M@C:KQQ_I;91F=4F:U=E&8A.M8F_W%0,2:"41*40:D6&(9\/*J+/O[=J)KO3> M]BA]T$34(A*()"*%2",R#/'XK(Q*XON@=*F=&J/`TTD[VPY<>*NCTB7:A)YN M$0E$$I%"I!$9AGAR,EUW?&*W3R_9)H-'_,FSSM+21*L8LO-%%0,2:"41*40: MD6&(AVPU4S(>3H3L%!8;[UYT)6M9#:A%)!!)1`J11F08XO%ETLR.]X_-;JC: MZEZBI3?!.%_+>JO0M6VL&)!`)!$I1!J188AGP^JC\WO;J2G6VR"PFAI0BT@@ MDH@4(HW(,,3CNTB9U:C,/*(#D]`S34#N\+0[Q@J(%JE$LF:'`R):!5\RH.A+ M!<1]93NP.EH%7R:@SA?+@CWN27O9S?'=?O'A>;/ZMMA2JTFG%.[U(9WUN1/` MS@G7;AZER0DH!M0&9%W1L>%M?HXDHD&(1084W:B`>C>9:M#1(+@Q`152DHFX M)"6%+-!TV:B?#TAE@Z!'=.\G8SW?;O!6IZA!7&Q!E+U8<9KL=(EBQVV&8 M/0W*8!7=JX".NM?!BKO/'C],L'(_XDC/E(>9/#P_DZ@4.U^T&C$-E9^R-\$J M*H/6HR$MLTDF,Y4AHE7H`HF^5+1*?65KF(Y6P9=AOOAH*TG,[O'Q@MFGUY?A M@@M[)UFYQ0;>,)MT&V_%!IZK.*1U.$E7-L,*7Y&LPA4E^E+1*O65W=4Z6@5? MAOGBZD+DT72M&A0Z0%0AN:@-*AY*UH#4]R`S>EM^*IS^YYB>Y50$?= MZV#%W(^R1IA@U;6>9]#JS?+TUHVXW[;O/UOOTIG>J58VUX&0;>Q-EVVS(Q*( M)"*%2",R#/&XK;),XCZQDCD=RN+KI6G2^Z-LLFWLC9.'#$B@E42D$&E$AB$> MLA6;YX?LI"D+V:%T,V8(J$4D$$E$"I%&9!CB\=$]<$%\UCK3:`ZEVP]#0"TB M@4@B4H@T(L,0BV]4E*87;RQV;KK`TX&;+>,+;W5T^R':A&FR1200240*D49D M&.+)L<+R[,%MP\HZWR.^_3#*TM)$JQBR\Y5N/Z"51*00:42&(1ZR59/GA^RU M9]QK6(P<2N]G1"TB@4@B4H@T(L,0CZ^@%\>4[$M_C(;JT>Z@NUDYO06RAZ0F M6L6^[BL&)-!*(E*(-"+#$,]%I@N/+U=V$.?#VZ%1?`QJO%6"6D0"D42D$&E$ MAB$>GU5)R5BV0NXC?>W$5KIH47B%OLX$?Q.M0L>VB`0BB4@ATH@,0SP7F20[ MT=6>)HR'-E8+ M2""2B!0BC<@PQ)-SD4@;H4CSR$XE?<#5*$M+$ZU"?"TB@4@B4H@T(L,0"WF< MZ;;CX[VSYKK4(UH=0C`-HA:10"01*40:D6&(QV<%4'(_V_'^H6,".^%GRY9' M=F%,>CO?N(A6(4$M(H%((E*(-"+#$,_&1:ILC*K,(YH_0S`-HA:10"01*40: MD6&(QVLNV1)MH%3+4 M(A*()"*%2",R#/%T7"3>QBC>/&*+F1=O<7UKT4H@DH@4(HW(,,3CR\3;B>'< M:[30,XNQ0_8XK9^RJE&VW]L$JWAHUWI$OR3\R=D?UI%0)WN&5:P.#S038DZE M7GC0.49]YA'MU(24-![1&5M`;:A(R8I9JK.!+["B/*NB8A59V)-,C"5A'^_J MKB+791[9'V^\57JJ$BI2]I**V=ZQP(KRK(J*5>31%Z1:->XZ_43T M*,TF#O$CN'&^81:LXKK4!D3S?A)]-G*%M[+O1216V>(OR[ZRIP%URA?/42;@ MSA\AJ.4F'O&.SN6KMV(CQ%6TO[5+HL]T@`@53^2HZ"N[U]0I7SQ'11%XSCCJ M95^8"A83A[)QE$^8P2H=1[XB&T>3[/83ON*I<72.+W7*%\_115IP@EK0HW2E M1-0B$H@D(H5((S(,\?BL;LL>!#[V7M+$**NCS[71)@YNYYRJ!230 M2B)2B#0BPQ!/3B863PQN5(43A_AS;9Z6)EJ%^%I$`I%$I!!I1(8A%O(T$XK' M0^ZLN3KT*+V?$;6(!"*)2"'2B`Q#/#XKW[+Q_J%=NZG3@>GL[5$V>V<*KXE6 M?6\C$H@D(H5((S(,\6Q8C91DXT1O.T7%0G:(3G5",,T44(M(()*(%"*-R##$ MX[/ZYOSXG!IB\3F4SMY30"TB@4@B4H@T(L,0CR\36TZT7[PK.>U56"*[)]E# MQ\);'9V]HTT8#RTB@4@B4H@T(L,03TZFU$X,;E1C]FL9]KR\D5J;(IJS",V>Z,:0RN!2")2B#0BPQ"/+U-C=KS; M,XD+=^&G*-,\RN;N[(FZB5:A8UM$`I%$I!!I1(8AGHM,N9T8WKU`"RU?3+VL MBON/#:(6D4`D$2E$&I%AB,=WD?BB3^_EAV@>L;G;Z[%XR-2BE4`D$2E$&I'] M)&`WAW17=/&Y3_RY+["]KG=/ZV;]\K*_6FV_V\_WW8]H([3'_MN"T]%L3IZH MZ[(2FI3ILX/=[@"4C*FD6Y>A9$(E78.@9$HEW<]_H>2.2NZ*+;BGDE+;YI,[ M:G4WNG)O5&)E=R&>"7DC=5HHF=[2=;KMU=S;U'YZL7LX@)*:2NJBMR&5E-HV M'P]G*K2`2NPA6*F$>H'.BDHEU`MTRE(JH5Z@`X=2"?4";=472B9T'=J: M*)70=>@IO51"UZ'GVU()7:<8Z7Q$/4=GH84Z5&)_YE`JH9ZC7P,42L;4UL3K]/P1+Z62>UK=B"$;7`/5CF8V=$ M+:!?Z96\T3AP*R34H?XAN5"J0_WC5#+4H?YQ9US13 M%+-#;]92G6+;:FH;_:H=O2UJ:AN]*%DJH;:Y%P7R5MZ*2A4%)1//2]%2R95^/9O)@=^C`*U2E&6E';Z&L=Z&U14=OH M=*I40FVC3SZ42FB,TELGA9*:1J+;\8:\T4BD5^Y+=6@DTI9XH83"*49#P11C MH5"*D5`@I3CF][-Y,<4+BJ\87D7AT3>K"DVM*#S:C2Z54'CTX:-2"0US]S26 M)VM\-UO0:1?6H2/&F3UYPQ)!)?9H#4OHN'!FS\ZPA#[J.R^WC!I6L%_8GBIQ M"J1XN]+=6DK\PLXC!3_T!B%&=4DD['%&=4MOH12>J4RI94*L7Q5;3F[*SIEC24HE]';;4ZEMJ02D']*[L MS+X7BG7HE=F9?2&V4#*\I59W=6[Z04;?37Y?/JW_OMP];=[V5R_K1Q)FM]TY MS\Y]>=G]X^#?$OJZ/=`7DVD?C#Z>2U_(7M/[G?0)W\'5XW9["/^@2]_TW]S^ M\E\!````__\#`%!+`P04``8`"````"$`CK^,K4@#``!8"P``&0```'AL+W=O M7[R\?2YR],2DXJ)<8>(% M&+$R%@DO=RO\^]?#U0U&2M,RH;DHV0J_,(5OUQ\_+`]"/JJ,,8V`H50KG&E= M+7Q?Q1DKJ/)$Q4KXD@I94`VOK2C*:V$%%[H=!$/D%Y25V#`LYAD.D*8_9 MO8CW!2NU(Y$LIQKFKS)>J2-;$8^A*ZA\W%=7L2@JH-CRG.L72XI1$2^^[DHA MZ38'W\]D2N,CMWWIT1<\ED*)5'M`Y[N)]CW/_;D/3.MEPL&!678D6;K"&[*X M(W/LKY=V@?YP=E"M9Z0R?*-EPQ6&_)D,K`5XM%`OR8F!(/]WN@'FX$? M$B4LI?M<_Q2'+XSO,@WIGH$C8VR1O-PS%<.*`HT7S@Q3+'*8`%Q1P4UIP(K0 M9WL_\$1G\'3CD6D0`1IMF=(/W#!B%.^5%L7?&E,S.8ZPYH![S3&)O-EU,"'O MD_AN/M;>/=5TO93B@*!F0%)5U%0@60#QL!\P8K`;`U[A:XQ@K@J2\+0.P]G2 M?X*%BVO,G5`3+>H`%##MZ6=J`1TE!4XZ4-V$HWB^LB$=Q:ZQ`-NXPND3+@ MKI2+1)'=?>WR@"IK6S`;;AK,/<"_7:-F7%>BCG1J);P>=F/Z]>CM8,!=J3I" M>F[F75[;/B+8O>^Y,>.Z$G6DZ^9FV`V!/C?>CD5WQ8ZAOB$"$VA3C\Z/'7BB M8K@@U/4T/^/IHKY!ZCXQ>>T6Y0K'8FS-*"+_N)MJ]&B@EG!\49H.-+8QPQ.L`Q^WX'I?*D0^O@"=>8W9^+U/P`` M`/__`P!02P,$%``&``@````A`#1.CZQW!P``42```!D```!X;"]W;W)K&ULK%K?;YM($'X_Z?X'Q'N-`=M)4)PJ_$;J2:=3[^Z9 M8!RCV,8"TK3__0<_FV>K/35EONF=#GO+F<]7UB&O MCB9C\)I+..KMMBK*L"Y>#^6Q8R1-N<\[&'^[JTZM8#L4E]`=\N;E]?2IJ`\G MH'BJ]E7WHR=C.@L]A`J>8[ MZ\X"IH?[304*,.Q&4V[7YJ/M9<["M![N^P#]4Y5OK?1_H]W5;TE3;;Y4QQ*B M#?.$,_!4UR]HFFT0`F>+>,?]#/S9&)MRF[_NN[_JM[2LGG<=3/<2%*$P;_,C M+-L"(@HT,V>)3$6]AP'`O\:APM2`B.3?^^M;M>EV:]-=S98W<]<&<^.I;+NX M0DK3*%[;KC[\RXQL3L5('$X"5T[BW%SLO.#.<.7.=[,;>W[GWEP^`+#L5<"5 M<]S.G-NEO5Q]0,6*D\#UZH&`['X@Y0_W M3?UFP!*$"6Q/.2YHV[LS#9$F;%*'Q/E9WD#"(,DCLJQ-$`; MV2P@W$-2:";!8#)()TA$D)@@"4%2@F0RH@0`ZLLOF'=D@34$3QG4.NY2G6F? M&9T-R6`RA(0@$4%B@B0$20F2R8@2$BB77[`X`FMMR`+;6:E9$`U& M@B@F1,E@(Q/=J$3I8"2(,IE(T0ZE6=;.ROP,=])N5Q4O?@WCA94Z,=,NE'-6 MY)%##0E#Y)!P1`H)1Y`&=H6Y7B:BX;X0$1..9+#A'*X6B.&^X,AD#B40V-^2 M_:X/Q(1V:!*$>/13Q7.$-4\X^P%'5D.&A`QQ8:%)^7"KCCX:C,3H8T*4<)OQ M82E!,ME+T0S[^E6:T4_5S!&X2'KN5#T!,W+&A1)R1-X*;'>NND7<2%D[KM8B MQ(0[N80[G>1VU`%D,K<2/QOVPZL"V#NJ$>20(V\4MJLE=""L^A<$W@OA(+`+ MEV.O-UD1=P2K(9DH5S):2?.H[U;I:"6X,H5+C1&V5?K"@C>&CQ08&SFT<'$( MYF;,.%>KJ`%WE%..0RX4`LE1JZ#1:"4DQI0K&:UD+FT9IZ.5X,H4+C5Z/$4?;_Q@ MLQRFW5YH12NPN974IG((+C_I4ZE/3'RT;3Q1?%2AV*Q)0J]JR&W>\$RZA^J76:$76,.>2>=4P41T4]#.(Z];VCJIY#:A^YU%K:0%B- MNW,H(.S,Q&&=O=0R-Q)/A`U4LM+.;^)I+NW4(WF/2XT1-GS79(C#.T5I,0A( MG2^]>>16,,JAO@L(^B1)O=X\"JMW8L3&Y:AWB^O*!\K;QP M2-XI*112**)03*&$0BF%,@52]7VH#80O340?@^0VD%M)4$BAB$(QA1(*I13" M+V`X+O9$IH]]T6+?*`YE\UP&Y7[?&D7]BE^K7`?VYP%FG]+\I0>'?K!X==QV M/6RDI^XLX$Z?S)K/H[WT'F%44S[P&.C,INZLX$[?3FMLO@,C@#F<\'%@!#]Y MSHWGPPY*?:!M\7`WIW*4PL>%]S@98A^43P4X@RCV[ZW:@\-;#X[(J(#DUH-#,(J']AR"T5=SC0G. M/3P\U9CRL<%G2C:\_(//U!U_Y?E3XPU67C"%ARL/CGXGG@US-V4?KSPX"J7V MRWMKD`T?=$_Y<_E'WCQ7Q];8EUM80O/^';EAGX39CXZ_*S_5 M'7S*[5^;=_#IOH1#S3D>X6SKNA,_X,'6\,<`#_\!``#__P,`4$L#!!0`!@`( M````(0`=@\W6,0$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**`` M`0`````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````")=3,ZV8).&G&BWMS?KNCK1*R_#_^?+=TZJV=8VV2<$ M-*VK"2M*DH%3K39N79.GY3R_)AE&Z;1L6@4@M1:ADEW0-S M/Q+)@-1J1/J/T/0`K2@T8,%%I*Q@]+L;(5C\\T*?G#2MB3N?9AIT3]E:'<*Q MO44S%KNN*[IIKY'\&7U9W#_VH^;&[7>E@(C]?AJ)<9%6N3*@;W9B^Q::#'%3 MT=]9I55OQU4`&4%GZ3U^L#LFS]/;N^6#?Q"-`]-X__UQ\`0``__\#`%!+`P04``8`"````"$`OIKGJZD"``"Z M"```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````"<5M]/VS`0?I^T_R'*.Z10-DTH#>)')Y"V42F% M/5K&N;06B1U\3D7YZW=.VM"`&PU>*OO\^>[S=W>YQF?/91&LP*#4:A(>'8[" M`)30F52+27@W_WGP(PS0&5V!L1(P(!<*)^'2VNHT MBE`LH>1X2,>*3G)M2FYI:Q:1SG,IX$J+N@1EH^/1Z'L$SQ94!ME!U3D,6X^G M*_M9IYD6CA_>S]<5$4[B\ZHJI."67IG\EL)HU+D-IL\"BCC:/8R)70JB-M*N MDU$<[6[C5/`"+LEQDO,"(8Y>#?$U<"?:C$N#2;RRIRL05IL`Y0O)=AP&#QS! MT9F$*VXD5Y9H.5B[:=9%A=8D?[5YQ"6`Q3@B0&MLEKO8W;4\2<;'#8)6?:3S MT#*A@S['N;0%X&T^X\9Z*(][G!L6+>.6T#:+C&J#394EO=B-:K,M]2[S[@V7 MFA*M$#)&*]2%S+BES04ON!*D9@=TNK11AJ\1.:BE:^:$PFRO^,!<<)3*= MLYD!I')NBLM+Z-8LN)(O#:"1ZZ)&J0![^>V>G-9ER4[E0DEJ&2H6=BZ$ MKI7U!MCTXKK-Q5,M*]=?7N@-$54+^5``.T=\4V,=ATTP9#.^Y@[KDDQ&4U.^ MIE['?[2%#N]%I%:+1W9;N2;<]_0'A*>:N+/IBG[WH88$\B=K6-2V=S:-UHG@ M5Y7-G2!^9N_$'0+W!!L"#G,?^[4>+**33]SYYKVS1Z,KL%P6_RO2I]#,G[3W M*=AX9WZAABO=7TS]S`VQ]R+W,/=C_:Q[K<2&&*3UFY;RH7M#XLU8^"75(]Y5 M*9R3RR5]>2#;8MX?N"E]W_X528Y. M#D?C$0W@'5L<;&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`-Z1T&&'`@``:P<``!D`````````````````G!,``'AL+W=O&UL4$L!`BT`%``&``@````A`#C+7&-O`@`` M:`8``!D`````````````````O1T``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+#-V@9O!0``7QH``!D````````` M````````-RD``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`%&1\6+K!```P1(``!@`````````````````K#0``'AL M+W=O&PO&PO&UL4$L!`BT`%``&``@````A```96<=("```.SD``!D````` M````````````:XH``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`#R(R,_D`@``U`<` M`!D`````````````````LY8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.>Q';\.!P``6AP``!@````````````` M````/*8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`-0P$LV3`@``X`8``!@`````````````````"K\``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/+&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`";;RW`."P``6CH``!D`````````````````R]L``'AL+W=O&PO=V]R:W-H965TKJ0(``+H(```0```````````````` K`"<,`0!D;V-0&UL4$L%!@`````I`"D`$0L```80`0`````` ` end ZIP 13 0001104659-14-080372-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-14-080372-xbrl.zip M4$L#!!0````(`'B`;46[-TOE&&X``.S6!``1`!P`87AG;BTR,#$T,#DS,"YX M;6Q55`D``[0<952T'&54=7@+``$$)0X```0Y`0``[#UI\-'>]8Q;MMK>U[L?')@*,DU@RBF`-O:7_\RBT,@@002.JR6 M/W0+*/*NK,RJK.++/]^'MO1*N$>9\[6A',H-B3@FLZ@S^-H(O*;AF90V_GGR MM[]^^7NS*9US8OC$DIY'TG?".;5MZ9QQEW'#!P!2LQDU/#,\:`5W_G-V?RVI MATKR)(;`G&-)48X4[4B5E9:DR,>:>JRTI=/O8=/W9VY+0)SC?6V\^+Y[?'3T M]O9VB+I]F^::*WT>KTC M\31I"H`LFK1-P^T&X29O M]`WO68".'N`+6E-6FIJ2)H96$(M%)BCWB'DX8*]'\"`'//582U6ZLQ"$+1)Z M/)HG16BJ'/WG^_6#^4*&1C.A"M0K25]0NL>>>'1/^I*0]K$_'KHW4 MBWLOG/2_-E"JS5AVA^^>U9".0D!H5,SQR;LO/1`3[5!8$#PQH]O4^MJX"$(; M?5*4)T5]0DA/CRQ]!<)XNB8#P_[F^-0?G;Y3[PFQ/CT"!>2.&']XYX9+?25.0*Z`#$X\_R[@Y@O8W^D```Z) MXT\`NC><0?AV?.>[\4Z'P7"BW4/P[)$_`P#P#>"/<18\#]\.Q0Y2(8*]Z`JN MJ85W^I1P2:B#9'09F\KYU2^-$QG^=+G=4_4O1^/7QJ`\,D"VDAMP*^P;Q^3= MM:E)(UHDBT*[T.>`V(\GQ-XX0>D=%\C]RU$NS$I((TD=YZDNPEY.=W42DZB_ M<1+?RNB_3EP%)C3&G&M#\RCXW=!TF2[>URLXAD\INQ@#I,K-@FY M"V/3?).0>TU-7MHDE+U)?`234-9H$I&7T-(FH>U-8JM,0BOG);1ZO<3>)+;; M),IXB25-XM1[NNWGC!1WG`$`?W1G&XX/`OCV9T!=9.5L-!6K7Q,(*E^8;5T- M7A4"]CV$&)=@Y]\H?1@<%QX);A M<`>FT(M2[KWVUZ[]U<^C+*+4:XAB073.(/%ONZS@0FZW7=DY0_2^"V^R"Z\J M[][WX6WLP[6%9-M;]K8O9]O)SNXAI7 MT/S1@V&3'].^LV@+S:F>K]U,E^ZF3[XZ!U](3]404?MR?MCRK8]^;]"NR^E^YZSUEA?6EA M:<>L$0_P)!YO6WO#9@I>EAU+TI+=O5K8C6=S]=4(;EN73`??$)/35P'QLD-(P7-R^$MZ3+XS1EB>90F'E M>(NTF\/<;JNRHSRRG57E)'/;J\HY<6L=G?2C9_QKZ[/YJT.GONX5X#U4+CY4VHER+/H* M@ATCQW8WP9"`!;!,!QD2PPLX.8F^9G;\Z\/%EZ/XYE@F^>\+L!?$84/J%`%& M:=-C[\6`=+0(\C2(+T0R/JTCFHRN&HDU!$1['Y.`^]]LD?5//@D]JFVS-_P8W27C%RQX]ON!';OD MC!>^[4_?EB+KO,?OTM7E6>XZ,DAJ>>(VP>1Z1_6[WEY296U*^:$DM7A>O3&; MNB/^5X/@^0EC/#H]Z#RXEAW3J7])U8`H!` MIA:XB(^Z3CA/X+(26U\%&15*]I(+"LS1;1_T9P:VD-YM_TZ$UM2\,T:B(BN\ M?GQCBT0RRR\P_1E`@D"X/>LL%,HM+X`A('V9SWX1T84, MA_9AV*>61<-?9XQS]D:=@;?;'4M-]ZQFIW'2E<5?KHAGB:E0MI/*X-0QJ0M` M'"O6]R:,J738/%-@D#RK[6*!E>!]E^26"0WGR4W1ZI(;LO08L?3=@,$4C)-` MY.%&#@\<0@Z`*^>>#`WJ6(3?]B^I9QKV;\3@&XDG,L*1039@5'H25=;*7PUR M0S"7]'4SH=>DJ'H9?[4L2W5)AP7;84@U2@=8JDDZ#\C:5HBGT]-Z]8A'\%27 M?.C[5DBG)W>TFJ1#WVN2C8BBMD,ZJJ9V6FH-TA$\U26?B=QD8SVKJRNM5AVV MDTU4OE,;GC"'1*$!9M80?L*O7UWFB-D&U[_M_\P-9Z'PJ-Z-2O.&^?:X>U5A M+",/$7/=LY%A^Y#ZA+2,M;7],L#X.9'!;&92?-]`]C%DW*?_#>>6'`MPAYOK MSIGG%V5MJ]ZR.(?9;J^K*A&S\SC(,.N#),*@^))Q[$FX\"6R^TD9S>9\/=OS M4DLRE4A/LQP@*/0+8CW-^Q7CV`MP339SM]*NM;2JKVXN&R>Q5<]C)<7U>!(0 MYW!<%_"&G0&\)4CO>P"_7)M$'22>T'ED(96,;U[YBZ;5:>FUQ`2?UHWSGZ6E MDI9P$,UB?)#9Y>Q,>T7J4WS?$X_P5YRAGYZ9OT!BK%\=D]DV+OF67F>81;CH M`K&O6QA[FH-0O9>$>./GHB]MGPNLHQ>$*TM:+,'RW.^@S&9-+$W+3*E#9FFG M:'D.)JSQZ<*^V6+B\O[2B* M^E#],4MSBC],[F/9QF-@+=*:)?V\:`K@!3YN?\'T+`9T37`4^9?AW=/!B__(+L@0&ISV MX?7'%\JM4\>!09%[!H>G4)\%_AGI,TX>""CUA]>])9#J<0O5FB*L@V!A52V\9)']@A M7XZF@(QAGP>RV]VX[E.A_=%&FA==\3%U<[G,&#;_@5+>DWW)4-1%\`>X-1J,`XA&@]\R&WE%)]3_9_F>+OOXT M\#]+T6_)\T&U!X=/](A\:0;\B;=,QAJPV<>_2\YEA1HF\`2P/!A#`]9:6)-F9,A M(R%+<@T+?4!$F))0-@G(HIYK&Z-CB3HV=4A(P1L1;STSVTJ1-`;2.40P1_@H MAIFY6(+2%MP2KQ@VA?@%F]5'=VP[4F0\$CA**3(?Z=N[BW/17C%KL5:/W'DZ M1I*:+R$U#N/0#>I1>R[7$TS^9`S=S\ZSYRY*_-HH3=3AIM1A1.H@D3H`@&D' M%OSXI.CJ@:[+HMDG5=8.-+B`K"-Y!^!P9MN2@7LF75\$RV-Q:/*!A/U;O']! MS,G'BGBL'4@PC+JX`O9*[-&!]*FMJ`?=;OC:IY;2/=#5=@:M"8,P]7`GLU30?[,G`#%5"/BPYVW^JQ'`4A?&THCX\KUI4!G1WZ^B(TX">0O?/$$=4A#W!U.DX>E\*T M'%&E!02^&%SQHC0%0]R,1:P+XG*`*F)`^&V3:)O@:50'AI=WG+F$^Z,[&R)] M>(9?FIZN>*KFDN+=Y.?22G M3!OW`3D`!M*>DD6RX^\!S^MUK4ZGI:#7"VVU5Z=9+]V0I7XUVW6IE0]V9 M>)>G<2$3CC9EK(O&A&J9@6]WP%7)G4E\^6/_'+3E==GM04BM=TMA%4=P)&?\3*X_ M[>?`EYM+5K9T#GQR7FP670LQ+LQ*8GWICA,/:_W0BG+FS79Y_G"3L^:/+P0G M?\.%T*A76SA5+@I0/693"U-LJ1\&'88-P.%&N+D@FDR7_`B(B()`E]%BYU@* MN.HI_0.;B7O_\PY>X?QSM/PZOG7Q66(\TR2$E&[QOV+RF0*BMQ=FVR.)O3E` MGQ<\>]2B!A]%V*5SQET6>B7I'QF8YQEX*5TEOPS!QN(SX.(QSJLCR[[8W"P. MN1'W'=!%=!D>\NE)6"ECS<6'D`_SR$4E3@FS]]FKI,P7XY5(SP0DYW+B&AS: M44>HE5N8I$IO%!D8^W\WW-QK@W$.B$,XUN;B<^1"O(O,X\"#K"&>T#:&P+-I M"(:\%Q;8%B"5\&0G?`7(_#UPQ`&5(3YA6H%%"\D&D/Z8_43H(SST(Q3KK(6* MMQ=J`E.@;(0/,I0Z*$2@$KV$,1'MS'P#E*.=#Z11^>3"HT3ZT![\G@$>^;.R04"988>$9PJ[2EDYL*C:N MDMCX(F%#LU++5BM:^9F*M;*A6#0'-[OJ<(7G26&]5+[6FI5-4D2F1MH((IDCP.LJ19O M"APH.S'`B1\I*88WF6.*`E-\=9]&K9!2"`XE-X"$PR-)2)H$:7C#1/WT;?;F M'63B58PY**C4$P'9"X@9`B";@B(MZ'C/&-/$Q^=YB$'L9+2B6!P".W'JSBA$ MF:09'J91$)=[DL\PNA;(R=@X#J7$;B8?B8`,#YC#(G\,*/U4V(FT4#\(HRAX M^P`?^RC7`^G9L#%+\.#ED43>38(!*[&BM`#>##"CP'@+\:"+(%J6./7^P,#>+)+%OG)IP?BUE&.?&`NPW"),1?!-%AV39%(0U;M' MCQUJ?VU`1R"-JB'.48V(9@V3.7BB%?([@]]RD0%;(A2!L5&4UU?BI)VWAS8= M]\['5P>!A1)8)7WA9H33P']A'(PT=V]TH>"FMSZ$1[MFLI=B7,L052BLU=)T MY7G!TD)2NIK6:W?R-9C&LR@Q%82C=%N=CJ:OCI8RN_7N+J[1F?DC+`];Q<:[ M:;X[+4W3U8UR/6^/XHHX5[1NN]?I+A M>'+)R,N^YZ.NL(B)534U8MX*7U!BPFT=?*ZE]T_QJK4K\NKA$9J,6=X#9-!U M%FSI+:V;+B":0+4`'8O57[5E55'K)&.AN1^UI;?57F\%XJA&A][K*-TJ6L%( M/]Z05:=YJ#T%G.^$8M+(%B%E(0MIM?66VFK52\EB-7?S3139VSJ!0*K4`<924H%C4O&?_6[X=;`^^+#X/XJ)_A.;F^ M.KN]+R/`7&F4%64X=S+S--<$RO<*D!$ MW'/#'#,L[+TA2VX[E+M:N]M+DS,'W?+4E0[Z>DJKIRE+TQ89>2T[I5N*HD\3 ME,6P(!7EP_*EB1@+;2EIZ&T]/:59B&1Q6LKO=FPKG6*9%),R?[=IC4EF1]8[ MF:XV'WO-]%;=(((U64L1G)QI<-O'-6)(U8SP='RQ#"QZL)C;/,.E\.3#`#M: M,++9?0GZC[HO(=Q*'7Z6P=OO1UCK?H2X,&2`QZ(12VIU.P>0T4LLTH;/DDH8 MR1.+'%C_X@F-P0,OP"(/:(2;!*";RU*HS"M1#(55Q7@(0%)//"['+U&'GUO? M+,`WGXVP8'OLL.)3AZ0WPY,^J6KWH-W6HG-X6NJ!*LMY>P2J[`;(.^*G*RL' MG5XWO&AKK8-.5UN,V0(TA](CP_+C?N"#CX[DGLMWJG#'8Y/MP"?++,JT)Z:HFO*AGIK3G8.X!BI+3HM2.71M-B(D,NK:3\[4-#T5[,[%MCQQY0-Q7=5KH.V! M\%=JDK$C2+N*F]BKGPJG+L:%]'/T(3?,_PV_`F*R@5.U3BIG%[^>F=9?&959 M85P:E(N5Y^3T!3RS-RG,#2L;=RSQJ+E2'44HA;4($*PE4I128MSY@7S3@?4X MBI/,:&^,]!JKQ`P/=I>8TXSJJYO>"R&3]=]Q+7HJ6K,PM`3MBBV#`IXG60`T MK-?&79[<;^(08(F0,"^0]D@8H:L+A5CZV>*=Q8:WVP7B_'T^.3HJ/`)U_ M+FA8D3YF8&);:797K;H)YUC\O;C4(6V%TTV5#U:4]58[=69%=?0K(+_\&2\MI9<. M#%=)?>JEJ.+AGN#6#@N_6SH^M'_)`3D]'-=`S3+LB4\0".^V.$2:`@&69F/M1]Y5SD?H$^Q)`9G][??5,Q%]*+P'B9\Z\V29S MX+K2T4I*0;"P+0Q7^@QX1VVWM37RN.%/O.N:_O_L?6N/VSBRZ.?[+X29"9`` M:J\>MB0G.`-T.LF@[YV9-)+,+LZG!2W1;6UDR:-'=[R__E:1U,N6W[(MNXES M)MNV);)8K"K6BU6#JB/F0M:[3V?WUI=X:`1^8&OF<#O<+T6X=P9K^WQ+VZI= M5VD)*JXF((56Z_FR]#-]!YN[1:KY]<'\WZV6N0[TBUK_X3VQ?WTP-(FT'9MB M__J@VVTC[3=>JPE#\-X47DE8?8`G*E2.-NN"&J9MFY4,BPU3MP#G?K5!#=,T M+>V4<.Z56C$P!GVM*F!/AL]=KP#T!\Y@N"^<>)(^Q-'83UND14O'AA45P[LR MS8[S[T5CAJG91K6TSO[S[T4[PX'I](>MS+\738`D&.B6L<7\]Z$;3>DW\D,6 M@MG!ODJ>C%@9BO+B+,*?37G1P0SU"S:J<-HKW&G/G-+$G8@* MAS&ZRF-62X5%N/+)O7P:!)7PNLGH'P_*Z&"1.U*D:XC$#RQ=PQ*575'SADZQ MX&8\5SQ_#,/R'T8T?<92>ZQT7^';CXL>C"-6`);5Z)MPC(WRDK#-\/246^98 MYP@D>0\%3"B!)3_YN`_/$YB1UX$!=8C"Z]\QIR2=D)!M&/P!*&I8O?+L!X&H M)H-%*0.,!>*,K.I@T[1(`[R68)*24>`#^CVL*H.K:1B?)!OA$NAEJ`!*03G< M#-4]P"':,.*M,;)Q)_MFZU3R13$ M+"X:2W&UL[CR,373'_NB5K!G"4L*$@ M]=`FRY//LC`N,Q0JK,=114#8Q1@]C7C1AEPS`\U MQ`W\10)V4""?%]*E'EEMC*/&N1]NTQFQ1=OQ!@P7JWJG:#^(CKZJ'2MY6F`1.J=: M5-G/JDVC?JCIAKW-$LKI6P9XQ\H5_:%9K9W:!L`+UY;:I!!=L_7^.F@7YMX$ MZGV(-QKA1&Z5/4W-&0X&Z\"LS-L6B#MB(Z^IETI>SBPJP&T=E95=\G+OO''O9LV>*EWTTI"4P1G MR/MI9["GZ\:,7VX**<15XB=I;L>.(_09`8V]O?8-J@BJ9]]+)S".]JK@A93K M5#0(!,^A1&:?DQEQ\\_B_1'Z5>,;%W!'9@E]F__QC@^L.%H/QJZQ\Z!?E7\, MH#0N/O+/'KKR@+-Q@C2-IC_5X;6,7M]Y]4[`5Q>H_V>[#=(UJV?9K[;=(:>Z M08=%"YP->U;?+[%_J;<;AC2SIQOM8&C9L[(LU`CD!T85XRVC] M>O4!HS-!CFDT>ZO/4KS42)6?/PSQ_Y3\1T:$*W_EH[/?6:\9Y6=>J:IX0!R5 M2^^?%=7'(,_F*YU+I#J*E7\<>'(64Z)>)7E!\D+G>*'90WED5C"/P`IZS[`N MEQ7XY[CV6>H.4EX>0UXV2[RM!6;C[R]&7KXN.AZ^D?0IZ?/O19-P]BDW^M[^H6V%U8*O MA*=]4X446=]'DU&M(?40_>,$#&1J75EK&P3R2_OTH)L]>RV.MEQ@F6K*Q0R3 MV.]^`GG]')/9__S$_[?PY54\?>,@(FG=4YX'_!W340>.)1W;D/&Z,IAND-F(D^"4_'.H31TMO?ZM!:$`7@5+\IP*TZ9 M5G$ECJ5S;L,YSX>!;:FF8TC6E*PI6;-KK*FIYO"@*,H%NS;X1TP=7\1+_NM% MI\R?]4[#P3OMC_16)FQDF*)$J.>!S^/XVBJZ/:-H?$KUSV% M>[?!5$M@''91O7$@WO%&O'/+ZGTT9D&*!C2L$@#WF_-!L2#'O!Q4%04`\AOE M^;,P["_<:\M?FU%^@W]6A1*OL;-?\6)^[@\"4@/`JF6?J^U\%IO5Z+Q3#>OM M,V!_-[;V83,MOVZ:Y>O]?NWU=CKV<`2O>;,H(%)UA^$[P3)Q;&[=4\=`G-=Y MQO$*,'_I.\53\.6@>@7?N?XK]2=E^/WK2N6RX;8YF47N3+N0+E8*85E>K`H4 M,-HT"U)_%M`FGGR-C%;>2+MKVKCBUP_OWBC/?LH*LRA_A2`CXD147/D41+'O M$>4+34`TNQ/E$[IXN#1X71W_KT]?/M5'1*:N#_:-_D!9ERJW69+ZBP-\NZV] MWX.7/2ID)HVG27YQ;GDE]?(FQ&6UK;"9@QMD"=9_?X[BP`.EIT!5(@JK(&VS MU@PI=2=A%$2/3E^F"+^"/I[R4B1C1*X?@M4_*VB-, MW6-MZOPDP?HJ^6'$RJ6(O_.#R`_S74!QRGI8\P=]7N8$,4\"!8CQ.Q5=,A2: M-PUGB%J-)\`(3.8EA6C-<9N_DA=^J0+(2D:50XB:4/@6ECXIB^T4U660D"Q- M\<@<*W#Y6/4G]E,8$(]3@`E.'U&EBL"1K>8KQI(!J:A!1H"R58'9*.:3%C-B MH9L"("Q)5)U]3/R`H=IEAY'T)CF_-6,)+V41`]9W.!?4%/FM7 M-Z)!]"RO;`9T^?=W/VVZQED,$!=_>0OCE%<.JCBL_%BN3:L^^H^B*(VP&IJ< ML.)O9D_5AU8TO#F*-[\7<5G'>@'1IA3G'?;U785"*M;1XB:O.'^^SJ=PCF]( MN5ZD"#Y/?D"\MY=IHH$HZHC=<=OVW\':IE6W\TP;LP_SW?Z(?@/!,T.9&$=S M$F!I+TH7[:97*+G,5Z+2W@HASOL'P?F+Y?L2$O!JB\4Q!)JWE[EP-)0,_SDL M&AA5;;H@B7)9AZ78IKS4=`$?FDJZH0Y`)P?FW923C28R*$M969$7FD!+R8X4!4."O`%+@3\72A6+*)"58JX/, MT+`)8%`5/\R8WL!:GY:S@7)C]NS!JY65L!;H^Q^E*%SOSI`2>4N)O#:XVS5Q MW02L%.7=V-%]Y/S].)="238J;(V:9>"BNZM4FQL$/"L+[,>HAL0;R"80R7CGASPRT5[.)HX55BX,:_/BN<+=3OF(\[SN<"X(*]+T+B]Q6,SI M1907J*Q,@8KVJC4MKZ=>[]+GH[%B*!Y[B>#0-V)LNO[L0X.D@"AZYJ#47F?+ M1\F.-2JCYQ#-N5R^5V&6`EH*:"F@7YR`%E(MIOYTE,6)*%Y<>AI0_&9T2\`)3%A+H9KP&.LHF.F^7KE`2!\AX[.F"1]/LPC)ZXX[UPQH,@6O7XM]*A_2TF83(&F!]CPII1 M/$7!4]XF8ME]/5]9H)RKE-3'BI=BL"6%+,'"ZJ2^R*HK@KU;^U547\\H^G)S MK9,^T2":)84LGDU(/"4N!5'K@E"&A4^IQ_Z$1['8=^[V6*L_]I0_(PYA\3BI M%?;F+XO9\96&FI('B>.+]@J?-13VI>HVXP7OZU'F825H;O4WQ-SQ_5\,TZF$ MZ:UA*X%VUA\@+JK/LU`2]S+A+SQN4RF(G[<(P#8NC.'P-["./,Z5:"=A2A.+ MM"08#9KF>0RBMCYV`KCV<,3Q"LYO+-&[5-.7=3QHOSF>.=`&CC6LP5:=:@\X M]FQ^I_`.R(!7W0K[5N7`M''FG.;?G6[-O`;7L-*7L[+=3 M9[^B,\#5'_OGU#>KG1^8D0#J6>RST.L8NUT%8/XP[TG*LGI4GA2$9M&8&8!/ MV/%I23O9#@JK-Z@A[.-M8\E?M&O9U\&PIVNR[.OZBV']EC!T&64U MK9YIR3+9;9+G-96,E[P@>>$0PKRBDO%F2_72+Z`\KM0=I+S<6UZ^F)+#EGXG*Y)'$@OIRJA'F@0'G$2,'1Y-.U5"&4];,/Q!&6QUM; MPVW+!1ZET(FAZKJE:GVK)`Q)^I+T7PCI@Q5OFBV1/E<Y4[F$7']*-MZ?757NO%2_?$V67 ML]\Y%?-96KSLW'S=;L6EO"_D^8_<9]7>[4T=C$>]\?;FROE:@&_[>ZZ:YMB: MW0)X_R1!QN[OM8(VX"-@HP:PEJ8Y`)SM[W@>"@V&JN[#!QZH:O%JL#D86DVT MM7J^-@#<_F:P`:1O'`)?DF1XK?#S^&L*G'L;>O\B,=9A23Y%\5=XP8G9J%0DV37A2ALZFM6,*3'^'O/O@`VS#R#L,'T4/GZC\?0#':5_1J';!@H&IF5: MPPKS-D^R)R#;X\+1;=.Q[?WAN-;R`%7W;`6,`BQ%V&2Y$5HJE=LHHILZ=-H- M!:ZJ'PZ`M%\W>FM&[,X*]#JX]EKXGQ$VUG@@2UMK1/-Z%D7?$]C]Q"YT7/D-=Y6R;,K5]K; MG."X5^TDSTF>DU?G10Q':ZG5]@5<$VQ11WG9.33M"="+$9<7?#.9QXZ[D@@A M:4?2SOE/J\Z=3:%@Y2&+7=:KH"C'SUO%/GSX77GO M1P^LP+]:;LE]Z/;J'8+AR?(C=AC&4NWD$89[Q+:PV*_0T%1'TUC*`1N<]Q9, ML&<6N[8)SY5AKWAX!6^A`5O!;1E9]P&.PSMI'=%2UR8%R7R]O4,W"<2SXNND(O-U'LF]D\(L!%$ M&L&2>X/B,&8%"- M`6)ZH/)6[?"5I=J.KO;[/*7#PJ^&JF$:JM4WV%=V7B/?X;]I?)_8;T/QE56F MCB",?-RAR1Y>U8GA\./KTI//SY*SV.9U!IG,^%;7>P-YVZ3AEJ6CZK:I.G9+ MEYDDQW>"I"3'2XY?Q?$#U00]P!JV=/N`FQG=($7I'&N#-S>%]C%KY`94X*FR M(YP9![@\Y-66]LZ&TV[#]6E]DD\EGTH^[;ZN=AE\NJ"1\8^[7D); MCK->3`;;I?3+0AVP406\PJS"LZ9V?@Z5SVX:U3S-W$%L%/V0&8VSGJAII!!E M,4B0-$4)7J.[O1H'R#O!W@$0,7'3>E#@P*""JLRR&*^WI.A=?Y[X[H3Y^_-V MR"#1K[(]Z1/HJ5B/5;SGA+>KX)]9F+ M1LBR8=D!(!8-RUCLHLN0%CW+*DVYR[_8%33J)3SRA&3%Z!P;B`/5(4VQ2\`9 M:Q@>*>,L".9`^3/":?`/W[LC,^7WB(2J4J'B$0VB9]XD#80UG.V9GTP:R3$H M;'>/CE(E&L'9R)L8@L44:$]0(,8?C\MUB$(7?C=U5)LM%_8$]PNKS?.4'QY_'N M\'F0+H_.Q2!8_#CO-%\V+P>9Y;O^C`D%&&I$\Q;13R`8EB]J8R!Q70"1R[X1 MA8,D%T/C*(M!NN9/P)@L(IB'&GFK;3_VZD\8&M("S/WD>ZM%&@](IE$*,I/= M"_!$>VNV&3/L9PO05D7Q,XQ:C?@N'12?,M:W^Y9%,Q>D/&_/C4'67_2AJ@WX M$*NFBM:=;;Q]N&IO'N,V>\R2M!Q"[_,Q:F<."?EYZ$^7SL>FXW%$TV=*P]I4 M"!&``<,Q+PI1 MOH$2N*?<%2*QRA0@SXGKQAD;LSY%G?#8CR&(H5R>QS3-XH*:9AF<2[.-I](D=H(`Z)@;@?]6Z[`*!"^/2)W9CG@JZQ2(7`(!+X'0<8\H%X^0IG*[$ M^P^P\-IE-T'Q@7)"SA>YXMW\2$F4_V3>(T\!@8G]RBF7@(V*V2HHI$B29-,9 M/Y5C&N0'3KX_Q76N(HT$I M[S;"_@!4_)GMH43\$2%=IV2N5BHL%6TWH2@AGQ0M@".7'W]?+$`:`6/#,;WR$$9%"66;$#ZYCX`IW85:@*_>)BA]0,B4?@+1 M4KEFR0-%/\2^*R2AT#J85EG\A"*M,,N9U,^F2RE\H(!QR<4:.:.V`5#E&AU3 MJYZC+/`*$QRV8?/A(5P&_,10A/I44U#A@"#?Q>$4+:C`A=4Q)1[-QQK5SC>N MA]93#/&DJ:+H`P5"_3M#>EK"*?K(<(X:\K9R1=24W&>:HTE*]--*]+L)"1\9 MR;&MB8)WRATRM93R)ZB2IF#,`O&L+HEM4C>,%G=I9WZK*Y)35`L7Y"59EI?, MGX-"@^5,5U^8,;E8$XIKX>6"M`8U=S7"0/"O&(*[`4:H7M,$UH0J[#@51V'] M$&.K69R%>P-63-X%*8X+3.:]/H#5Z]>1F27JDQ M`$'K8E<0S;['D0S1M75` MO8](C'4>&3G*6-RYS`XOBW-W0.X77^L$!Z+WTX`SN\_^1[R)3%&RQ0Q>7N)!*OB!JB7-QP\@!H/H`Q@!&*PH^0BYPE M+R-[I>Z;7!49P,5X@O28AX\&W-DB+(E&-SW>TU9N^=V8/RA-A0?CZX3$5)0Q M:YSP-E68Z2.NU4S%JRR"P27BUIM08H:C+(RX7Y+A'SUF4Q#E7A&J*9;(XAZ> MP"1_B[+SI`'G<"3Y7,J&(.P6H<:)^-S<9X['+:Q-`()G%IP7*T*+/^9`M0`M M*,[>V2B#/2O`DJ>Q+%10>^7@B@31)C@GIUPE3 MJ*K'/X_9C9!,4<%Z(G"FN_,Z]3%*!;TD"](E)8Y%V(4$83J!1TDZ06TSIE/< MT4:J6+YJAP1;>V1,_(#17J1$(Q9QXU/]G?F)C]PE*&9M%*]*;_FR!6VC>P6U MR0J9;S\2,-PS0UP8B0!^1:#ZI>A"DL>5";1RB:#T_H1#$"P(:P[CH MC*Z/M"3=06,5C,\#P0G("JQ62N(Y"UIQX:_R1^K#%ULMV>_(^3>+@3Y#%-A6 ME?\;34+E#_=WDCU.8`1UF6GP5,9S$<\'1JX5'D6^"_PGEKH#&YK!YD>IS\VW MB9]4692S\Y3=.,U)ON%DW^(H+S-6EA)XEHS419["U\M8!RDT":\2/N)+X(:F MD$2NBY=E/>6/:H9!B;4ZSY8HJ"Q?V*U"80G9_0-VE&TU9!6/N!?POI!+N73$ M48$82/T.=55)8@$9(=I6RAN1&`!L#$)Q'<); MO=5@]0-FEJP^C#GW&-5A6H8?@D(PI5X->H8K'Y-@*5\^6N*A5Q$QW'L1$+=4 M*E:!RC0(3.,`MI.RY\3Q)230&6._+XB\1.+_3/9>SF^S84I!PV2%Z*U23 MCT(`TA8GTA\O<,JP*`]H! M/VCL@AS#C\P+QO2&I3$EUYZ6:[]03!\5]E8(YS4:8Z$GF;<#SAHXLOW(*S,S M5R6D(2_4Z$$<=+$+^M) MSR$?!RVJ0N]#-PDFL6#]>0XT'=,8U5GQU5@((/1US0%)S.H"920L)DH69RJK MRF"")*"&#:5RTR_PTYMLEG!+%9:0)"QYAK\'LQ7/O\%'0+5A^9OS_*=Q!A,R M;PB@)F4KAR%HFN1:71Z^P=XX'IW.ZOG>,5B7:`@&[. M],.W=1\!-]NJ:+<;5S^/9.R4)8,D\#X#F%F$0,4NLIC-`IJ6ZBE^"4<&>HK0&L6#4J"$Y7-X6>'.JZZ1B25` MT^?R^I!:DW@<_#R>M=I-5KE^E*W1TMD95HC=^J4EDN80HYH0/1=)':L'Y!DE M7`6M7+WR(C=C*DN3CE)-M:SJ*K`KC^S(S*X0)5KI/GUJ8)8_V"*X!E7TT(#K?9@.!U" M]UC,GP2OC7P>?RY"%[(16(N-P(R7V@CL<_Q(0O^_(G@)Y])[D;2Z&A_7>/A< M2#6/?'.4K]D40)W+?3G1Y4R\/:D$E##?Q)1ZOHO)'=2=A%$0/3('(WO.8S^) M[!1T6<\F3#\,6=H9E@KPXUYSNE@4I^,H\",>4A=YV1BN8M,!D.5%)(3FB?A! M[GY%G1%/&ICV*^:;):IR1T+B$1&4>D(8FC+U6?39RCV/<><7,9MO*' M>)`PRM+I""G>HF$P>Q8S, MDFPTS=PH(5BM`@PR&@190-C-MMC_4:\?\_'NC[J][$9DEHK3Q/>X-43#!#XS M/R'G`.84K.&Y3+GJ*JJ*RB'-J`)$%#7O\_H@6%*,VWK\79CE/\RN6Q0,B4AG M93DA+A6YJ%QBX/V(-,Z$'V7B,TIFX2E&K1'0;\J]WB1-P0IF)O+U6XOG/!@Z M+ACQ>"B%7=/Q4/J1>IWFN0NL*\2:1@#%96/BIEF\9@/NHN@[5NE"+4*Y#T'E MFT6LI)5PJ,6TC+?B&1/%@??L>U@H`0[HA(41%S>2N=G\$%U9B0AZB5'QC,3, M-I:M'H"!9V+1,LV_9QDD7>1\^82F.$^[E MC0Z[:5@;5[DE9"=;Y6Y;>6,ZAFD,3[K*S[G(.=U>.IH%1&MN7.:6H)ULF3MN MI@-69]\9'&V9>*!-Z>]1TBZC:?V^HPVU&MCE5#M#8>\%A3D8&+:CMP7$?ANH MZX8^-/2V4;&K3#!,1[?[6P+Q?.LR7P.0#M!9"'_R-/;D`9/PY_S?(DAS90[N MEEV!7RB[:%]B5*FC5%J`Q[UL]`>95ZYV./E-(U;M@&LS&!8N=P<4_]`C6."- M7Q*IN5$^W7Y]7_>CB,RXQ@'^FK&+/+41;K_^51_@SZAR*P1AN]&&ZK)R?7BB M35ZED27GY3%\D5U_ER4IR()X.9JP*\;YS2)@!E:R`[`["XIP.:P=S1?T-7$_ MK$_SXJ718PCC%/6?V$7`F>]R?UZU0M1C%/$<5W8!S.4#N#GX:#7EY=Q83D-, MQP%U<[=@I8(%2R@5<7ZU7D,Y]Q'S0G>)*%):W"^'*?)K`B*)($KH,EP<$;AD M5A@O2*+\?A0.$$[0->&AY8C%*3/,?R0C=&`*%.2)C2/83CZWC]ZW"AK+BV.L MQ@2_T!E3]$\C&?(\[(171F65]?B5[N7\9[THP::12NSI"IH%GEF6SZ_?2 M'V(Y] M;.#V4VS[`%U?'YX(<[MJW7T3=']M9^`^UY]IVRZR;##FJ@DE#?/M"=!^%&88 MMC4<]H\!T'Y496M#W1[J1\30KI3D:,90VPE#&*P]B?"RAA5GUOII#P=Q+P(S MC=,!N*<8452M/>J#LPFD1^7D7)[M(&AV MPY'AZ)KN&+M`PR]6?8MN^:TG>`QT>KRIAAU>O9DQO;P^YEC6PUH&\$H:CP+XCNON&8P]:`)[E M:WA"",!S3$KP+1)EY@]+E!Y:=E75VV*^-@#L:7MM6]&13*)#LF:]JH@_I1?0*-!()@, MI2[[G,R(FW\6[XNVQ^P^ZBRA;_,_WO&!%4?KP=@U_AWTJP*/`50VZ!6?-[0@ MMHS>0#MI"V)GG];6S8+!V;!G]?T2^[=SDV:SI[?4I'FYM/JV5'UX>W4@)R`Z M6"0H`>M[?`\8G2WT^&YLXKU5B^_5'<*/V6A];U0?@SR_8I7->JC4U-0E4AW% MRC\./"J+*5&1DKP@>:%SO+"<-6#J1V<%\PBLH/<,ZW)9@7^.:Y^E[B#EY3'D M9;/$VUI@-O[^8N3EZRPDF86Y4RS/Q&&>BDO^GK\6'<.,I-_K> M3I]MI=)V3I&N":'NBIR6>8*)E\ZPO=S`"]_`]N1VYZ0T'/+-(GI$W.^/<92% M'OI/GSY=G?#^E,6ASWK0U[SV1Y/DK6'VS")B$\]8G5EK&U3R M2_OTH)L]TUF'HRT76-Z.JPK/GT"UQH(K__,3_]\B[%()RHR#B*3U*&9^N<`Q M!JHUU"2Y2W)_$>0^--6A;1ZN)72#!,ZO/UR;EO`[)0EKR8AWY>+HJ>%2L;06 MMK46SLGIAH,'FR.WJ+M;-#!5Q^I+BTU:;"O3K+"8&]Y>EN;:T:(`G=33=%4? M]E5;-^3&7MO&:OI`-9V##F:I@E^W"IXD;[$K$Z087+K>=('Y3L=%>6<#ZI+>)+V=/H'CTNE-VH6[W+J4 MYM_V8>NVM'0`5_&B#*]UGO(&SY4$QL^X"^)>J-UO6R_DM7BPUNK+U\\HQWL_K ME9>*I%^L6<8Z016/;E=TR1F:0]O<8MT,^O.L-']VQZ7IFCXP'>E5'W8MW7C(I9V`*$:#FQ@V_SX M)SVL5"5H!Z`<;`$43'002%O7:P-#HM9ZIP6(KK5`FZST)*LUR-OP70]A7UVU M!EGI2?*"Y`59Z:E#K-!B,HK4':2\[$RD_^KDI:ST).FS0ZB69Z*L]-1=(=1= MD7/5>69R`R]\`R\X7KUW.N#+R:&7E9Z.PS.R],U%E[Z1E9XDN;\@5GMK5 M'ZY-2Y"5GEJT%L[)Z;+24^>W2%9ZDA:;K/1T[BA`)_4T6>GI:C=65GJ2*KBL M]'1^\?!BB_/(2D^2F&2EI^,3TX[GFZSTQ)`J*SV=2$C)RCNRTI.DMZNB-VD7 M7K-=*"L]'<`8LJ!,9P+C+[2@C*ST)!E3,F8'&5-6>I*5GMJK]+2BOM,7FE`2 MNQ-X]`-]HD'$'O[X8T;#A*ZMKV%6ZVML+$RB]X?.4*O4`5D[\<$PVOO`.!B: M5M\\%8C-94HV%9W1^D-+.QF,]CXP6HYNF-J>(*8$V,O[2.(0)%9R6P:;/M"Q M[_J'5<>YL8V^-K!MIPK\86_SLKSA(8*G&-)1A+_B2KTR?=HZ%(E&BLD5$@?I(FJ MI!.JS&+?94.-_1\P"OHC/)K2>.J'J$BH\"F`X>*Y,B&)$@$GQ;%X#EZ/V:L$ MX"!)Q%Y02)(`@XB)L>01=5FL&S[A?`D)`#,S3(>B7M)3Q&)@_BA6`%79F+AX ML\7#9[S,31,V5_$AP7S6-((YW2P!]8W&"KS(*!*^`_2EL3_*>'3],:9\P03@ M7$057SP;%=<@EDG9X/A;=?ABV"A6%9+"`+X[45+89/@GA47/8-6PADVO8A8N M[(JG*I/H&18>XQ[`>#X'QR4)PUHL-G@<1U,4/0FHJP`80UUE0QC4?*M6+`KP M$+`5PP1$@7UY]%T2<.Q[@.2>\ADWBC0B@M/'732=D9#O?A@IXRS&;4="&R.# MLGT>@3[-)`/LYX<:=&,&&DE*H.M;!\*59T(`IA(*^_5(\HG"%KH3X&A. M!?DOG#:3B3^;8?[>`C&1)-^O1/!@0;?P('MKF:C4*EW@XBG0>)8@%"5#X.[' M0A%0'H&GQ)B5R07AP&[X$6-(9+\(TTLH.OD3\88?RJ]N:(9I5\L;'K#HW:;N6[9N]K6- M,T=S$J3SW@"3WU-@>A1VO\N)$*M:.57&L!Y^@CZ]!\D_DY3^%O, MN&6!3FNH:=6UU*#>?46-9'32%5G]5A?42)TG79!A.L?8HC.N:&CNNJ!<-6S> M(AWMOGQ)E4\>]?_].QR]P<<0U)EY6;'WVP0TJ`=*OB=W9.:G).!PEZ5@H_`1 M%9`/=)36:_T*0.ZQT`=-TH<,SC#0;FYSE6QAH"^HF]9P]P?YX4^SZ<)S7[-1 M0O_.T!9^0@?-8FW:A=^W0/.-]=.O)O=L+J-:K**.ZJ_N!)2G@'X>X[+O0SC' M,W:SZD69BUVOL5K%G>[4O+A[)6_9O:&LC+;6<6[T+.=R2P7MGAEC]!Q+5I)L MDSR[4E6US0F.6^U-\ISD.5F]5<1MM0LN?+ACHER+.DKG<^4N1&FY&'%YP<4Q MNY6B*VE'TL[Y3ZO.G4T-2=S\8'HY-Y]R-USN_E)R_Y=2.,"49S^=*`\??E?> M^]'#A,13HI9;4U^_SS#U"8[M[!D^7'#^_>L)@4>>0A,Q8U_,705$?3 M5.1,-CB9`J[31)F1.7.I3`'223#'`.:P-QR\PI>P4U'A^T\GL#N/$Z7!#D,[ MZ5T>]55@5I@TQ@%>^V_*IXIA\\!;'LD$6%_[U2>3&77]L>\J?V^9"NQ@@)&_-((E]P;%YQD`)$9;OQ)#ZRG? M8!53/T07(ZPJS#`J2N8\6"S@P,`9P=A?$$3/R5L%4:#<``RJ,4!,#U3\:H!? M6:KMZ&J_K[&O+/QJJ!JFH5I]@WUE,]3!'P[_3>/[Q'X;BJ\LDVT=?]#0^+A# MDSW<.YKJ<^DW3+85M^9YK_9V`\U=35K6>X/SFO7=+#!B.*INFZICVR4_2(Z7 M'"\Y_FHY?J":H`=8PT$[',_-C&Z0HG2.M<&;:])T><6A*'R\P9B\\F>4PM0/ M7/F7KK-]SXP#7![R"EM[9\-IM^'ZM#[)IY)/)9]V7U>[##Y=T,CXQUTOGB[' M62_G_D\]&-Y:DOSFW,)5N8B?_-!/Z>_^$_7NPY2$CS[LQFV24'@7-T8F)W8H M.?'8#>#[ISWP+RY543;)E&E3UY&J*'E!\L*Y>>&*4@AELUNI.TAYN5E>7G`> MV/GEI6P`+^FS0ZB69^+Z^K/]-G,FNA=07(P?^BZ[$ET43SE>P\!+#TOO%*SH MQ%J[&DDP>W9GNSPYIJ,.G!9:K'2#!"2Y2W)?2^ZZI9K:04VT9>GZ`VSISBL( M#R25;83WME/.R=KV4+4-7>Y0=W?(,M3!H(6.[I>Q0](XV]DX6VHG>9+ND9=^ ME%]@D*B;RN%KLZ^K0V-P3)*Z!*-@/[^M)+^#R4]SU/[`/J9Q'Z'C1#"5-Z) MZ.B="-M[HLW[Q!\^FWA*'+R!NS>J8L)=LJ>5[3G0C)"Y(7 MY)T(;CY><(7Q'7V?4G>0\G)O>?EBDKCIU@4VB2YND&V&_SA]^%Q('[)C+IBVI(Y.G#W$* MG7$7SBGB3=7L6ZJNMU1G7C*I9%+)I$=@TJ&C]DWGQ7L@^$=YV:'Z9A4+&R\[ MK+^KL.J&P]<)B>E[DE#O@3>RO7TFL?*;O&?/4_H0'2Y)A';63\C,%L\XK/VZ9$-\ENZNS25?G]_]<7MJ@OYPRL_GEA$D__IA1%VO,L6["K_U0 MF5,2)\<3Y9<>=3A`I'>#@L_I/^GW-!D?E;34+5IZD='0%Y.A61QP3U%`4C_P MTWFGS91N29US,K@][-FMWC^XM/C-JR/$;\Z_K8[9,UK*DCI]_.3TV]J:-?5B M3)HO?O)=&<>4*C%)J31DVE`^.ZD!ZCW#O#YSHMLG1SO9^O49`Y=[V%S; MD5(8$4!O/@!QQ/OAUW=XG%5AL9 M6`O9732`Q3_>AMX?)/Y.4_@;SQOLS[HN4\NL9FJ9/RE9Z/,'_X(_=.,GQ:.N M#SN58$+2K[9NP_]KE16MG/4PZ.Q]H#/L@6WT]>-#UYSEM@&ZH6E8@Z%U,MSM M!IUI#+2A;>\!74')=]$4?V=`M$AS`[-OV68%L,8)]P=J+U+3^X:A:<<#:B\* MLS7=&MI'Q]1N0!G`E8-6MN\VCDGXR!I-OY\W"]!/Q(]1<-**T,RU[@]"Z?Y" MTD-$8G5YYD^_@A:QF0Y:A+Q+B%I/"-U#U&CS=*-=IOM&XZF^"RG]^M#_WP44 M'`6F3JQ],0?\?&MOF\S^6<0`6Y0E?601QS0VRN]6@>\6MK87*`Q;]M"VK@5; M&&[X%%-ZC^EU-$G;IBQ-L_4CX:H)]"YA:D>JTG1CH[K2/4P)J_$W>#!-[L,' M&ON1]UL<)??NW;%A@*+:!G-;S;((2_#;;)?8@)J?X3?0A( MF#Q$@>_.7\+-I#7]"9F?#+8MX@M_FX4>C=F;;`Z&T!N&4:6*TFW<(A?MTSGG MS3'FV+EAR@Q09\W.2E(EIKQ!=\O$5#R97%0X< MC(;3C$%XH=CR&L$89)X$N%"H=$]"0`I=-9$,TI MOP#U\P\`:?@.W_L[\Q,?!'9"XR??I` M#"#I6+XEF3GG`!XGVC?;WU5W8&=2:4;2>>[T%EQ];FI-,%C&%-:03;/Y]2W;#MUM3[F:%_B!D!)JN2N M%YHFSY_SE#J[FJ6T3,3HR:*^()F8+9.J5&--.S@I9)5DX4U"\\4W!7\YU^54 ME[+-4<=V/O%N1H-'NZY-4U\8VFFBO+CA>&W&&M'BQ#*R.-K=CF7I1#>]SU)J MG_9$9?Q$F6HBZ>0JK6:)28ES52ET8'K)E-P_VCD2_X;<0!%_;@#0":4:536U M@V[I\4ML#CUO[*FLX6DOB"/[[B>:U$2G%?&+B*AHZ=HP<_#,ZH]9(9+15E\8O*B%NDY3*UH6-IS(A[7:B4>)F^&BDS:RXH M,;QU.J5E&A>:>8`^5,0P"\QYH9;,7^NM6#:AY=1&:Y[WI,:RKJWJV#Z8$2NA M,5%T>MQ7-$HUC7D0-+45R+M,.-TR:J;2+AT:YNY:5V:4B=T3_W1%]EXK?N$N@/;VJ4B7VM;M^9-?3*W*4B M/^`=W6W-L9N4T*4B[Y:R>6PJI4M%?J#&9I>*_`@]B"X5N4M%WL6PU?9(QB`H M+KF:Z=Q'@TKP71#=ZJ)"$3!6S5+C&T%(6M@,_:3&_ZH--)(/(=T4+!I')A(K MVCA#&_0H,7YAZ^-T,D%48U%R2*0/CJ-WW$^3LI@GIJ;W_3P'R>D,4>P:^ M'4<-H[4@%+::D84UI2$DHWI>XW#N4BLA=OF09XP; M;P07T]O+Y$I3[V.MYSQ\0Q(PG:0CE5>#&[+0P^%_)]6DE^U!$5P_KZ(E,>-M M";8,\RU.S/F;R?EP>#[D_F!3.;>/G9SZ`^"7JV[Q?+C2_N.%W>7LU>^5H+7ME?_!T?V4)>`9; MGMG[6:GU6ZT^FE.U2"N5?:O9'3W[BMDUS',R&D&*$(_R!J?:/-;J/J&W%0S# M#RNQ)I.[,6QX]6OX^S/).-S(P6"=5<,/MQCI86R-1M;EM>72Y\9UHXF?U7,: M/^F)(L@:CIB;I)^1I(6G#9MS`6^K1IXR: M*R4+I!AQO9D&]+7@"]*&E=BJQ24Y7I M12V)7]-2RX17+'!>*ID\MXHYV&F*O<^I0$'SOMD"64^5-[.:V06$6S M1JK/%UZE_K`KXUXR*ZZ04-.3U#%KU(^4X54K[0:SN\%Y2M.S1MLE&I=B%Z8TB4Y0`6Y!"6V'80V`8/R M/E^05F')0/OY(AK=A(>F3#/H>.N\HT`K933MUU0Y8O%#RN650C*S^#`RV&37 MPB`YJ<0UP[;TQ)%T;9`^@:]"#HXG'YI2P3-Q8QDDKS1M(;E3Y52HP/TBM&EF MZ6+!B4LQ,2GC]LOZN0W=TH/\UCI1]4*ZP.3)VT%>4QDR!'8?F5"JI%EQXM*: M+QE[@S;YL!BE[(,B:U3>2'-AV\?O!ST0E7F*Q#?(-?[CI4_>$V%W6K!?5789 MUW<]TE=(1ZW+10'I[3141=S#:@,*#/LSR8HK$XM#ESUJ<-J1S&B9LV62I;21 MT)\7$%O$W_6<]Y1Z(+&"TRA)UR0]1RK.IN=6<`/=H0<-AV2\L:1@>'.,F(1D(/(9<6QWJC36O12;D=D7+6@S/P##3M#IN'J_(- M/'`J.XL(EF[O[G"D?D/*8$-*")JR3$5J0,@594I#8\%Q6<`]L.?(+)I4<\Q- M,F/,Z=I<5KV:U%FB7`_^]!W.P65*\X$?0K(R//J5=HT\QB*09`Z]F9*H^4/E MROHK*Q``.%^^8LMS0]=+ZG):9ZI$PONE(*12;VG.U]@X]_<&:+,0(I6<7!<$ M"/=8#&C0"%9Z>LS^;L\))\$A6$I;DL>?$'_DQ3P=-8_3]#9MQ17IA4J#*R9B M3MKS[#IWOA0].6!?^Q)"E]66:FEL@64O:D-K$+;I#,AR['P&>:,E9+ZP(P0(1E1`;]B&`WX-I#VQIOL5BJLP1Y59## M!M8A7>_YEGT&7`>!0JR"D//&-5]`%340)@S[<60F&'!U@.:1YFX, MZH(#VEL'6=+[5XV'_N6U' M[L!6?N>>_!/DS?[<"^5Q@)5RZ>"C[2)!LAIR1-G]5=D(UY-"+E51T?-VH>32 MM?P,*;@''35=J>BP`I/$Q:&(V6`5O)_L;T9="Q>ZNM(DKF@%,>EP`10;X'(J ML=*0>SM#&&!8'V254%L!=:!.QH$;GJ9RA.;T9 MW8`WK8C6W/R\A_0LK,^/1_;OZHMWN2]((JS\/.2?#WKH M%-?Q1!#9LE-4=SG2R#AGZR+TN]B!M9O!/MH&,X8=1C"Z'A$'0=1E.%=+\AH[ MS+A5NIB6:C&#',H03T`<:G1PZ#97'W52+SX#+.6,.-`YW'.26X;,'C5V\02, M9A6./_9@.5R"#Q:+S$33=#$:]CO'9L;;>>(0,]F2W9I"GE*?_F"U\T%WQ0=] MG4.B%["4NRVYPY$&ZRPN)?$8L9+F&"7@FZE<(*0J1B[K)3DK$1(!$UQ%G5Q" MEUS_;IE'<3PXBA;L/S^=O+S!/?7*C&BE,,+_P@A[#)I8JW*\BT,DD9V3/,8- MTRX/\VU95':8D)NF9HLWL,\9OM&?0I`5(IJ"T2^?3-+2(.:AE\A?9%K_G+"] M@[H3C?-N*N?)>'BX#KKM@4"W/7#\M`U[%N_7_4?BWR.%CA?NFQ=:SQKNFA76L=DZS+1K)5YVMD,G+V\L+[\E M=-2CDY<=VFE'GSNTU)U.[)!O@BB^-$_-3(^3:5'<(43!;J!C?`/FV9FY;H,X M?MP^/0R/!GL[BPFSWQL.CWM[AUN%D-L-?$'!ULB_5W"1+I_ M<^*Q&0U_%>5'A)39F)J=]FIVUX>Y5W;?)V8_WG^H0$??V68='/6>'V]5,C^, MS>KM*YG?J"AE2NDQ5UGESC^@6:3>MQF%O;^]9[^G>EL"9.^KJJ"NF+O)) MAIU/LAO7?CNO_![(/>".'=EL2^K0<#GC(=.[6/-SUP^%[G$7[E/$'_0.#H][ MP^'1]^N)=DS:,>G.,^GS9[W#@V??_0F$?.R@D.\Z"X;1:'-=":*7Y$PB5S]. ME3QX=M#D2OH/7;+DCN[W;1+11L5<)^_5IRX3[9O!D0MJ7=4@7CATA%1VHU*? M/`*V!2%`YM!4Y[I!IV$>7O`7^=2"&P'H;J(9"K%IRJ:^V9Q800%/:N.R45W" MM)EI;7-*U6AFP01M1KV'='2=CUTW&"J0'FS6:98*"$)JH1,%Y-Q"EEO@;N1# M<<[YR*);Z?F"J+-<6D!S^<$EUG/*E(<,D)ZQE]A$D1:D5XQNBQTF= M9:W=@@8N,$%MH/4D4L@FQ;>T3T]_:5QV>7DIB%(FZ:91O:9QC!U"C'U+,!E5 MB(FI+E6:<9+6.JDQ-L^2=OA*E6,&Z;IHLJL%]O(U`M,`U^.`04^+L28%PF`% M@7YXMH_)`8_'U%G58,`M>-SC0@I,DJT#P.#_K6^SW+!0I@V4J^#/@=[!`'UA M@#Z^Z(.^B8,O+/R*(U_7(%$FJ+9>S'3FL84`=".`'U*L(:-)`6%#?6+LC[J: M%4#"&R1GP.YLQA;@M0@87IV'-10:UG,0("3@8?<4`K;BQ!'CD+8P?B2+6W#M MK,YP&)]!>RS3VQ>4&'YBEY*-/UK#3:..T00%(L0_"A_`(Z-163-8CH?2 MV[P.-!S_8EA3@_Y2&2L*\+F7+O:1&-4O1EAH$&WH-9DLETD'FLF_+`*$_J2` M%2P$(+N\)I#.;&4.4I7`!>*'I"&I\M">C>,_T&CV/"0#3-Q?[2I;;8X"%+"U MH\&8(+BC,X)WQ`A^I=(R^5^D>4-XO/+6QNL&+;/;JCM6-HUW*+8%V/O2;8F3 M:T7>MR*R+^9JC";JD$T#9W9L$;,FV&)NSX0FM2$Y7_4!`)7DB@TAT1Y&APVR M+#)Z0V].?&Q$_NRUX]%`/[CO%VH9?LG2-9:$S02<@FN5C5F13V4^C/<:K(3A MFC_LN959X^7:XHS*,2Z;TN2A.$E;%^1[W MZYN-]*PJ1A_[PD11_2H&!PG,(X,'?9TI1DWWCA*XZ^24+(B]_80;3*2248+R M12P1`)]"A@X;'/*$+W$D#\$OU$I`DJ?.0;1TV MF:D<9JCDMTS1=IR-9@6Y"_T_2&G`F^5&^Z@H@:?FY(5FXC#7QD&W4E=SNS=D M8S<(]H)1$]U^546X";J.-V!+-P M\&C7M=F@!<8-K]1@BW%Q_?%/EDYTTWL`]QB`:3*0FTF)2G4^ M`<'U-=P8DK&0`@R`ST6W]#B*NN%Y,R+/JG80NN0.57WW4U`'+QZ[)PG@K?6Y M;+EW7DK>O]QYL0R+N4SA5`8&OU>;]."'P1FU7C)C+H6>C<5:SP/[(/!G6''' M1_'T'*96M*QER,*;0-`7*A7TBN6 M36@YR3S2/&\Y3UI;U7&,?92(HM/COJ)1,M!HP(.@N559>?UZ?!V^T@/!5WK@ M"")?21QWD?_^)SW8D(RP1/.9>:/Y^)5`.[L4S[6SR=SW'U?ZZ+`<6D&9M@EU MTX%%=$2_@T2_#K_T<(B^@[1HL5^^)6+*]Y-^]=(7/H>/](0\#[ZJN3M1_M"S M&6XATG>#@N\S+O-PL-?E776TM%NT]%UF67TWR`]>P36'P3OMINR6U+E/!G_Z M?/!TJ[A&#RTOY*?M$^H.;.NS@\'^EK*OOWU>QK??UJUY4]^-2X/"H@G?,>%J MJ7-DMF%\[J0%.!SL'SP^=V*W-<=N4L+>X.GP\3D##U?9/#:5XIT(?T??^1`/ MPMC-^XE+E!CE:T M\9HK89GI6`+[4.&:YM),F+-21SZL$G&!=8Y02>R&#<,+2X9?/Q0O0`C`C3>" MB^GMI>2CV7RZ-#5%J!'^[ M1.PFY8C8K](NXPAQS\3`>4WE@@\%D0`U#(FGX'8WIQ]"'G M5.VSBD4_=70RUXC&;C+^@XKM)!2X['6C*UAV!1&[DAA/,M?*,=,[<41]C!$0+)2#!V@;3BE9H#:GV>9:A;*M MP1IPR0PGHH,D4QW!T\B/%54CFJ::%298IBYI?6?EVCN-E:4=]6SSMBSR`BG4 M7;[G78_T39[\H99!)O4S,1`D_;S)OPUVYPS&!])!DM\*9`<]:5)63G]]=7+V M6_/YQ:\_N^2AU@8^+%AN1"V>]9,VA^?+,\=LO:47< M/&J_!+#)Z"P_3@O)9K%I(J=D6!8DE])_U94LF&M%ZF5\332W$RD&#:7.((A;DUZ;F#DA@^EXR0O:XI23S*G M*J*T'C;F%VHIYK0W_N4YZ["PF6^L_8LLN"H3O:8_B6EM`D:A\KR. M8&M<*M6%)J[CG!\U(0'?@C4P/&*F..[9!&,\R[E(Z=RW`BIAA'!\?'`0#&FM^1MT__S\8`^]'WZI]_YP;_CL>._9WC4&X+,' M7P*.KEFF:!PO:MG>\^$YK\/A^?LB&-8_[>F;WYO@)"[,3H+DLY\E6BPZ-/O2 M\?[1L\'12MYWTK=?WHLUPRT]!QR-S\"41;R9JO^JB7:VS%?:,G\6EZNR>]\9 M-$\@_$)+X]:J'*+GUHU`E+]`T$%H]/1LHOFM6^\A/WVP/O-#1'2N4K"U+,"&?S34HM67%N0]WCH=SQTXAZ*S5`H^-L/ M#=UF.)XK@3125DL!*L(X\_'MFW\_0PS+6ZT^FN14+6#L)F>#6[>K;F_UWKJ% M<@?&D&W!^H^HB'(B>*M^ZG M0_"#3Y(YKQE_R<^,(F7/(3%^ZTRC\>#DH/GKM>LC;=">_H_4#WV+X]DJ>8X, M>_AN[#22CY?5`D5!ZP0R1@^_O_[MS3NHS.&`GK478WR:>>O]<49,`JAFOJUY MLE6S11#X9+=.R>GS%LA6F-#M^.W)5)Q-.5!09!_^Q,&9@^0#\Y<#(AL!T-&" M78:0B3.YV7)(-C@P*=45Y*I#7*7I__BT(>APC0/C_CB:0,;4:&C%_!*?=S?WD"=%Z%MBR<@SA;T'_IPXQ!_:?VY^9-4=V M8]TY`Z/Z\/5KV]Q(<"<;YA]1R#66('QO?17"7V/59V&&'/(,(\E8)>(VNI6K M5T%7^*:$Q`G3B*<5\M14@Q0G0*#SE,]3E+G877&P,K=Q>-W"6)5I(T>`^V8C/?'+O5N.8BSF^-QTQ>$9[HEZ=0?:7N&=-/Y/R(R;GUMW@4+C M84#+OB1S,U3490`LI9+2_EY:*70P>'KTTV=1$_U=8+U(>#)S]2F=DQ*&_7&P MY\5UFC>/0C_04@SW)?[!G[J^MO$KEWQS2G^UB3Y8`=`,5E1'(R8I`N03@+H';]Q1BG_"S]9WG/`HCS^\]- MAV9SN6$RUQ^CGO@0(P_$%B.96T[W355VRV3@\'NS?Q39M\&T10@AP0'<9 M:IN&C\S1D.-ZU,#M&]%=#9P\X!D;_QKH_$5MV!-G\,(QM^XND`5".4(&W6Q* M;!INXYA@T#'J/:XNV<`IKO2*YW;0K"B)M534,LD2N35N5E#&2DXCI)H3<20> M`OG8!K7/%Z9$U).Z9/>FN,C2J86-C]]N4\M)\>75Z!3W75;9"LJJV&OOS7ZI MVWE3T,8/>P=/48C^UN;Z\]L?@!@`21N+0]N`@Z[0'P7!T%)K) M#!2ZZ=0YL??/9Z3+MWQ\P_5Y;'Q&@<`\*_)&6LX2!T?/^(R-9[F%P_T-EC=7 M>-!CX\("-Q[2;%@5*;PV),?%+RHVQ!ZW^T:]5<2!U`*S6G#-H6726'_.K'/1 M1>)2O7WQ^U=@K2Z#E44]IKN3Y="9\[7;F163D;.',G3!O.`GAX:\]\_AR@1VQ>(HPI2!(1%/') MVN1.3@5'>$V-JO;#K\9!;JZ03(("%2B#Y(.H6Z9%[=M+9:VCLSO.SB#+@C-K MQ@T`.[=!3;YI>*OCG#O%[%\#,7>GUJN&<,^:@5Z5W_X2Y/.VP*W;9V/B^/"@ MAZIJ&Q3YJN:.E(R5ZA%SXHM[5-A/][>HL".9X>42`E[?UN5H!E^@X>4+$1YA M)<)0J&!=QJ[$S(X=U\:I7Q!MN#)`G2[K[:P;*"O;S'1B\T<0.,R"'W4'Z"]S M\]2&AR.CXBW87N3HIBC(.%CR/>>K!W&HZ7)G`B?O)RCR M"RD>;M62=W'1)3)0$0S=Y%B=DOY-JP1P/(^>JN_U;JNM"E8I];Y2J5P3'JU0 M4Y<%](`]3.(2D*K)V4WFQ"(LIE#PO2+KJJFG%=X&<;%'3D`C\RL\"?/)8'B, M+W'(^.4JLH/DCR84?J6>25/"=4/7<+VF=:;*.'(>@567Z1CI`"XQ(E@(?]O, MN1!2SL8]%I]G-S'R_FZZEXR$A*6HBJ@G5\\+1Z?%G+1K<)6=;-J**]*&I"N@ MB:VE*LFY=0Y3&-X&/3D`1R&=.Q7SHJVZ67"*%[;I,JM+7VW7'><]?H5RGZSW MEPZ(TG($'ZJZK>,4$OT)-D%RO$=VS3(P#1PC_&34&L^5QJ[4A-KI#S;#W`HD;J$3F`IAZA/">X.BA-9-U!&H.MN=HZD#/Q M$4Y`@Q2R",ZC:<7>C6SDXB^HU[:MC2MF_7C\O`>L M:3Y"/;)_5U\$IFBM]LMP%;V@.&G6Q3_=Z4@CXUP.+T23H"";G`':S6`/?H,9 MXRK17^B1@L>K$M)\Q)9YS2&N2%C5Q;14BQGD4`9P%!L/X%-6&?``$3>;X@J\ M$0'XV!+#( M4\A3/C4A_AQS4;M[='"_RG.-G=T/1K^9>(B1SJOM`%EV1!K)55X'R%)T@"P/ M%I#ECL1\++-C>?Z7+>YY(K4]_V2M^V;"):K?-#[);\JD(](4+]*LKACF;+/< M/PCE_EIN_.%J;OS^_M[1L^,@._YF0[J[:3V]T;0.#^BQX0Y/JUU+?VE:3P\/ MGM*_W9W6TQM.Z_AX[_G3[4SK/_K]5T51H3PUKJVXIG6??OK[WSY=E!G]\?]0 M2P,$%`````@`>(!M19?HW@6D"0``-(0``!4`'`!A>&=N+3(P,30P.3,P7V-A M;"YX;6Q55`D``[0<952T'&54=7@+``$$)0X```0Y`0``[5U+<^,V$KYOU?X' M1+GL'F2]_*[QIC3RS)1K[9'+2C:YI6`2DE!#`5J`LJW]]6E0I$0]0(*TM6K) MOF0]+D87%4FNDJUQWGEEW_] M_6^??JI624!GJD$*GOSQ^>&6-(\: M\U\2"U)^@&GWN(!MP\>/2_.<1BB4O MFE]J;\A&]%9Z4;VN*L,P'%_6:L_/ST`^H:.R'0I)Q*&&2]+/K42V4?OC[K875;[*A0ZI\!9:8)-G ME+(FOU:KN)S&Q<5%+?JU`MXCY).2`7M@?1(]NPRG8W95T7PT#HRMZ-E0L?Y5 MA;X,1-504+]HU0W^GWLAD#EB(NQ(X3,!I,,?6@;<-R1_IH&I4&_(6*@KQ!3S MV\/-4I7HBQPPP85WY,E1S4C4"MF,H#JYOK9=K/-?=;??';-9@W@KT#;C*-%W MJ!Y^#>3S-L"G;/\?L5]S[0523Q3K348CJJ;=?H\/!"0GCXJP[7ER(D+(F/=0 M98\S?N->$CR<_SXSUG`)98# M^LB"JTKRL+:S"G4F2H&/5^JU4>;/T];)2>/XK''2.F^=-X_K]8M4S5,!U%;+ M(*CR$OOPYUI,+7,42]2TR;S&6I5#&"3Z?25'"[?%A<@B%9;*9PJ&UA4RT5`/ M.39ET*!"GAD?#,/HEUW08;I22+GF'Y-VGVA@NMAVV*%*3:&O^0\-)LQ"DY,N M'OK""+?V=A3K/,4#D,F@LCC-EM8F/W1CQ!E:6: M0OTM;*9%#H.]7$0Q6RUL;-TK-J;<__(R-J,-R#/=<,B42T_IH'D8W)8%&E-^ MC(_RV73G/C!3N]2MM`_\ ME4"`->%>LSZ#G.$#)#.3ZT@-&*3P9HG$3F*NWC[P6`X$UD1ZR^DC#WC(F8:< MT@NE]V,H`ZBK-ODEG*XPF2^^8Q"6R$M)X(DQ5]^GHR\/"-;Y4JK>V4.R=4$\ MA+F2D$G;/BYS)!.[>,$2HA6>J`GSG6DM8`$UW^4FQ&518XV'I`]\8#!EG+!L MZC<++^-M'=<;]7UEN0!`K&/R6RD&OS(U2F]+V!+T!E'49+JF:%=<6#E<"8J'A#%)<%B;;,/YA2&8/X7 MJ@07`PTC]$JQ[!_NIMG*H9;LG7:R'`E,L6(^\ M-%V/O"Q*(;)/2AT^W$&+^,["&P%^9+=2VQ;6EF0,].STY/3\_-F_>+L M8C=M.?:P&.36?X,DOM::[^3UANH*#&L?_$U!C>^5[%OS;DH"'V6N[E\G+@\6 M5L+BF9:MH24_XZ,JS^&;.L$,+%CY,1M5W?XW*7W=@X[?.B59DCH$MEP@Y0Y* MJSMDS4R;XY,;MM:U*H:/M_()T0D;6@)[+`";`ZC_'54_F/%`#,2VE&-5P$>J M$S4;5G>*0<2:41^89N`M<[+U&GJ$0$;'<;+9S=0Y&(*+H\2Z*O"-"+2!\85@WI=L]F_*RVCF.I.!F0L-+6[5_*)`[>?I[]I(51/(FB#/-+P[NW]P/6:7JI;2P<+&^1 MK8TAD>,#K`Q?L[%B'H_0PM\!B\B!26EJ`&0]!)>O^D[CH;1KL$X&E\?#JY>P MG*8/JTKO-#1*.`7KLD_6)*G$C/(C(-Q<@O4^7&](%8M>O->1(S-9RNH\-@N_ MTQ`HX(R8_!-LY-]H/3%W.KO]Z'P<]'6_4Z4H#*R_2M5CZHE[3'=5)Z!\9$L. MA6R\TU!YO8_B"#K%%D&SD[#_YL)/EEPM8;(N^$YCP=$1,>%GV`A?G6O?B/67 MX%AW'?)5WVE0E'9-'";GZ%:MUQ$EK]NQ7UK/U/F(#$>?Q"%QL0ZZQD2:R^!^'EPCO%[KK"2\T"VYKF-A\Q4\`O27B@6VJU^,STU?JM]^X()K"WMW;W&#UB7["%A1IORO\JV M!ZY:O.=\[2UXUGFVJP$\\;%%GC?-OU_E(+2GQM9P.>[WY.HMN^$$W-!\EW'B MY!>TI\@L/IOO7+QE!^5H%$]@;:F#>HT?L&X?`D:/,5]_!<=%B]G=J&;ZRPM3 M'M?,=L\N5P]/-&R1U0UIII1?L!Y,2:-9;'KDOTMZ7&_5FZ1*%H68@Z^SHI8X4M5Q-/H]_$P<9/"10$ M@S6/S_'\+M4/LUH,:4@7H]6NN8>T%@2#=75ACN>!/M_1$,:W-"C&JE5Q#TDM MAF6'UT5/1;X,D:V**K/>D1O_;`/EC.4 M\#1$%V:(!M19$LS5-: M#P``8/L``!4`'`!A>&=N+3(P,30P.3,P7V1E9BYX;6Q55`D``[0<952T'&54 M=7@+``$$)0X```0Y`0``[5U;4^,Z$G[?JOT/7L[+[D-(0F!FH(8]%0*CC3A&-C:TIZ5V MBSDGIJF-&%\PCFPA0.MTO((7R!*EQ),_+^['VM%A?_/-6@*C9UJ_W^T/ND>] M_K'6[YT-CL[Z7[3A[:;HK5!C2A3*FH3^/)/_/8G7:F\6.;/T9SQ'8Z:[>IT? M/-OVXJS;?7U]/7Q[XN8AXS,AJS?H;FHEEI!_==;%.O)1IW_4&?0/WRSC0!/F MHY;[;H67K(L+#0.E7P?KLOWNG[?C!U?Y#J&6C:B^K25D&O:FHO\5)]W5E_ZB M)$6AB.@(`$^E_NGI:=?]]D`86M.^SS5W&=G]G*!SP\L,E^84I;[[)GC MZ?D!>IO1CF2K=SKH25/]=DDLW626P_&#,Y\COIQ,'\B,"H9U1.VAKC.'VJ+9 MW3&3Z`1;E]A&Q+0.-/G*[_([*`70$!U&1=AA'_[33F M)TC*C=9!ID`15UG.X7&*<)=S:&*%'? M6.GEM@<\18YI5],@UK(]C<7?A!*Y'!\+N9YTJ4]U"SL?*/QF8VI@8_.4V/+- MQ[U!KZ]UM.T[Q!_>:S0VU7POTK9OTM:OTO[NO>P?.08:UQR20J8'5#3E;H7Q M6,.[HJ;(>G+EB7W9#*&%W`T-NMBTK?43.!NTKJYH$O&L[P\(U8(=5SU=RHN6VR0QY46'2E]1N\7E5PL&#'Y\&)R?]X\_]D\&78ZG!T9OB!W719K>]O-"]!-6>-(.4;ORDIWIC-KXS;XRL0S0G1]8>"8_ M;+\WF86-\P.;.V5Y2^ZQA?D+OF9\C6"KZR46>AC?J<,$[LI=L\*]F:F"9[E;%\H=TEPF9C>!M1(]*)GH';$#(3N]$^>742NEQXU06DV7+6F.5D(P'-LV"17 M32"NLAQ-5HE$/\3W3F+0CW4D_IW"<<951VPL["H6Q-<.%P84LY[08S*=$AUO MM$D.TRA4@N"TR]$P-ZM=!6@`NMP8BZ7%,S.-F_F"LQ?7&Q(?5E.J`<&WD),L M)5P`F$KO38FE(#@!"C("L;\D0LGRSZI4;,XSJPXKWB>;M;"LWPE;,=U_<&;E MIMJK!'J03"4\"QDX?XVN.W/'E*?<+O&"8YVXA]#$9Q.[9J?&<,ZX3?[G/D^$ MEQQS*4D\Z%$ZW;]3F@V@-9Y$5;_AI`:17@6"\[;D?N_B:M!GEWPB3<5?=Q+U MUVT%:BN)^^>JNY9&Q6/R@HVP>=2<==D"FNB.*5I=+&_1?QD?F]8@-Y]@B. M,[#>1A!K"@#M8DQT:38Z&\XX5O%+)9>'X$(LV,P#'JIDA`#XNA-;@"R.0F4@ M;(1+X"6$"@`7>YZ67V2=TV;B?[!,_#;_NR8[M_G?3:^#LV(+:E6;BR[D@18? M7\B>$?8UPI""+"W&D%T-0BQL`!@]/,SFRX-0JYW!92G@Z[\ MI,8W(+ALR([$`](JL-VIAL&Y-M8[+O,T0'QBOZ`6.R;>QM MOV)O;;P'`@%MO*>-][3QGC;>HV;G&RJV3_C!%CMO-__6^X&4E%$\M48#XWJ" M)WBW<3T5)%S:4E>^&76`S`8*#5*!*$"KV-*I"J;*G1SW!D=PL@;+I"\6*`!& M'[!IRC4X-6X1_XGE!?!7;PMAI_2U5W8U""L%I>8:"(]GP@)`69O6$.4-=%I# M8A3%%EO@5=3FFO%'S.>$>A[HU>88;[?&\2&57`(@K"D+QE=RX:P\_'7/ELBT ME]<86]NKM;Y3@5N)MES5]S$1(3_*RBGS-H6>4M%F$\=3=IU]3"A0A%8Y(]M& M,9F.T&(A+QIUU2'8$IW\5JS/R,+$GHIW:.DVE4>V4I7QV*Y5@M!]S!@H"WL- MW=#$ELTH]EX_8NY/#HE/WQ>,NI?7+>S)]`^.DKIDGOI[FU"0#V;UZ1Z.1.I> M26$XNFVYH_@E?L$FBSO+KUAG'],%%*%!2_?P^KRWE4ERIX<*U4=;ME;,E&HK6,SFRQ MS9`*9=Q<&5\43EY%BO4#T=A8&`#&KK!BJ;[&I,)`_,%IS2J-#$`>X!+H"+I" M/QWW!@,X/M_=*(J%5HD+0BPWJ"-S`S$72\4[A^O/R+>!2[X?4K4F!/]M>F/S M_8*!&B0`W2Y:Q-+-^>AS0#@[R*Q,\^^'BJ335$Z'OW+N911+UH4@OTVIUTP?Z`%\U[F82L.1FW"=9MPW29<5V'G-N&Z]6:\3V]&>DJ2/P?@ M&[:]>3XE"2FI`H3NH$"."I3*P^-!/:\Y_N5@JB\GTU7&&M&]*/[JSPF-Y:.` MD#WQ6Q2%5U<:G[_=>"']?/TF7`E"5M@.?2<,I[G^,T*F+B\KNF2NL*?W$("6"%EQA^(#7WP?"@ MS`G5R0*90VJL?0;9O4Y)"(0DL&+]3`D>M)[ECQW(FQ9L1VHW?!*@D*X2-XFK M!"%1K&#\)`Y.Y7W-KX#W>H*M>[SP1F8Y!4<;TPU=7?IER-3#:V+IR/P/1K$> MRY)?`,$%H=9P-UVU9`N`;1)2O80ET,XB(6P!:Z)]@QDVT4)R[)ZD!*$0]I)U MDKU"#9KN:^:4.KIO94+8H-9(]@HT;*[)2^D]>R43PD:V3JY=T*"Y?B!O95/M MBH2PV:V1:1R;ZR1[A1K:=CH4$Q+@U#*^W(*U4GA:=OS+ MA0"-CSO.=(P-ZUJ`O+$L!U$=3Z;^AI?`CTK%>K?!O9T)4\%4_2EOQYZX$N_Q M+X=PO.K70OX]LH4V]UB,`W0;?8@;+7.+J)>HXI'E8NA@I?FJWD+].7H+=4*: M+_0;J-LTWS;-MTWS;=-\F_:&OZ\TWS:3#$HFV;M?L>V8;5;!@FU'QD:B>:Y4 M$OOFT;-,(KVA\LH8883B))8A%4)40977,O`VN#9_<)XL-_''OGJ1WI1\5XV< M1J\:V0K45A+WY;J1D"52?PPFMF@CU["&-$E?I2>6AK-03V,A<'-G$A0`BY(8 MW5+7ZRGE@2S9,YI9!C&`KB$IC9K@C1VGQ[W!)SB7D91!5RQ`>`RFWS8=7Q;" M5BRS(::05/K^R\+ZX8R]B#4&61$A/H3M+Q[]&.,9,J^H+<,UT5DFM@2/7RV#$I^G7#LT-*DU@;-*@O9&N"'-!S6KC\,3MAZ^CF0=UA]-,: MH06QD9GL'TLLVN0HG-0V-KNZ1*VKCWQ=CJ_$KM%>/B`S_EAU!]#'DD__J.XDVIC'A\TYB'#^6.&:,K8'2H!8>&L&,,(JU[]J=#W%4%* M2:Q_7Q$DV!?%)&1!JX[M[4TQ'^VF&.`WF!2\*0;<#2:A#A@)#Z4[HL80(L]9 M$-*\A/M])^M^GA-7YV4V0`N%\63D4)P"L^>H- M5XN'!51B+3\U2&<$5-A*S^R_>F.0^_JD"MJY.Z$@;H0 MSH"5T_4"L&KN.TBI6-AP M"_'E9#I<+$RB2Q?`2&SEA:S+Z+JP44U`'.13[K5-66DO&N)P*F;[,*0+Q[[` M4\;Q`]:9*--8XRQ+NWH;[`Z.)'"6VY]&',&T0?OX3'C3C;@$[>IMQ#NXW;Z3\?GA''EKR7)$)[9NEZN=S! MC9F)!#!!_T9FXF8^6JQ>2DIP1D8A0./";2EB,Z@GGE[T%:C7_CNX&N.4AV9Y M+U4\J?&OOZW7YCLX%2.:%SJG_+6[L@99'>T53_X/4$L#!!0````(`'B`;44W M6#%]M#H``.C``P`5`!P`87AG;BTR,#$T,#DS,%]L86(N>&UL550)``.T'&54 MM!QE5'5X"P`!!"4.```$.0$``.U]ZW/DMI7O]UMU_P>L-U5K5[7F82?>C#?9 MK1YIY%6M9J32R,FF7+=2%(EN,6:3'9*M4>>OOS@`'V`W0()LD#B4\\76=`/G MU>?\4J]G`;D84\^TC0-HXB<)^DV2;V<$2!G9T7#]U[&6K%/_O?] MW37Y]M7;ZIN20A+_0-Z^??WVN]??OGG[6_+VS0_???O#V]^3Y<>JZ4&%ORG(4_9/XCW7C7B<_E^N-7CWF^_>'UZR]?OKQZ?DBC5TFZ M9K3>?/>ZZJ5M`?\Z*YN=P4=G;[\]^^[MJ^/V9"W\6QEGNQ7[=B]$,6[@Y*J\6[!JVB$U?'R+ROA3["'Z#S-?NKH19]SFD\SH^`U]]\^Z[-]P,\,E?+Q)_MZ%QOHR# M#W$>YONK>)6D&^ZCRX-C^+BI^,=U^ER::?"D*,I$>GOT8/`URDU+VA>$JS9)?ZM)=OR/KV M_ MMP7X_>XUC?*L_`2<_+NS-V\+//S7XN._?LY9_()D]]Y#C2*%?;2-D#IPNU+@ MK>H6"%VS0]"A?EB1(S]S@O\/@>"-0)1PJB>[9$;]5^ODZ75`0^&-[(]#)V0?_57`\!U=AP#R^<>7[J15M]!(]3NIY/U1/\KR!).ES#"4WE@F9#>,[(*I0^^1NQO*D5*-Y._0^I= M2A%/GF4`M:D]Z9:F8<*F4,$%&]1;-#UL-P/?4JIVZ&2-1LB]32WKR6XGR++Y M;4"`\%0>N&3,`Q#@,O+6"JT/OT?L<4I52D]K?(G4P]0R#O6LBAH!H&Q:$B:!,@/3D(%>DH4*2 M.[I-TCR,US"#WATNG!@T1^R<)HH>S".4;9$ZJ9'(I\XJ"G^MR!-!?UI?O0PC MFIZS$%DGJ7YR>]@*O6W)EAK/P2I6\MORR6`*RXID6]I9O5I=A[,5^R+1.LK#E_$[/KDB]>(@! ME#O2+?T0^O@@\0>O!B1Q0&,X-LG^RI(H#/@YR?=>!(?Z6+Y`:>[0]Y=9QOAW M>/E1(^3^K%9*]MQF"\0^JA%T\!(I)T=^+@D>'9^PHE!.TXQ>3ZV5ZR`JUE&, M8NFX[2Q"2J/B<60=-$0?8#IY3_/(1;6VAB/@;&M9:N=QZC^X"\!S+WM7X`P)_/]9,%[_YW3OX>\$(9UOJY^$3:^$H%9R/ M`;]_U\^`TZ'+5?S$S)6D>V8[C9T/FB!'#Y5",EK(WR-&!Z680YVY(K8@C)R; M:!U'H7%T27(OFEX7Y8\S'1+^"!RF8\$&0LR$':TMN<&E*$U#!).,V2(`/DJ5>D\4V M_"'<&:QS"4N[WC=)F'4-F795N@=VQ&^LVKH<.9,M3?/]+=.&UU/X^R[6UMK&8VG; M!4L.M'6'4Y=A'.;T.GRBP56<,YW"AX@*8-8C56!# MW5F0/^/T2DNJJC.-::!J:BV5J#P=6%W0%67I72`.M-'S)&-Z MLG`7.9\>KTSZ(8P'I,H8-`!4Y)\WW$8LT=WY#'5UQ!RU)GV11R7O548ZO82HVKM@4U5 M79_O=*8_O^]8L/JWTAI?LX$S],/\&Q3`8'8NN[7#?(+?X(2VOO4\`MSV*6:) M-)X#VR/J6ZH8U2P<'MTN3PS=>GLX+<30BWV2[FAP;`%=0M.+`O)0'F`.U:$^ M@^Z(@WV(%B>?6"N8\5&M8$=4T.#VU-ZD)ME*)O$*DY2;\>Z7N.[H$XUWM!T< MM(V1XT"[DJH5K&9+Q-'=(?#)BS4%7<!]J"VF3-LXI<$?AF:C[JP& MUQ$&C.F&R:[%K1&4:QZ:D9)FAR&7Q.M[FFX^)3DM,P*=0=1-L8==BX*-P%.T MPQQZ;>(.]4].K,Q>Y:T91Q/7,704,7A!'\91ZHFF#XD#M8!8->\X*X=R."1` MF1HYN66*/,(K9LMU2JG;4S`'^4SM9F;Y3Z,]&N M\6@\70$2"&`"SF2\.T/"'XD*=31Y-^)H4TEI(=-VGF!;&M519-10Q#/,-_QN M?!R<)S'40::QKX^C]A[(X\I`W4:)$'USQ'%G(O7PJFX5;5$51*;NJ-+#A.KZ M;>I.6;BQYWF/.9_PZ'>F8Y:G.$8\MR"3KLXI+/,\#1]V.9]_Y0F;BJ'8^QW3 M#(WC&K0XKA$4QS5<5O"J*W6W%NLZ;H8\;'6*'8ZO@X]:.,QM$Q-,R$AK]Y]>8MV7HI>0+B_T%^]X;7-8$Z)YFH'>_M\L+WWW_MFP<=.N%P55\[FU#-I&1=-=8QZ@C#Z&/W[URK6O$B".SQ9A)U@5<+/N&/&!-%>]S<0MQ,!N+;O>BEO--LW&4%3'=?C>+ M*@TPX;2Y+/]ZF:071?'7XUJT'5<]>M)`'O.#3-*85_ZFNV7W3=$&-G'^GM;-(P-H3%@6`DMFS@ M)4>1;SC?M!G;",4^3K6%@R+:Q;/#RVKGJ-M,BA[SB6Z=NIJH/FP^CVC62FTG MBHN7JFOZSB-W+(6+B#W:7D44N6+#V]1$5>NY16Q3S=9H%4WG%*D'$MN,4C0G M(L;0M!F>X7B*]CO`8%75`FQQ'60X4O:F/D%B:I]FE[GAD4+A5E"2VL\)F51B MVX6GFY'/'O7'J!%T;@)5RW&K*=^A8GA"JX?,.XX_ZULC#]P.-9L/52F;(@[7 M+HF'>ZWRY?F*$1^.;K8T]>#DC<-C_,6M.=U-&^EKY&YZJ$CS:(SX#K$C'HDX M_)B+(.3J',O(:DR9H67YS>K')`FRSRQ5U(Y]AZV0QXE&K6;JU6B".&ITD@Z' M[8P_E\DIDL^*&<)4&=4X>JVY7FYG/C^F29;=ILE*>X:SV0)Y/"G4D6-)^AIQ M'*FD'.IKG!81Q-P<^;"OS5:IS;1C$1Q?*9[\RSKF&BW-D4=3EZ*'PY2J+>(X MZQ3Y%(`OSEJ5#S:ZODDY@:YE/4R'=R<_TXC17#,]/WKI+Q1N9A<*:\S2V@%Y M='8KVSC@K&V-.$(-A!Z\#BU(<\^MB)?Q^LK1=><1U?6BXBSDIB3MP1W]T(>PX9J-R:<[5T0Q[&IY(.G M9UDNC!3MT0>:2WJR<&F:(8XWMJD'>J9%4TBB)*O@>Q( M%]V[XFX,!8$(`><@"8(=]4])G#25+#"F8]'6I!_RD#1670[0SDZ(P]5<]N%E MRFL.5?P63+YQOL8[OOXW^2--25@H7@RJ+HOEE07BVV>>QZV0AZY&K>;IKD83 MQ&&IDW2H$U:/`HPR3WPG%(KI&LZ(M87;:'I1M5X37E#?)&D>_H./W3>KR_+) M[S)+OP@S<=U38Y@>W9''85]#-&ZD&_9%'+F]51A\K5AB!"=C*E:DGJ%6W%S% M^V36.`2"LZ!\56%5V85/;1W.9B$1T.8;NME&5R?D:&"F=&.ZV]H#<>0;"GY: M'MF:3;M)H2?1^S!_1C@[[CO#P!^\O>)VCB$[GM4.:?MIM'FAZL^*70*4[H.^]+/3Y?"7:Y=I*"X.)(4>=TXPD MP],P2HAQ[$2%A@9.R984?(E@#,L`1:T`B?F"0G]Z"8V M.2,/E:D"M:FFPZ:RDG99@LH,A+I[(4<;0[5E6.GH@A@_3"4?ZOM5I?BJPAH: M-!A;=;ZG#FJ7]1>`B2K"R==A3((DBKPT(VR")%HZG+A4=^QO5N=>]G@9)5^Z M[DMU=$$>\B8*-PO/Z]LC#G8CL4>MUP!L">?K=%H.8MRFR5,8T.#]_B#6.$H']]4J`1P>NUD& M?]MEXA7<^^2.0I"'$6TLJ-PGAG;L0,&16"''Q#$-W'R.SCX?Q'@YJKJ##S_4 M0L'R;B46.5X*9E_WQ%GG@#H'DZ>5R>-B%1<^A;]]L/8.#`SU[I&A\`7=,LE# M/O2POR,*?\#%)>F@BN97,>R*'"7[&$!&/9-^B%&LE_A#0T1FLB`5&W%?3V+D M!E4F-P&6PYA7<62;*:T_;GG8`W$T&PINZVAES8`( M#H[2@FFU#FNM/:76.`Y7&QGKJ,NL8EFML.G!Z=G$L4;LD0Y(8XCAD37&=P:Z MW.FAP7FR@0-B;0FWMC'RX&U7LK&1H6R).&`[!#[I@8,S^!NV+VK"CDI*C:0D M%(`OE/3'5M+@M8H)?LLV-2>\\)AE.WA9[V;%?P(VY?FSEZ9>G&>72?J9ID^A M3[.;]#SRPHTNG>A+`SE$#3))XRIE'P*(`6V8'H-O*17<^$$M_H8++`V4'/EZ M6&GZ*O93RB2[H.+_ MT@[&N;<--^ MLT*$%O$M8T'UI'W-REW=E`G,L*Q?I-?IZS+@K^(G&C-NH;;89E>?V86X0N7V MV)8ZS"JH57);CF:)!9XHMJNWH+7'%+2W*=VR>+`U[6H74_?C"Q MV85Y'R.UQ[\)I5D!0R^%+"-&P;NLF<:S85&-9(Q3`*?`R"16*LU1U@7F]N!% M'S`!3IG$W'I[2&#@?)/OISMFT7H>TSO)ZB`V.\#I8R2SR40;I5D!3B^%QIIP M%,S%P4'!GDC\L2Q$3&*KRBA;R2A>813W-#)1Y(!@QVCV;J,BAA)+ MBKF_?>JL#I5K\W5?A"HZ$C2M9NEH^GM(H M3/Q'F,XF*[(MN(BWY71&<(@5AM=$3?K-#1E,+HMV=IH3#EB_/*D*_Y&OC9X0 M\?;OC@+=+$1X=?2TQ&F4;`P_0-@QFKTI#V)HL:28^RD.JH6<*)9@.-:(!J/2G/#]V&*C@2RM4W^V>[D#.U10\73:QSC6^V'.L^/-/4#S/M2P(W2#* MI'8!_`@KS0/Y!+5?FHS_06M1'-9"W&VW$7^;QXO*]X"NXE62;CB<=KWX9-P; M.8#T-$.C?*)95\2PT5>#P?6U)#[U*U!$8N5\8=2)*8(P\Z,DV_&'(%<"'&!5 MM,PU]DY+GHAB35`'2F.S@R;((UVE4/-J4/T]XIA5BGER12Z@YNI:CT5].+;P M:\)B,U5=0&VZ(+I)UUY\$""3QK0 MPM#D_2X+8YKI!BS#+DC#JX_"$&DF[1$&72^QA_JE3)\OAY0<'&X)>3F;?MVL MNK=Y5`V1^FRW]6Y9@NH; MO"[;U@%Y/'8KVWA52=L:<7P:"#U\Z6RS\=(]?[T@7,?A*O2].)=SN9*EPU7U M6K!C2P"D<$31K4&:=D;NYOV,T%A2-^J)V/U[*C`X%-K]'\'H-94A9H`)V@NN M'2.=23_D2&"L^L$)P_9.B./?7/83#MG5%YFUM[D1>/=%M;G5->[U)#%7GV\Q MB)'[*_K/,1+:U#@U*(I2!\W8(#5'!`.C$[M@`8L?DR3X$D;1DK\JU+@$7JO? M,2SVI8$<+@:91,:+7@00`\8P/4[8^6ZOCC#I20N-MET#IUE/Y`'00_V#XQI= MW1`[>Q_IK;DXKH'0B0F<%OR!^M%96:;:B[I6.MM[((]J`W4/ROOHFB..8A.I M3RX\KJK&_L%YX7&3XNOF`]EP:LC#X$0S*;8#^I)"'#ZG:C1*:$F\<8V7**WE M'H@NZ$-N/'?4-D8.(^U*RBBA;HD8!#H$'KRIG^2TH8P+5,P;V&P)T$8PKXZB))/YJ9.%536"PXJ=? M[F@$92O/DRS//C]Z*06I@[)29=DDBH@QPI)B@[>_Y0(C M,XBR][(5NL;#TZF^E#AK-]N@0%.3?`F1UJ'9X,>AZKF@J-Q524`*$0B784&X M%&<\X$E5F-G].._:@$BPZO/N(:-_WS'=/CP9C/4MS9&C2Y>BS:OLZK:(\:!3 MY.%'RDK"1%#&XZN=!TA;VL_,6]N/B>H:S\A?;9Z!/'!8!(/-A-JZ"\_BW>JXC,1] MZ@6P`WN3/]*TW"!EB$69L`\1%3;1F-&T+W),.B+&A7[R#PT#SH6[ M/.=#JEWXFA,^A)C&-`I3'&,#7Z1+:1#FY"[,'-:7A[>$8D9[;Y8UM#1'#@A= MBC8/[ZK;(@[[3I&'GU$M"..+Y]%U=GHO\RKVDPV]]YY-(U/;''UDMBO:C$QU M6]21V2'R<"\%PH11QAB:HROM,C8OO3#]DQ?MJ%2=[BK.\G2WJ2<=&M.8]D4> MM;U,((>P44?$\=Q/_J%^#EP(9P.I8L6(2)SP13T:TSC<$ZNVJ.5-;+&MS*\. MPAP@?*)PO[8=)X910HX:)YBGLL%6=^ M;SU#AS?N#/?^R'#N(.>GC.'MARP/-UY.=?4!CQHA!PJU4C(&-%L@#F^-H$,= M\"?Q9EE%$%\:,++"+A]H^R)5BTJ3F/WI4RFW,9NJ#R"#/%J'&J;Y[%H_&H@C M?K`JP]_V^=(H*M9@B0\@)K:'QUW7W[QTD!^'!=6040Y]"S;;<1G/7'#$I/9H(M-HZHQR`:'62"5545M MQ*_B:@OA,BV:;UTO2"48D21#"'[H3/R%ANO'G`9GWA--O34EGF0_>-6J>$6; MK%,OSH\?$T=0^7-PO<\9X9VY\D:U/>>`2SV$'Z>.)Q;TF,`04EWK1@U/ZKZ& M9XV=EV$L&?KNF!/K75YS)M7$KI.O!C*;!:'4>)U??:;_UR=-NQ+;38( M,$,Y[03AWGL-7_.4+#`)UCJ#FA$I7+W>:=7/L_$'B\Z&`+TL-_P4MG!5>)>E&+/,] ML`GJFKM^MJ4^/,1$0$'^#&TN+C.5]W8@",1PDU8BO1IED%6AQ)0&JJXJB7)X MH+C``2GR&2_R,W";-O@ODHT7#G2>JN^\`:!I@AX0(#K.'P0.]!B^^;\5[TQG M;`99(T(*A:5@F,N3EP4-ELQV``Y++3@(?A-/0YS:0@^4&EN<`I5K^OW;^^3= MFPMOGWVDFP>:*DVA;(8:`/6*U5AWW`8]K+6(;`'!\D@.6ZQ;",9W010#MEA7[T;ZM1S6 MK&/"JQ9^5-\C11ZM*HU:<^67B-U"WFX%_'@YKB M:^P^9FL($U[F!)9'U.>$*:6=N/D8QN%FMVF-G,,VR&-'J9(=0 MCRNH.8ZA471R&#[>[FJ#F.GS&T,G]2YZ: M-=[K,*97.=WH)@P]NB,/NKZ&4#W.V=47<:CV5N'4M7[CHQ'`FG#>CI_>G,PT M8Y>VU*Q3WM&,ID_T,E$4[[R@=$.#GV(_B2+JYW!(]):F()6W/CQ^=3(QI$AA MQTC5RNA@2MC73T]7S-(J:RH$X?>FJI75@$M`=K(("T*?H2=<;/,8%I%M)=/$ M*ZLN;5<;2P5$@CMIL"I8Y&O9G;ZQN:D41FOQ4 M%6OP&C!28RE+;G8L2;2D]NU!PH[39P=.%R= M+Q^AK848#ZRL<\]-T0 M+WOVD=["$Q\E%\+9+`AC!!E(R0WD*,`Q<2QJ3@@RW(1S1"J?E6$$<0Y7?>EX\> MLTWH1?V"O*WC7&*\4WEEB&M[S2'"NX6W$.",":FX8`OO\2P`:F]*T@ABNZK, M9QK3J@YSB66MLLH8/FH]A]C5"WURS$KU*)&$Z9C*UNLYJ4;9B=_K>3A\0F29 MIG#X%E;%WN_K)G(-SNJM(ZGNYH=BV>F>IINW&@N/RA`Y6HQO[*-'@D;AAABM M)E!Z'Z\>H+/946PS+_I-5^\'9X,N4TJN8_6XTRZ>";PW?7Q-XMYE^-.A6,?VU M`'>K[@AA&^0E(#`I)7XIJ#W*+\'-M0)SI8S%,1\T M=3?$OM]'^E'JCS5K2)3-QQ#;5I%`XEXNX"MCT'T;="'I@M68:F">(` M'"]_,EYWF&M\-I8UBF_>88UPW!1]I-8HS M0;869U?Q9AQK-)ZTXO!NLXL\V'B&0C1^R%=ZV-\1Y9O9<;#<)&D>_H-_KC62 MQJ@6R2.'"-N&/*AH;(4V8MBQKN()97]+08@LR8)4LO`0EJ59D`-86S1QS2Z@ MO1/6C.D:A&R#-#1&O6;SE!^@QE!EVD"2AQO+DP3!<"@%:J3D]#I\HL%57"XZ M+[.,YIG9L10#`L@AK;\QU$=3NGHCAJ4!2@P^,R>]6"^8G7%NI&9'!#_W9U5: MC/%^_]'[6Y*>1UZ6M9Q9Z4:`,,(<<*3VZ(PZ5(5J<4L"J)3X>]H0S))RC M\],M+9:I[?+)V[2?=.E/9;Y1TV86P\A1D9AG]+1J$#7!V?DW%C M'1V^+,S-,^%6=.C3#ENN4FFQ$M[1'#AR=JC8VH76-$8-!M\R#)V(E95*3 M=KW]/+*R4+B^).QPV9S->KM"\K`-\C!4JM18`Y<;(`XWM9R#%WH%-<=1-8I. M*%/HHRU6\]SA>CX[S'T,8)@A'^]1X@O-7N*/-)MT_^;=)%:0%/;ZFZT M)2P(LS"#ZJ$_H,2YMOUU@V[SQ3?M'GM7GWGBFIWMYJX9K,.-]JETC[CNX6&@ M+\C:[99[B_[2AIV\,=??D'I"\\6!#N,8(H.&RCRQHDN9L=!#WB1?MFS<3K71 M[C\E<0EQ_$&R.&"ZB96A\R3+ M#^%_V#![@-QDE(QDN8) MV1:KJ-4KAULARP*>EB7^+DW9U]&>9+N'OU$_AR[R^/L*$&(7YR3,6$SXT2X0 M-X+SA'&$0%F)_4_-'$%,$2:^-SRZ[9L,2,&!"!:$\W!P97@*M<]DO0M/$CZ' M,E&[W/$KU)(_0QVO.*/GPN^7<7#)^GW>^3ZEH,MEF/E>]!?JI=GR(&16`>/1E%P M=6"BX0!5$'HQD'2HS[0@!-P)8S\'T+%E*1;ROYL5LC#VNFMSPZF]/'21S70B MO@"IEX4P#8U<8`P(,!N4L6(M!@#?SPEG+IGIK9FP(/;B4$8VTFD@`Y1>%,8T M%'(`,-#2'''0FT@] M_&H"T"85<5)2=U[(0*-U:]F"KC[S]&9]28+6#O/S:$L7ZEM\VFEA`6Q:3UCI MBD81G$V,@X]>^@O-V=_%L-MZ1]F@&_*(-E6\4WH"=3'DXP;"KEJ>!A]>QM'OI4'!Z^3-)[FF["F$/)S:HHN,_KSM$F>$G*8%;>=Q\E:0DKQDV#O14/"<_0^O`'K>U M/>Z;]B@KD"RUIYHF.6`[I4V.BZXP.,QI#`>PM\J+&B?`XEVR]Z)\?TEI=BL> MM/76]"F$$BOVZ8X;$`8:H`+%'7^QP.$25P:=\!"^R8LS*YY09-[+C)W^< M(Z$+4P`S,4C9N%Y[-^2#&60^ M25*/%`EA`Z@<#*]TUKO MTX[U:^"M!O*;U;FWW3)_$DJ%-&.)[L<=^VL;T4+16V_/!;A/A,))JLP);1#% M#)#6C%8AZ,D4L4.L/06'1M0]@]&-]\RC2DHU66"5,?;E,?0?69L]>6`3="\L MIN>L7^9%%11G4*MVFR;!SL\79+M+LQT\P@.79^$Z[O8`D?F-667.,C%4N_\% M;AM6+V0@E1#"7@H"!*U$<(+Y[\Y46R7+/_P5$S4-6`QL2BE8Y'`Q2+"C)%0G MW.P#)M43A2A9@UQ%PB[EZ/SCC&1;ZH>KL*B5H$+^R7/T":U=,2N!F]3LR([Q M(P5#L!IGZ21[=V*1%:7"!,*7>*)`;A]9*W)U13YOO"@B[W=L2D>SC%S%V@ZV[F]6M@/^,K^)0QB%,"LM*J1HC&;2#WE8&JLN1VIG)\3! M:R[[4-\O.9R5M>PD'@M2<'$3Y>,KO_3]=`?G/+P]$RER^JHU"/(9\.8\V6S" M+&.)9GL\=_5!'LM&*A\\*JWO@#B&S>0^U84Y>5+3=QR[TRCM5Y3=OD@/PKQ/ MXEW6-0;KVLXC5M4J*F*TV1!_;&KD/=4]"[(X0G%<'=V%WP5]R*_B+$_Y`DW; M4^?JELA#KT4].?`4S1"'79NT@V\V2,^17R?Q^@R.]A#@1&I6")XB!]E`-)#L MGC%KN5:K:8K<8]L4;#QTJFB'V&=;Q1U\^+SAJ`L"A)W?FCW4M/6ZK+;QS+Q4 M?T%6W7)&GFKIK8XW*:ZW]>B*-P0'JUY<_C+IAWR[LJ<7P34/.AI1\2,FH/L^[(!Y9[<0# M`_))NB^/K,?#OO5\!IN`>]GC@GP)\T=H5!Q"$&>J08*`)#&C7YV_]G+:>``# MA`C$-OVF.(-;$)G\]@F:'\31#61D5L`RG[SN>*Q9WQHI]AJJJ9];7L_@%>8N MB8?9GCN9UJW1UBNLW\#7[YA\(GF14:BS(DZ.B`-/G-E#^_5JUNCGU$9"6_I]&4YH9'O<10W M;6*:LZD0Y^KF`OU8%BBO"#6T90Q(P<'='?F1-99_WUC^?2VB4C//N82+RC3V M]S@XU2(5IO"MA1;KA"PR<"F9^&V[)`$*#? MJF3+CR07C*N%&_+U)HGSQVB_J&_@+X@7QSLO^J:ZY%F69&*_-IRXI`T&4>+! M;9XTV:T?R6?V'5]VX"\3`>0>7?IQ==G'Q:_1G(!>RC]%R;6Z#534>6*,'8#S M],:I`+OPQ(7DJ6IO&C>O+"X$],LMCSIA1FACI=MRS&8/[`ALKH#%3.NFNO)2 M9EON<\OQM4Z.M,:18XZD>3//+.^*3YAKGGN1OXN*0GL'*)V)?Q\_MF>))&:4 MLV2P[JS4C!YVA+2EWE@9JU^+47YO(8D]2%-5^<:W;^:1O4[V.[7DLN?-'^DP MM5/D[[>*>4+V/9?KWT?'@*?*?=$VEI MCG1(,554OP-;MT6\,](ILB786!"@301Q#'NP%E6]AUT8$BAV*-WLOUI4C?]H MGO)'LY;:'BXTI&'LAULO6L9!>?*D&]S-B"#%FM.,HDE8#2C,*T7MH]#@ZS)5 M)21QH*XH1'J<>$)NN2TEX%?/P_*4E*)\*?OM\]3SW::.4]CO,%D\7NMLV*SD MZSPWG,(V?_+2/3^^.1A.[1]F>;\O3BCLEP\9=U&#@P3*3DBAM9_2ND,NQST0 MIW2&@MLZ]'(99FP:(UZ`+)F1GTMV#N\>X`N'XFD(94IWFE MLY&DEDCL)JER1/@5[N1?0!IX'.2/N$QK>9=\J'*@BV;OZ722+W%H.3#8R8-) M0>^E#A^'ZB$?,#+*/@EZ#1,S&2!L_1"G#PE\WN%F>\FU\1AN_PX+Z#/*RJ-3 M-HB^6."7C68'^H'BBP;_AH+(X3]_#-.7B_Y6?@E;^`_"S&T$L&)`!N/?(QD# M+IEQ;1NIH/E21P#99%8&`"#XDO&_H1]R^%\Q6?/'EXK_5GX)2_`/LLP,_:V8 MC^'WOV,!__#)>OY?T'RQX"^9S`[X,X(O&OQE_;"#?[AZP=AOXX>PA?U,EKEA MOPWS,?C^/1+L_QP^VS:1(/E2D5\RF!7@9_1>,N[+ZB&'_2Q\?KFP;^-WL(3Z M3)29@;X-XS'8?H<%\^&^HW4;%41?+.[+1K.#_$#Q16-_0T'LZ`_"OF#\M_); MV!H!0)BYC0%6#`AW`+%<_`-+'%BIM2%29.]6KN41#]8*\6GP%F&M7>T#JACN M]%G13J7,=.%UFR8^I4%VR?SR*LMV'O/9FY4,.AI+&'5$'G[FRLOAV-T+<7CV M$'ZH0Y,K^?&.])0!E1J#&15Q.@;\B7Q]!_5+\T\26,(O(@,<\3 M\=)$.37B,R,0PB-0`",-(:\/GF!\+[]+2<):IC"K"D)>401-#9:I?T?&CPB& MI.1(2I;DKO@Y!5>I$I>#V=#4AKG2^_2!/\LU?[^9>FC#;9OR"6D6HUOF:(EP MM':+G3!(GGM1)`S!)L3GCU#XYBH^AZ63)!H^;EJABGDHM6>V:G0]G23V`=>B MAB]Y#/Z&1;K/K<,KK0G[]!N!H?7#-TI!_,>$X6(&_.DS,VS(QG@O+G&&2Q4P M(IP>5,V9>#!'X",@0CG`P^JFD`)L7,B!?-A'8,(AH]VQRY\^Z-E9]OG\Z*7T M/3S%=IYLMC3..,(MZX?>WN_K)D61DN47+PW$KY#]R!KFV54LZIC\F":9[B6L M<3@A'4@G,*^\$C4"&\1+5V-J.Q05.,,S\::A+!61Q"(/>R*W*TL3<=D6!2QG M"R+D`U`6$L(G3$8W"]THC9TG_B_%L)Z1-7"HMD<9SKTAHL%5#.`:/E%RRQA! MED,R$#5SB+7^>A`%%*1@K1B`Z>%Z223\`P M@]\&?(-X\-88V?.7C$H)W6`Q7H.+2J2K'DS_$WEG#BN#.]Q M01WFP+N'C-7I33C8;JILB1L$W!1AJI:(<8?UK%'9Q;5$0)ITI^ MYG0'/>PNNV=&_5?KY.EU0$/AF>R/0X=D'_WUFJZ]Z`-?SU@^AX>3*74+I.[7 MH@YXG>)KA,[6)N7@DVA`CPB"Y&<@.9E[":87"=2"4FAZ\#5BQU(I4GJ5_!U2 MEU**.#C=*3Q)D)NX\N74VIQR:N+B^L/?=XSX9R^BXJUZY?Z9LAG26.A2K#[A M<-P&^Z9*F\B#G\:H7VH-XU62;D2"NJ5ISKR-'Y=."&-,!&<"K*?>]!]![5MR M01HZD9\%Y8G18CP%+ZXM(@6OD7)+O5^R"%6IHVF%' MCBZQ1T4/SIQP[J1@3SZ_6KZZ>W7]"AZ)(MYJ%49AL7UTP^2*^%Y6>DO*$%QQ0^Y[`JJCUW-H@`\MCM;PS] M3:BVWHCC>X`2UFY.5=<:@=V""(9CG^WI_:#8J#:I3,`/\F3"`EC.Y>CM\-[+ MPNPR23^L5M2'W6WXL+)'NR9C@0CGRF^R5WSY-QAN M:(YO':%]QN:'7L`/`X;/_+E5L$QQ`O7M:$\9^;^!(X\]./G.VWJ@E0 MO^Y(46&H(30/%[;VQ;[B,425P6MM]4OTVR2$Q1`O",2NOBA!]UP<>TTVVUU. M14UJ?D)`G)F-JQ/8)*Q$=OI$X;CV.GR<4$"%8$=N8L(9BG/6Q=GL;YT_3#BN M10S`\L@$&)*O9?%@XX=8=^#.M"]22!UD`K/T2NHXRZ1*)?\XJ13QR@=,"6.& M+7VR:8R.-\(%FT.1, M;5WGE3(9:6)AWVB;Y'`JO3XNZ54,R4/%D?!#DV'&K[<=9$H9"5?$%UM.+,=Z MHC&_+P`;1G!B`CZ>_,&_"6UYF$V5S$C-C=3LG"=2H]JBTKW%E]SE47?)WHOR M_1W<_]SIUJB.&B'%S7:EY!2HV0)QKJ,1=##("7*DH.C#*>;S*,D8K8OC M%6.WDB`->00_3Y5VN1$#>PKGV"H6TD%8"=O6ZVG)BB2UX'))V$8E65[&%%3B M_X+K/5"XX=$3].J"!UM1AP&.%_$JL-P`O)U'4C`"-`JX&:K'Y&$!G_46!6G9 M?ZM5/68;>'B^-$XIBU>9B!0V(F`DLMM"D8'CN^\+DL'YPZ+WQOM;DL*AQ.+? MA2[_QB3,,@H565-5Z::":B%;T6GBG'>FS@=BDT+NXDP$*24G-RLBR2[YF1"? M,/D)5X#<)T2H`"N8-RGA6L"G7`\B*0)$EVHG<9"=S_E7*R=]O*!*MGBYX($L MO5JNF$\=_M+O=_E[RO2EG_EKR^Y2+FO2O?0TS.[/:#4ULR/:KR%=LVRI%YO" M>6`G#?@^['+RP.TE/Q?_S]SN17JJ]7R/ZZ5(\YAJ1.A&A'(O.PG$]//.(S$< M$Y(P9HQ'/E!YQSV\T.XX8[0AW:\B8[3V,]K/&$\6[5>3,=JSU*\@8U2@[P$^ MYV"T?V:,+]-31\H8%4FAE#)RY7X%&2.2GW=N&:-]2!HS8U35(.[K*#9SQ&GE MF556Z."GTN>!$PHSN\S/A6TLY7K::OP"H%PA;8VN_TSG7I3[J1*X9CW_FZJ> M__!\;FX9V^Q^056.]N*@9,PTK#YS6U]98[\X$SYDGT7[9?`$C_X%Y0]_\^6H MD+95PK-*C$XQGC[#&4)U=JG*24I:RCFDH^#->1T/\DH4&'2Y+!(L"+C(NJ-^ M@BS`\:COY)=4#=_2Y0;I^BT,WO5/N3S^*4$>#&.O.SNJ!M&38X,D"KM._&K/ M;1KZA[-_90.DHXY>F:.G;?BWB"]2*(0\Z2$9PFDY?/#%CBZWNP>6\;&X6C%D M%PFI3_D[+$$215Z:\>L4_$T6AZ5VB@J`&G/4WR(/HP,UY!@JOD(<0(<2#G_? MCM-Q$SFVE%A6LS6_J)2YR^17%?G;A\6]))YP>?Z@M\5'J39YS_@I'B[H;HT\ MO#K4;'M&HVB*./RZ)+96:!(H6WKQP*K'*A]$,&D_/Z\]?C*AL_&\/-?2,P0: MWW7RQ@(V;9W%JK(,>U?;><7H<2'VUH;SB4U+);:/BQ<[*2,^K9(VGS8H5EA: M7C0X;($T@%K4J=\O:'R-?2%9(^VHKQ7DL+05,:93OS1@5]=ZA<[ELP(CZ22K M\H?7-=MK]A?[L/RHZ,@^^?]02P,$%`````@`>(!M1?]:<2DC(@``T8D"`!4` M'`!A>&=N+3(P,30P.3,P7W!R92YX;6Q55`D``[0<952T'&54=7@+``$$)0X` M``0Y`0``[5U9<^,XDG[?B/T/6L_+S(/+EH^JF:>.F@2 MDC%%`2J0E*W^]0OPD$B1``$>(@@K)F+:90-)?)D?[LS$+W]_G[F#!2`>Q.C7 MO>&GP[T!0#9V()K^NA=X^Y9G0[CW]__][__ZY7_V]P<7!%@^<`8OR\$=(`2Z M[N`"DSDFED\%#/;WXX+GED=+T=_\Z_SQ=G#T:;CZ2R(!HV^#X?!@>'QP=#@\ M&0P/OQT??1M^'8SN5D7O:#,F4**L"]&/;^S_7NAG!^\>_.;9KV!FW6([;->O M>Z^^/_]VK6MP2[%_[2;%]]JO]X='^\?#3N^?L M#:CZD!=^6^(C27':PDSIM^.D[/#@7W>W3V'C]R'R?`O9ZUI4)A1\)5<^UZKX M.\.SL[.#\*][5'N#P2\$N^`13`;A[[[YRSGX=<^#L[G+9(6_>R5@\NN>]3Y% M^\P$AV?'APS_7RZQ'E[(.ZZ)Y\2E76D@N,'(`HI>D/'G:APRA\;KE,W4^O M`/B>-$@EF7IB?;`(+?<*?&A;;AO`-SZ@C196?_7&D_$<1(->4Z;G"=<2_87E MO5Z[^*T-\"G96\1^"3W;Q5Y``)V[(&W&`P$>;9#B$":6T@F>,9E:"/X9-H$. MJ>>!!Q'PY"TG(:D37$_!;&:1Y7CR!*>(+A1LBTX9MHT#.F>@Z0.EE@U!%9BR M@CM!_4`P'1S\)9L,/$]E*A6)Z`1)3!(Z M?RTMUA;DT-^0`#A7[W,VY%6!)B&S$ZSWV`=)HRK`RE;O9OSPL?UC/%>;PWG5 M.QH!7SSP,Z!=]VK!YLY*8]VF"(W'\M;'](['=KE&/K,^TYX.$O':S&Z5\8J$ M:3'354;&$]3Y3%`949$0C?O@)?`MZ+;7"5?R]=?!4=M*..J#%H[;UL*Q1B-R M=?8+I6DQ)E?'QI6D$ZXJO94O2B=D57H@7Y2>^\?JY)07W?D:HCK(0BFZX*G2 M\XK%Z(*H2H\K%M/Y_K_&>JY(BA:G`776J!Q)RKC"IB?@BMJ1KG\6M0.!*;L2 MN+5>@+M7JI$B62XA&5'LUO:,W=H./X8L(:NB%-PP+L/D`.3RS;3P2Y3+V1),EZ!TI- MC!&':#U@?YKBQ8$#(//&.&8_L.8?[Q\.8Z^(O]!?_1%]_!%,(?LF\N^M&=AH M+Z_8'Y^/3T^')U^&I\=?3X;')XMU^ANV+)A."9DD+C5F!%5)@X@/RZ-]P;!!YM*P[G$T MB[S_`RRY%MHH9XJ)9&#%-CKJP$8)L&U\MJUI@6VR?R]_S8IAQ/;XK0#6UP$ MA`&^IEL*R_TWL`B_R_"*]M]"2LAB8WWN;B40M?81S#%AY\_,)2OP^`N"PN+] M-YHRNMAP7SHSW#5T`;F@O)IBPE_`94J98J9R4+%UOG;7K?!LAE%X2O3T2O7@ MC0.?^6DS#WM^YQ)4,L5VRAAC4YYUN/Q;#^77]#=%@R.G9!;0"04T[)G15(`E MN]K#SDT5+5CEC)4J:YJYRJ`E!N.=0_QRL'EF5_LD3RT.0N9`;WC(#O16_M2RYA&#@>M[R6\VJ1S_^H\5G/'D&B+: M;$BMB3TH.`:4JU*])U8'$UVR!P#P$IO`F@"]'HID+0 M_+#M?NZDO0OKQBMG*2-OE-7&U@JVXQE\T4)0 MQ2AR*`/EWDU4Y\2<+A4)762&9U%=$.0&,:<#NJ&GV#F$2!SR(_,(?7"LZYTBJA<"Z@AJX24 M#N3.G/D5M.%#(_85TN4#G4MS0][RZB@Y=Y20H#.%ZIU%5@5O"(N2I=4C6``4 M`#%AB@N;QPT%G,;.-M*SC'GF5QL!:N\]NUZ48C1]!F2VD;*JT/@%10TTORS* MAC:8"T!>L$Z3P'IK+32A# M/\Q*RSPV<)B6!R";;W5!C:RB3JFBCK1A01-[3%7HAJP+E<^H9!5M'D,4D1MR M,BI@-F4`>66X=!)PKBR`Z8WHCVPYF@C2&MJ0-Y&45S2/*A4Q&S*5 MY-4GO<8PCPJ2&)NZX^[Z#*ID*5;Q0E0[6K1W\26/OS7*=!M%M_FH3LJ8@I"Z MTRHA=8._9C[VM[U=B-W65IZNB]^8*:XQN<3!BS\)W'Q40@OM,I&W/N]!, M_JQ-CRU1")YP MC_Y3)?IHR[+F&^(W&$9AL;#-^(65$L<`7O$^6E@)BR%KY"?@4IE3BOK.(C\` MZUX64A&A+U?H\1SB).LCV)=PRE];3A MA<+6H1HH0^)*;A!M`?!*%HD;I;2QB$%8REC$58!NR MOU`ER,?C1B5:]'T/<@_\TMU'IHPVYE=97Y8","1Z]9\`3E_I;#1:4!Y/P7TP M>P%D/`G]%5+N"N>6!^UP@G0#G^O+4TU8'_G1(%+NRV#]FBV28)O$S5&.,26U M^DB-*I"X[X_UVO&'O5YP[>(W6;^?XVI^/^PS@^0[&OO]I-S(5IHICQPH*-K1 MK,]:\D#P`E+;G2^_>RR][.H,;F3[E$GO$CL#&R8?@:RAK^,Y;4>]E; M5"U\ZF.S=&L:-<0?X!+0]MHPU#7]V04A,9"3/M/DD%>FJG9DW!H_\M2LK"]3 MQM7,,?GF*P)2EPN;E7;TJJ4I0\8PT?U+A3NK':EJZ,F0:XKDD(6=0\S8Z;MH M(BPNO*-1)0T9D[B5A6:RV/[Q)`S6HQ/]/RU"+*K]:TR>`%E`&WACN)\IK]`R(G<6GA4"U?<,TT=7_7N2^830`=K2]!]-^4 M!N,,>27G&O("M"/95D\K:NK)D,567@OY)#C21,M7U8YB-:TN0R-)+1CCPIC7 M0/*<,3]CMK#.1R1-&7QC7!7ST..GCI,7!0J?/):FD8RPC\BORGJI.\]I3#R9 MIZZ4YSZ1L(](O,IZ,20^/*^1C:=3I!FV42^KM"]4:2?&DTE&!88<'M3;"[7B MEZ,=X[;M@]&T[LQQ("_2#%O2>FVYDBD*UX:Z#;F2-0'?D!M(NK"(CR5']L\` M$D!U117@+Q]<"_DL&IG^-DPQP3U]E16@#8NVP(ZB<]A:>C+FO".G!TEWBM)Z M.WJIJ\>8`;&AQXUV M+*VWXY2Z>@S9E];3="NSX\=F8PNZ,V1!Q]3"7F^F_V%[^(7ELHW8`R`0.YN' M\!QBJHC0AH:JB[/:(`TY\"W6PXAV+T*6M-<(7SR6J6L80V30-71M-0_)2)M- M_`]&D*'9#!DVYN$:4>0*=7G:]13,YVZH-LM-U':#)IC,(IN)SP@D:_=V%*F# MSY#L,XFK-W/^YGI(K(MH8^HF3%CD"5$"M;5]>`OY9EA.1A=[091)QQM/'E*R M]C+&X626&1[2_PWV!VM)]!^A,)8^9D.@"0@]S/42"M-*JG M\\"#"*RSPI2,!$?YD2`M<&`A9Y`2V'9\6%(:?:;/SC`.!U7 MKDHG)UF6S\Q4\.[?YNE4KJ`V/5/%()E#(SE(_>QY3\%L9I'E>/($IPA.H,W\ M.%9#S`,=O>R4"W1)1SS.=\18/IN44U\8K#\Q2'U#XWDZKQ-.'Q85[&2;);+K M,S7ENBG^8Z^EC18 MB=*XC[.78M^@RYX/V]3!&A:GORO6[>A4C-.NLBXO45.;GE[)B!O'997`]K.S M`BM*T&14D#)G)GM8@W'Z."_?8!PE\R2'@2WX("*4,UF(T[NJ7X,4OG>5Y MA;KHX+<839\!F;$VE77?PK+:=$ZQZM/]4AY'/WM=VL]1LM=]+3@Y8U(&:S$Z M][KU0?XDG6'P$;@LI"9,5QGF(&0-=)(H'U[OK"FLDS3.LFT^3[>YK+_7E*K/ MR-`(/3*YG%O03$_'FN#%`S\#*N>*90^2'6_.BD[J$TF#E2B-QYQ-X*7^0KSB MW?@^95M3>@[/*Z]-'Y'QX5'U>[;!7Y.?_J9W M#^_ME5NDJ(Z M-D."PYZ)Y:RS[^42AD::X!!#JFY/B5$=FR'1S4D>T*7<(,$KWE/S*\$Q)T$@ MGH%GZUW6XL7%>VMQ!3B&I/:[MB`)PWQ2;L`WB.HHF*VG08[YI>IFE7=&E?>Y M#URHCLV0W/_%3[5$I\#A9;A-]0`7@'FSB&E205)/2=,44D/BIKY[M/=<>3Z< M63XW>W&V4$\-+P&BM5>XMYU)XBVE&H(1_=$&J3%1;N6@*J:GO&@$9LR<,Q// M&Y]#-PJIT\;C0_J_.J>-T;=V9XTMK1?L5^`$+F!/3L8;IXN`L&X4ZKWT8D&R M>D\'@EKP##F`7.L@=R,Z>K.(D_968$OOR(J>%\RBWRGRJ(F/])YMK2FAM;// MK0>>*$U!)_DIJ#C\I"?3C>EQ*)6C3_0;`IJ-.>EHQMEJI(E2SS[-]^QT:(NB#6[@`N<8J+A:D)6DS'-0.3&D*?#_'BK1#NM(X\24_3F3< MTGLR1O3./WU-5]:JU%&\?"?G5=2F3\M[KE<$U<^^*G>4=`E\"[IRW?BD7H:( MP5_CCVG>R0TX3$K\+L(Q]A9;B,54ILVP4'7S7Q\M=[Q0 M(P4G)U&F?;1I81/7S1I-P>@=;MX;*=34QH!MF&9M^+H:Z=K(EWAF053-S%%= M;0Q=UQ3*1A7@[_S4F$>(*?@\?,9GAY?6TKL#LQ=`"FV?+]8W,PN,LVEH2;`M MV'1.(";07X;.:TT9>+P`1,+`F\6,-K`4V!:.U=<&/NHH"L%"A3-Y[N_:F+_= M^5H.-Y<)G9FPL"L7E-#.C&)%001GP4QHUDP9/0TK:%O>M.5X M3#&N]5YNW'29C#*.#JDROO3.N*5X#(G8*5F9W$($;GPPXTVXLM6UHT2[\W$M MM70>\L-9C#]2(Y$%N,8%$4R7`,R`\QW9V'6![;-;GP=`F(^R-=T\2ZLG3#LF MU;+UQMJ^6:UT/O_P=G6NB]_80XP4YR4.7OQ)X.;QLGW.)/_KPOU?'8%&$ZIY MS70^[]4BE7A04I6QHX[D$-3W\%4Y7<1NN+REDHH,4YG5G#(:"I-=`/*"M;V! M/I*^@JZ5/"7^VN!H=PG=&;TIX:)?@U^TX)162=KTD;IL2C]79GT=9`RU5C!+=B MWPFA!LR05><*/45<9GE:I.\VYD$PY'7I%&+.U.?+7#+@,'QRE1LF%3+)'J"P M?>"P=.)#GA]J:Q_LZ=BR9848L@DISC*3UUHN[%>DM=^Q2\6XT*>K-I_K2-W^ ME_O,Y`XT8\@FJE'U/4+OQS4!('FH?%N$+OKNCLX*>C%D!]C*6'`)%]"AZ\QM MC\[I[^[(K*"7UC*";CU!AEI@G?0#K7T)HC,D1<;:=XJ?$T(JADY<79LQHE*Z MC%HH&XJC:IFUY\MG^FV!.[Y$36V,W(C=\C2HJH)^,(!!*(RY4ZBI'0.JFDS! M^"7H.S]=X/A870<$09_E$T#.>#*!-E@AX@=GE5;J#P%*S+;A0%4->*MQ>1V% M;=T"NN!ZQ:YS,YL3O(BRE@KC"00U#*1+5=2&'-F(!Q%.*8-IH#!,]/V`@ZNT MVY+`D_**6;71J>SDZ\=868HUT-"84>0WJ0EU?B/84Z9-6$D[RE2TL0)9^+@[ M7X0V=J<92KU4- MU1W-SB*2(C!E[=-Q-./[?HFJF$LG9=1-K91R[F-;34"K=G)^FC\Y+\A`VX]# M\UT*VCAW:NEQ>ID`;0:%+2:<55O:=/)L&A_!^?+.^@\F%Z[E>8)C=@4)VE"@ M(4OFJ5%7&7WAQAK*O343'\(K2M&.(W5-JD02:8T8LC^ZA39`'D33T90`F9-9 M7OD^T4;:R`5GM$KX#2')`]T=E1$C4^:#D*$KKU^&K<4CR&3J&`"*KONE*FJ M'16VN;>7NO2L>P;<_:6G0`.B:\^R:MI1I[*EE4AC_.6G`'OJ6BY]_:9.((Z@ M#THI%6T8E MEK)*6@L[J^F%?D];$4,($U`BAT7OA2=Q%]CS"U]Y*JMC(B>J`V\M\\J67;]2 M1!]/-M7(<^@25C*1)S60QT3YW*_(5(YOC6RRS=-\LDV^160C+TD[&SX#L`!/@6T#P(;-:XK)R'I#33QO,;;H3$L:RL M.FKX#2%)Q:@<#4C0^/PBAFI*5(X&EA,KFF,8\[MB MS:@<70PK:%O>M.5X3#%NO:BS80 MHMB/.CJ8`.MCB>+P!`4!VA&DLCW7U&A("YV/,!R"/.*EY?K+:P`\"L]F]IF" M[\RU3XH>"M6-)4=='72^6^%0(]Y$Q_#R1"_B0UD=8TE0"7CG3EP%045NHL=QI1S.Z+DGNH`L\ M'R,0`[G`X2.']*?O<_;NN@W@W!]/?B,6;XB1KV\L96HKH?-`2MZ"-6";M/`A M"B>P?2^<1R_!`KBX*-F]5!UC65`)>&N1D5N^JXI&PWAOS[NNRA0RD0<*2&/# M?^F7:V/\#*Y'!SJVD6=O,M@V"8`30U7,/_\YGW\^^<(@_D3X@FO\D4'RE;[D MI(\Q>(F>+)<7$2HLV6F];&\X M9OZN'3W76FZ M/R\JJHV95(V0-Y\T/*WM)W3^*"ZLG0VE+5%N1`'"SM>\O-LUL``H8.%Y@*K> M?PB(_6JE;@7X;Y/+U=3>W`*;;=ZB50=LXL/DV;'OML1[@U-:.WI4']%5$+:P M_^F<#ZQC,;>#]-I9,#-L%M6<"6)[%D\-4A`[GQB:M3[3VCU&MG`O7%S84`9( M@&QJ.-CN,ZL%FV39-)!?\FD@BW?)VJ>`W.V3=_ODW3YYMT_>[9-W^^3=/EG# M?7*/8LLUL'KU@5J,R90@<@U,)%8TQS#F][F:0>2Z&%;0MKQIR_&88MQZ0>3] M-&XI'D.\*'8'R;4/DK6+ST@B`5)Q`_?`CU>&A:MD407-C2M[,E@1:.=C.,?& M625<$_`S`,A>CB=1%"*T8\__Z)]C5&AW92$F<:$9\)U/`_)C0!P&H#8.9"ME M57!"53#LK?VK@=5US.>R^<)R;?:L9QB,O$%M+_IW_BV*)D2:Q)4V5-%Y`%X; M"\AKRV8YO0/N[2.ON"%LJ013UV"[+(C-:9%`9,.Y%2==#D\;RT<1"2&&,*%! M\(:$Y*7OY%F>73]@+C,E#]*)*QG"E1I@6XO:JSEVI*'$0"#P'L$\GAO98BM/ M_QLD\]Q;\Q_0CD<5F+`Q]+2O'UVWQE61%S_+UH3(';VD-*+K7KH6UH+GTYH1 MNB.5I$YTW;+705OPS%DC,G>DDE-)YYOW-CB5?XZL$9D[3LFI1-=C@#I@G^![ MTY2B(G>,DM)(Y^<&;1"*G>%Y@(1N,)^FNPN%!>47#>%$1<,R3LYH\60#R M@AM.7!KXX[`UC^!G``F(ACS:MD?+I\@>`1TBT?I"N&B:411A"",:@YZ<&1[V M/B6-[..Y7_*/YW*B[71_./==-S&XRVBU%H':U5*]JN0S.I&J'X M]D\*GM;VJQUMIX$-I2U1;D0!0EWOS[8;;:>AN04VVU@2U0# MBL:7,//W!?9\[^F5$I(UT$G(1(:QGL/:=+]=% MXB:/WBSBQ(8.'SKQ;E#D@?L;P1YOA=+"E[09F)JA4>8US2UIRY#%HP7=6P(G[#C>,\LSE_X[T_0]]O_-XEAM/$7P MS_5,R'D*H_'O&JLGQG[GX(7+PR)\Z\63)]JJ[2S@E7:2N`@DMB7E=JF M)DJB6_C%.YF>LJT179@4%=5F$)`U1F;RD04D6(HTD@/8`_:G*5X<.`!&EJ,_ M;!J,_NJ/6S"UW"OD,Y>@_)5)00G=S2-SRB8+JX4;$EF[1"TKO`79_+,V%I%5 M:]80I5`Z7[5S3K#"4($'8/WP+JPYI%,U_T:#4U0KRY7:8>-P2053J[GSATV= M5E_>7OT,J$CV"!;?E@7%>FU'63RMYKL_UF.I(G8EJM>TZ^/7: MRC4`&W)'53&=O@96KS'9BD$)@O\[GF%K)-?7P&!BK7.LI//XJT7^=5T,*VA; MWK3E>`PQ[L8@=5OB0,TKKIW)FSO*$F-L(6E&YZ-X*RE5]>.$V+!Y7BCA;,5_ M>LV,SSHPHT;.`M/8P$78ZN7'B0XL2/8FS`_\R6=>3EQ/>W4!9K-&&7E#[EF\ M444[/IU;'O2N,;F:3(#MPP5@OU0F5:&4C\,L>?@M9)6K02ZIK.`AN"?:/LL9 MHVOX#IPP'B5L^=$&4U2KFT*11G"WNM!5]L1H>^`9Q!T4_GF!#\!M%T+7YHEG/S:^. MM(4\;ITO86,M%#.BN)`I+%!`UU!FMG8G@>]SC"X`\2V((K?]N\#UX=REQ!X' MON=;R(%1!CIV_7K+8DK(_UG>(YR^^L_X$LQH@3$:DP?6LF=\#8GGCQ"BZV[B M660YGHSFE769W]1TV!)3>*F;"MM(/=?\3->$PD83VL9-59T' M_CF88`*>@(UIF4[MU61-_ MH28^V?6\SN'5TK,ND/3<:W;Z$_K`]3 MTMOL,8%32'_G+D?.@N7&=A+MC=]R*1B:$VPV0QO32$*U=BY3.CHPO\"S&49A M#JLP$87'TK)STWUP2IM"H"HP$U;4O4;1[`8WI8+?+9=[`+99S&`F\/$E%*A[ M%:(9!4+J/Q!H_=4T0XM@)59N^5JC M,(_2+P>1$6"4>(C^YO\!4$L#!!0````(`'B`;44Y]`4__PH``,1P```1`!P` M87AG;BTR,#$T,#DS,"YXWNOLGM;IER?/IC^2OPV\BW"6G]\?LO__GTWW;;NA082>Q8LY5UBX4@E%J77'A<(`D"K'8[ M(KQ`/E#!G:\7TQNK=])=/XDE<#:PNMU.M]_IG7;?6=W30;\WZ/YF#6_7I+>@ MQIR4H'WVG8%O+_`261()%\L[M,2^AVQ\WEI(Z0TZG:>GIQ/TS%W,"+-/;+[4 MHD[/^F`PDE*062#Q%1?+$9ZC@$HPGGT/$-4*@$\H7F(FMP@2C\&)S!^`&EOM M/?5/N'"AH=-NY^OMS;W6<$T\$Y1LD:L[,4._0Y@O$;-Q3,\X8\$RF\&1HB-7 M'NX`41NHL"!VS$<)^V9H1CV>`5AKM:B!^.L-4"<-<.2:.DGYOA,^C$D=3+;I M?&R?N/RQ`P\4#OWV:;?=[ZY-Q3)7B;..X!0,Q6OAZ-EEI6`.R:%/NPAY:XXY M\F=:>/0@0Q^!Y[GZ?.C`TXWBKNK;Q#"YY0XRBT7B"H[[Q<82[]E$7!G%8:U;K%V#IX31K0E MX-'34ZMMK>7!]5JDE91I14*M4.JGSJZHW58"D#!FO^MK3V`?A&OOJ1$3<4S!N-,OGB^[&:+THB.NG_G@^]G`X/91",X?3#&NO+*P;Z1:?6QOY M#<`'`'R)_,45Y4^5\=TPFN'M[P>O$F]I^0V\*7A'Q+'Y/ M7`8)C8V8'-HV#YB$+'`"SK4)]D=8(D+]7HCQWMPFH-\!T#T`=R-F1FL]VFP-H*L4%*#4RF< M[KC$_@2M$'@N!Z,L$C,^']/X:"%6)*7!QH0-MP,=MZ*_*I;!S"%7UU#*B*6V M(8*H#*4Y53D]4ZE*+"!YJ8.>EF8EQ#5X'5(>3I``N@66D!30RK7B-G=1X?A^ MG\+1^G6KD69XFD+G!?()5`63A-6[H3.+Q`1<%X!+A4XM1"6423$-,@9DQL)% MC/RKM8:@>!'XA&$_-;'ED9D1ZJ412@K2@3,6U:!T<"&W7P%7@&$_C6'YPJT! MM6*Q5J9**P"L='G6@%.A*"NJQ@I`*5.&-7@8\(B"2UQ9&8/?,O("Q6U%[`T&QGQNYN/O`5C\^5&]TTAG;CO/S5B<9>5HL00K%-'@ M<7!^?5B>72K?[AWZHB2^:M8C#L?[0Z(=\9JP[@/6_4.P#MMHD*Y:9&7C M:J`TH_@NC6+>^[`&L>J55S9:.51FI-ZGD+]/?T&\#VVBJ2V;N72 M%6T62=4>^9M%FKU8>V&5&H:Y=$58E_& MK53$S*0QH_8Q'2VSMVXUD;(R/JDHF4E3A$]10=%$Q\IO#/(JAPP2,SI%[P^: MV+;7FX3G%=GQ&\1\P]^1Y26,2)=]P'%.#O.NAJ.%8!!)V2DKJH"`(T2N14&1U8N5; M5JKLG+XOHX=F4;_6I[25&GVE M1I5NDGV$OJ0",8-J^?U6F[GM&8^^FP9&)F,'4^G'=U+#1)]$+_-UA(2CHH\N M:,W/6W&MJ[-SJ*%O.&+^%-N8/.JJVL7#9Q*E-"JF_5.6(0R-^GL,`U\*PMQK MB9=J7@MR04WRV+$4I5 M*_'O4#Q$.L*=!]V@$XAHB_L!)H_X$A%6R>B8)30[_*S$P-$W"^TF`U*7M;&E M&\U=_*'[P,].1VCEW^+E#(M6[(?,1SMMUFF/2?^J/3G+T/$C%CF&9CPZ$D,S M^B^E_$F%PRLN1CR8R7E`XPZZU2?'\_3M9*<^3$YR@,?F[>&Q.:)^;2.[E$43 M+&R5V[O5G9%DC3H,]!8OO/N2QHF7]&>":O@4KHB'2/"GV.&RW@CG_>5V[^K M."AH$P]1&`JZSV-?YMI?BC=I_Y(S+)%8U>V!67A@$LS',R+W]8OAQ.XPTB/I MBE+DM:!?7X)T!6$+6A3J!=)X/B;4YQPYG[@-5GV&;R%H&5 M1*T=3+$712]U.#3=E:_9%"NC'"S&\ROBVXC^C9%(=(F:Y?[0D6/#))<]=(IG MFWWM5F9>D4=<@PLWHMZ&UWA01\?;B'H37KO'CYC5Y+9(UMOP&WFNRVM*TIOP MV<-"X+H"6R3K;?AMJ_HX6-+1^.R64-`<-(R2:55_0K8(5U\\SG11[LGQ_$^! M6#(+K<9V-+GX+6%D&2RG?(6HA/+J!A)0YN.A"P-A2 M_!LNOS#U">4)DAI77R87IHM)C\AJ"9"%M>05%VJX$Q:M*^R"N>V"2GRO<`7O M+E"5E(IAW`ELZ7]1-<`($@O*O9U>7DR:M(]`('2Q^,GFY7S*):.6+J3\N65T MVK3-TI]:"%/OEMTP`,'L!'WQ-H`KC^(H*,6K8@\\[)=<)/MQ#;)^Z.IC&?<$ M,EQ0K;P66YGSE2V\3K&/Q:-:5T^OIX]4+'*^,)M3BFU)\E;G#Y#Q4[V16FV: MJAHIP'%:-@F$O4")J+R]Y%2:^FC7G:(A?(6QOP%-1W+3/%>)Z^=&@G0/B()6 M(L3=81DAW=IV2RY1-MY[F&CHPK6!F[0BFJS7EICR0C,V7>9'2CEK?EZAY1O&UC]J-C-73[_8W^B.&])S!RQNR*/&-'S[)Z_NVU M,E\7%;&\X%A],3>$VB,Z=!P27EUP(?@3)&)^MA<*.#*=L&Y1 M2P>76$CHQN'6ZXV=R9`U%L2%BHO2U=!Y5"HX<4`8/ZDMB:'GZA+V&F>!=)Q4 M*W43C+[YD,D3B>A.P,Q]?*P!)85N7*X`HH%4;E4+$S&4-UBE+7\A?TK&AYY'B:U\LPSO#.63CNWZY".0%GG.![['-@>:'XE6;1F\+PY1CUBY[6!#Q,S"L0Z/C MQ#!K3:.J]PY%[?_`5!+`0(>`Q0````(`'B`;46[-TOE M&&X``.S6!``1`!@```````$```"D@0````!A>&=N+3(P,30P.3,P+GAM;%54 M!0`#M!QE5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'B`;467Z-X%I`D` M`#2$```5`!@```````$```"D@6-N``!A>&=N+3(P,30P.3,P7V-A;"YX;6Q5 M5`4``[0<951U>`L``00E#@``!#D!``!02P$"'@,4````"`!X@&U%D2S-4UH/ M``!@^P``%0`8```````!````I(%6>```87AG;BTR,#$T,#DS,%]D968N>&UL M550%``.T'&54=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`>(!M13=8,7VT M.@``Z,`#`!4`&````````0```*2!_X<``&%X9VXM,C`Q-#`Y,S!?;&%B+GAM M;%54!0`#M!QE5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'B`;47_6G$I M(R(``-&)`@`5`!@```````$```"D@0+#``!A>&=N+3(P,30P.3,P7W!R92YX M;6Q55`4``[0<951U>`L``00E#@``!#D!``!02P$"'@,4````"`!X@&U%.?0% M/_\*``#$<```$0`8```````!````I(%TY0``87AG;BTR,#$T,#DS,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``OO`````` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details 2) (USD $)

Sep. 30, 2014

Future amortization of license and patent agreements

Remainder of 2014 $ 15,000

2015 48,000

2016 48,000

2017 48,000

2018 $ 48,000

X

- Definition

Amount of amortization expense expected to be recognized in the remainder of the fiscal year following the latest fiscal year ended for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment
9 Months Ended

Sep. 30, 2014

Property and Equipment

Property and Equipment

4.Property and Equipment

Property and equipment consist of the following:

September 30,
2014

December 31,
2013

(unaudited)

Furniture and equipment

$

825,690

$

893,973

Leasehold improvements

285,698

53,864

Processing equipment

1,194,712

1,015,388

Less: accumulated depreciation and amortization

(1,692,926
)

(1,581,536
)

Property and equipment

$

613,174

$

381,689

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O5]O9E]3:6=N M:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K7T]P=&EO;G,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M-3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S7T1E=&%I;',\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G-?1&5T86EL#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X M,C$X7S0Q,#5?83'0O:'1M;#L@8VAA2!);F9O M'0^)SQS<&%N/CPO M2!296=I&]'96XL($EN8RX\"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^ M)S$P+5$\2!#=7)R96YT(%)E M<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@ M("`\=&0@8VQA6%B;&4@+2!2979E;G5E($EN=&5R97-T(%!U M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF%T:6]N(&]F(&EN=&%N M9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M,RPT-C@\2!A;F0@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-#(L.#'0^)SQS<&%N/CPO3H\+W-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^ M(#QD:78@6QE/3-$)VUA6QE/3-$)V1IF4Z,3!P=#LG M/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/D)A6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA#(P,40[*2!A;F0@:71S('=H;VQL>2!O=VYE M9"!S=6)S:61I87)Y($%X;T=E;B!#;W)P;W)A=&EO;B`H)B-X,C`Q0SM!0R8C M>#(P,40[*29N8G-P.R9N8G-P.V%S(&]F(%-E<'1E;6)E2!F;W(@=&AE('EE87(@ M96YD960@1&5C96UB97(F;F)S<#LS,2P@,C`Q,RP@=VAI8V@@87)E(&EN8VQU M9&5D(&EN('1H92!!;FYU86P@4F5P;W)T(&]N($9O2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O M9B!R97-U;'1S(&9O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`H)B-X,C`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`@/&AE860^#0H@("`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`P,"!A;F0@)#4Y+#`P,"!A="!397!T96UB97(F;F)S M<#LS,"P@,C`Q-"!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`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`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*'5N875D:71E9"D\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D9I;FES:&5D(&=O;V1S/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,C$L,S8R)FYB6QE/3-$=VED M=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/E)A=R!M871E6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`P."PW,#F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F]R9&5R+71O<#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I M9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#,Y M."PT,S@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)VUA&EM871E;'D@)#,X,RPP,#`@86YD M("0S.#,L,#`P(&%T(%-E<'1E;6)E6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE M/3-$)VUA6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE M/3-$)VUA'!E;G-E(&1U92!T;R!T:&4@ M9V5N97)A=&EO;B!O9B!N970@;W!E&5S(&%R92!A8V-O=6YT960@9F]R('5S:6YG('1H92!B86QA M;F-E('-H965T(&%P<')O86-H('=H:6-H(')E<75I"!A"!B87-IF5D+B!!(&9U;&P@=F%L=6%T:6]N M(&%L;&]W86YC92!H87,@8F5E;B!E"!B96YE9FET('=I;&P@;F]T(&)E(')E86QI>F5D+B!) M;B!A9&1I=&EO;BP@9G5T=7)E('5T:6QI>F%T:6]N(&]F('1H92!A=F%I;&%B M;&4@;F5T(&]P97)A=&EN9R!L;W-S(&-A3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/E1H92!#;VUP86YY(&ED96YT:69I97,@86YD(&5V86QU871E2UT:&%N+6YO="!P M2!O9B!T:&4@<&]S:71I;VX@8F5I;F<@=7!H96QD('=H96X@ M&EN9R!A=71H;W)I='DN(%-U M8V@@<&]S:71I;VYS(&%R92!D965M960@=&\@8F4@=6YR96-O9VYI>F5D('1A M>"!B96YE9FET2!IF5D(&$@;&EA8FEL:71Y(&9O28C>#(P,3D[65A&%M:6YA=&EO;B!B>2!T M:&4@26YT97)N86P@4F5V96YU92!397)V:6-E(&EN8VQU9&4@=&AE('EE87)S M(&5N9&5D($1E8V5M8F5R)FYB2!A6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!R97-P96-T:79E(&-A6%B;&4@86YD(&%C8W)U960@97AP96YS97,N(%1H92!F86ER M('9A;'5E(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&QO;F&EM871E2X\+V9O;G0^ M#0H)"3PO<#X-"@D)/'`@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA'!E;G-E(&]V97(@=&AE(&5M<&QO>65E)B-X,C`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`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXT+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3`E.W!A9&1I;F6QE/3-$)W=I9'1H.C$V+C,V M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,RXR-R9N8G-P.PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C,X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B4\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V M86QI9VX],T1T;W`@6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C6QE/3-$)W=I9'1H M.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)V1I MF4Z,3!P=#LG/D5X<&5C=&5D(&1I=FED M96YD6QE/3-$=VED=&@Z,#,N-#`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`Y+"`\+V9O;G0^/&9O;G0@3H@ M:6YL:6YE.V9O;G0M2!E=F%L=6%T:6YG('=H870@ M:6UP86-T+"!I9B!A;GDL('1H92!P28C>#(P,3D[7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`E.W!A9&1I;FF4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$U+C`P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R M)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N M,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M*'5N875D:71E9"D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,34N M,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,RXS."4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,RXS."4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$ M=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C$U+C`P)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`Q-2PS.#@-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/DQEF%T:6]N/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(MF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C8R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0MF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P M=#LG/E!R;W!E6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^(#QD:78@6QE/3-$ M)VUA6QE/3-$)V1IF4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z,3!P=#LG/DEN=&%N9VEB;&4@07-S971S(#PO9F]N=#X\+V9O;G0^#0H) M"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!#;VUP86YY)B-X,C`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`Q M+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C(N-#@E M.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M)FYB6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C8R+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/E!A=&5N=',\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXW.2PW,C$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.C$U+C`P)3L[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI M9VXZ6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH,S0Q+#DR-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@ M6QE M/3-$)V1I6QE/3-$=VED M=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`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`H)B-X,C`Q0SM51E)&)B-X,C`Q1#LI M(&%N9"!5;FEV97)S:71Y(&]F(%1E>&%S(&%T($%U2!A8W%U:7)E9"!E>&-L=7-I=F4@=V]R M;&1W:61E(&QI8V5N2!B92!T97)M:6YA=&5D(&)Y('1H92!#;VUP86YY M('=I=&@@-C`@9&%Y6QE M/3-$=VED=&@Z,3`P)3L@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,#X\='(^/'1D('-T>6QE/3-$=VED=&@Z,3AP=#L^/'`@6QE/3-$)W=I9'1H.B`P,"XP,'!T.R!D:7-P M;&%Y.B!I;FQI;F4[)SX-"@D)"3QP('-T>6QE/3-$)V)O6QE/3-$=VED=&@Z,3AP=#L^/'`@F4Z(#$P<'0[;6%R9VEN.C!P M=#LG/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M7,@2!F965S(')A;F=I;F<@ M9G)O;2`Q)2!T;R`S)2!U;F1E2!O9B`D,3(L-3`P('!E6%L='D@9F5E6%L=&EE6%L='D@ M6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@F4Z(#$P<'0[;6%R9VEN M.C!P=#LG/@T*"0D)"3QF;VYT('-T>6QE/3-$)VUAF4Z(#$P<'0[)SX@)B-X0C<[/"]F;VYT M/@T*"0D)/"]P/@T*"0D\+W1D/CQT9"!S='EL93TS1'=I9'1H.C$X<'0[/CQP M('-T>6QE/3-$=VED=&@Z,3AP=#MW:61T:#HQ.'!T.V9O;G0MF4Z(#$P<'0[;6%R9VEN.C!P=#LG/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M2!A('!E2!T96-H;F]L;V=I97,@8V]V97)E9"!B>2!,:6-E;G-E($%G6QE M/3-$=VED=&@Z,3AP=#MF;VYT+7-I>F4Z,'!T.SX\+W`^/"]T9#X\=&0@=F%L M:6=N/3-$=&]P(&%L:6=N/3-$;&5F="!S='EL93TS1"=W:61T:#H@,#`N,#!P M=#L@9&ES<&QA>3H@:6YL:6YE.R<^#0H)"0D\<"!S='EL93TS1"=B;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M=VED=&@Z,3AP=#L^/'`@6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@3I4:6UE$(W.SPO9F]N=#X-"@D)"3PO<#X-"@D)/"]T9#X\=&0@F4Z,'!T.SX\+W`^/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1'1O<#X-"@D)"3QP('-T>6QE/3-$)V)O&]'96X@=V]U M;&0@;W=E(&$@)#$U+#`P,"!M:6QE2X@ M5&AE($-O;7!A;GD@:&%S(&YO="!R96-E:79E9"!E:71H97(@9W)A;G0@86YD M(&1O97,@;F]T(&]W92!S=6-H(&$@;6EL97-T;VYE(&9E92XF;F)S<#M/=&AE M3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M2!F965S('=E2`D.3,L,#`P(&%N M9"`D-C0L,#`P(&9O3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO M<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6%B;&4@86YD($%C8W)U960@17AP96YS97,\8G(^/"]S=')O M;F<^/"]T:#X-"B`@("`@("`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`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA6%B;&4\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M3I4:6UE6QE/3-$)W1E>'0M:6YD96YT.C!P=#MM87)G M:6XM;&5F=#HP<'0[('!A9&1I;F6QE M/3-$)V1I6QE/3-$)W1E>'0M M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[('!A9&1I;F'0M86QI9VXZ;&5F="<^/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1I M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DYO=&5S(%!A>6%B;&4@8V]N6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/B9N8G-P.SPO9F]N=#X\+W`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`Q+C`R)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$=VED=&@Z-C6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8W+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M#(P,4,[4$1,)B-X,C`Q1#LI(&9O6%B;&4@;6]N=&AL>2!A="`Y+CDU)2!O9B!. M970@4F5V96YU97,@=&AR;W5G:"!397!T96UB97(F;F)S<#LR,#$T.R!A;F0@ M=&AE(&=R96%T97(@;V8@*&DI)FYB2`D,2XS(&UI;&QI;VX@=&\@)#(N M-2!M:6QL:6]N('!E6UE;G0@86UO=6YT6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XU-B4[8F]R9&5R M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,2XU-B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI M9VXZ6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY,;VYG+71E6QE/3-$=VED=&@Z,#(N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[ M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XU-B4[8F]R M9&5R+71O<#HQ<'0@'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I'0M9&5C;W)A=&EO;CIU M;F1E6%B;&4\+V9O;G0^#0H)"3PO<#X-"@D)/'`@ M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D]N($]C=&]B97(F;F)S<#LU+"`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`D,2XS('1O("0R M+C4@;6EL;&EO;B!P97(@<75A6%L='D@0V]N=')A8W0N M(%1H92!T;W1A;"!C;VYS:61E#(P,4,[1G5N9&5D($%M;W5N M="8C>#(P,40[*2P@:6YC;'5D:6YG("0Q.2PP-3`L,#`P(%!$3"!P86ED('1O M('1H92!#;VUP86YY(&]N($]C=&]B97(F;F)S<#LU+"`R,#$R+"!A;F0@)#$L M-S4P+#`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`R,#$V+"!O#(P,3D[2!# M;VYT2!R97%U:7)E($%X;T=E;B!T;R!R97!U#(P,40[(%1H92!0=70@4')I8V4@:7,@97%U86P@=&\@=&AE('-U M;2!O9B`H:2DF;F)S<#MA;B!A;6]U;G0@=&AA="P@=VAE;B!P86ED('1O(%!$ M3"P@=V]U;&0@9V5N97)A=&4@82!S<&5C:69I960@:6YT97)N86P@2!T:&4@0V]M<&%N>2P@86YD("AI:2DF;F)S<#MA;GD@)B-X,C`Q0SM$ M96QI;G%U96YT($%S6UE;G0F(W@R,#%$.R`H M87,@9&5F:6YE9"!I;B!T:&4@4F]Y86QT>2!#;VYT6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN M(&%D9&ET:6]N+"!I;B!T:&4@979E;G0@;V8@82`F(W@R,#%#.T-H86YG92!O M9B!#;VYT6%L='D@ M0V]N=')A8W0I+"!T:&4@0V]M<&%N>2!M=7-T(')E<'5R8VAA2!A9G1E6UE;G1S(&UA9&4@=&\@4$1, M(&)Y('1H92!#;VUP86YY+"!A;F0@*&EI*29N8G-P.V%N>2`F(W@R,#%#.T1E M;&EN<75E;G0@07-S:6=N960@26YT97)E#(P,40[("AA M2!O=V5D('1O(%!$3"X@26X@861D:71I;VXL(&%T(&%N>2!T:6UE(&%F=&5R M($]C=&]B97(F;F)S<#LU+"`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`H=&AE("8C>#(P,4,[0F]A'0@86YN=6%L(&UE971I;F<@ M86YD('-H86QL(&EN8VQU9&4@#(P,3D[2!S=&%T96UE;G0@9F]R(&5A8V@@86YN=6%L(&UE971I M;F<@=&AE#(P,3D[(&%P<')O=F%L+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.FYO3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!T:6UE('1H97)E(&)E8V]M92!A('9A8V%N M8WD@;VX@=&AE($)O87)D(&%S(&$@2P@ M86YD($%X;T=E;B!S:&%L;"!T86ME('-U8V@@86-T:6]N3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/D]N($%U9W5S="9N8G-P M.S(P+"`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`^#0H)"3QP('-T>6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/E5N9&5R('1H92!2 M;WEA;'1Y($-O;G1R86-T+"!D=7)I;F<@=&AE('!E&5R8VES97,@:71S('!U="!O<'1I;VX@;VX@;W(@<')I;W(@=&\@ M1&5C96UB97(F;F)S<#LT+"`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`@3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/DEN(&-O;FYE8W1I;VX@ M=VET:"!T:&4@4F]Y86QT>2!#;VYT2!A;F0@:7)R979O8V%B;'D@9W5A28C>#(P M,3D[2!#;VYT2!O=&AE2!#;VYT7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78^(#QD:78@6QE/3-$)VUA6QE/3-$)V1IF4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/E-T;V-K M($]P=&EO;G,@/"]F;VYT/CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.FYO3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M&EM871E;'D@)#$L-3`X+#`P,"!A="!397!T96UB97(F;F)S<#LS,"P@ M,C`Q-"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^(#QD:78@6QE/3-$)VUA6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA#(P,4,[/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V1IF4Z,3!P=#LG/E-I M9VX\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M M28C>#(P,3D[2!!>&]'96X@ M0V]R<&]R871I;VXL(&%S(&=U87)A;G1O3H@:6YL:6YE.V9O;G0M3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/G(\ M+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V1I MF4Z,3!P=#LG/BX@*"8C>#(P,4,[5&AR M964@4&5A:W,F(W@R,#%$.RDL(&%N(&EN9&ER96-T('=H;VQL>2!O=VYE9"!S M=6)S:61I87)Y(&]F($]B97)L86YD($-A<&ET86P@2&5A;'1H8V%R92!-87-T M97(@1G5N9"!,4#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="US:7IE.C$P<'0[)SX@*"8C>#(P,4,[3V)E3H@ M:6YL:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/E4\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/B!4:')E92!096%K#(P,40[*2!W:&EC:"!H87,@82!S:7@@ M>65A6UE;G1S M(&%N9"!A(&9I;F%L('!R:6YC:7!A;"!P87EM96YT(&1U92!A="!T:&4@96YD M(&]F('1H92!T97)M+B9N8G-P.R9N8G-P.TEN=&5R97-T(&ES('!A>6%B;&4@ M<75A6QE/3-$)V1IF4Z,3!P=#LG/DYO=F5M M8F5R(#$S+"`R,#$T("@F(W@R,#%#.SPO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SYT:&4@26YI=&EA;"!# M;&]S:6YG($1A=&4\+V9O;G0^/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/B!R97-U M;'1E9"!I;B!A(#$P)2!R871E+B!5;F1E#(P,4,[5&5R;2!,;V%N)B-X,C`Q1#LI(&1U#(P,40[(&%N9"P@=&]G971H97(@=VET:"!T:&4@26YI M=&EA;"!#;&]S:6YG($1A=&4L('1H92`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`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`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0MF4],T0Q/B`\ M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'0^)SQD:78^(#QD:78@6QE/3-$ M)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF5D('=H96X@<&5R2!H87,@;V-C=7)R960@86YD('1H97)E(&ES(&$@2!H87,@;F\@9G5R=&AE2!T;R!A(&-UF5D(&%S(')E=F5N M=65S('=H96X@<')O9'5C=',@87)E('-H:7!P960@=&\@=&AE(&-UF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\ M+V1I=CX\6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.C$P<'0[=&5X="UD96-O3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D9O2!E>&-E960@9F5D97)A;&QY(&EN2!H87,@;F5V97(@97AP97)I96YC960@ M86YY(&QO6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.C$P<'0[=&5X="UD96-O3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/D%C8V]U;G1S M(')E8V5I=F%B;&4@87)E(&-A#(P,3D[2!A;F0@8W5R2!W3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E=E(')E9W5L87)L>2!R979I97<@ M86QL(&%C8V]U;G1S('1H870@97AC965D(#8P(&1A>7,@9G)O;2!T:&4@:6YV M;VEC92!D871E(&%N9"!B87-E9"!O;B!A;B!A7-I&-L=61E'!E2!A9VEN9R!C871E9V]R>2`H-24@9F]R(&)A;&%N M8V5S(#8Q+3DP(&1A>7,@86YD(#(P)2!F;W(@8F%L86YC97,@;W9E7,@86YD(&$@ M:&EG:&5R('!E2!W2`D-CDL,#`P(&%N9"`D-3DL,#`P(&%T(%-E<'1E;6)E M6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA2!A;'-O(&-O;G1R;VQS(&-R961I="!R:7-K('1H'0^)SQD:78^(#QD:78@6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN=F5N=&]R:65S(&%R92!C M;VUP6QE/3-$ M)V1IF4Z,3!P=#LG/B!.97)V92!'&]'=6%R9#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C8N-7!T.R<^)B-X044[/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V1IF4Z,3!P=#LG M/B!.97)V92!03I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\ M9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`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`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$ M=VED=&@Z,#$N,S@E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`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`S+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)OF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`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`@("`\+W1R/@T*("`@("`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`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQD:78^ M(#QD:78@6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!R97-P96-T:79E(&-A6%B;&4@86YD(&%C8W)U960@97AP96YS97,N(%1H92!F86ER('9A M;'5E(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&QO;F&EM871E2X\+V9O;G0^#0H) M"3PO<#X-"@D)/'`^/&9O;G0@3I4:6UE6QE/3-$)V1I'0M9&5C M;W)A=&EO;CIU;F1E3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/E-T;V-K+6)A&]'96X@,C`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`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\ M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*'5N875D:71E9"D\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,3,\+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/BAU;F%U9&ET960I M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V1IF4Z,3!P M=#LG/D5X<&5C=&5D('1E6QE/3-$)W=I9'1H M.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+C`F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW M.2XW-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXS-B4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,S@E.W!A9&1I;FF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E)IF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C$V+C,V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N-#`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3I4:6UE6QE/3-$)V1I'0M9&5C;W)A=&EO;CIU;F1E6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)VUA'!E;G-E6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.C$P<'0[=&5X="UD96-O6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA#(P,4,[05-5)B-X,C`Q1#LI($YO+B9N8G-P.S(P,30M,#DL M(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US M='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[)SY2979E;G5E(&9R;VT@0V]N M=')A8W1S('=I=&@@0W5S=&]M97)S/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I MF4Z,3!P=#LG/BX@5&AE(&-OF4@&-H86YG92!F M;W(@=&AO2P@=&AE('!R;VYO=6YC96UE;G0@=VEL;"!H879E(&]N('1H92!#;VUP86YY M)B-X,C`Q.3MS(&1I3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE M/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q M,#5?83'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO6QE M/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V)O6QE/3-$ M=VED=&@Z-3DN,3`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*'5N875D:71E9"D\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D9I;FES:&5D(&=O;V1S/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,C$L,S8R)FYB6QE/3-$=VED=&@Z M,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/E)A M=R!M871E6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`P."PW,#F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F]R9&5R+71O<#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#,Y."PT M,S@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0^ M)SQD:78^(#QD:78@6QE/3-$)VUA6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/DYI;F4F;F)S<#MM;VYT:',F;F)S<#ME;F1E M9"9N8G-P.U-E<'1E;6)E6QE/3-$=VED=&@Z,#,N M-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\ M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*'5N875D:71E9"D\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,3,\+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/BAU;F%U9&ET960I M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V1IF4Z,3!P M=#LG/D5X<&5C=&5D('1E6QE/3-$)W=I9'1H M.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+C`F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW M.2XW-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXS-B4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,S@E.W!A9&1I;FF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E)IF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C$V+C,V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N-#`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$V+C,V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#$N,S@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`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`Q+C(V)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C(N-3`E.W!A9&1I;FF4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$U+C`P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4 M:6UE6QE/3-$=VED=&@Z-C(N-3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,34N,#`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,C4L-CDP#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX.3,L.36QE/3-$)W=I9'1H.C`Q+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C(N-3`E M.W!A9&1I;F6QE/3-$)W=I9'1H.C$U+C`P)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU,RPX-C0-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E!R;V-EF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,2PV.3(L.3(V M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#,N,3(E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H M.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$U+C`P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED M=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,RXS."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV,3,L,36QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXS M."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXS.#$L-C@Y#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@ M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S M='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^4V5P=&5M8F5R)FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/BAU;F%U9&ET960I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HQ,RXW,"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ M6QE M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`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`S+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(MF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY);G1A;F=I8FQE(&%S M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXW,"4[8F]R9&5R M+71O<#HQ<'0@'0M86QI9VXZ6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU-S`L,SDV M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#$N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE M/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q M,#5?83'0O:'1M M;#L@8VAA6%B;&4@*%1A8FQE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV M('-T>6QE/3-$=VED=&@Z,3`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`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#(N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N M-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB2!A;6]U;G1S('9A6QE/3-$)W=I M9'1H.C`R+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$Q+C4V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXR."PQ-S,L.#6QE/3-$)W=I9'1H.C`R+C8X)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$Q+C4V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2PS M-C,L-CDU)FYB6QE/3-$)W=I9'1H.C`Q+C`R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ,2XU-B4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$Q+C4V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2PS-C,L-CDU M)FYB6QE/3-$=VED=&@Z,#$N,#(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N M=&5R.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X- M"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\ M+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS M*2`H55-$("0I/&)R/CPO7,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P M+B`S,"P@,C`Q-#QB7,\8G(^36EN:6UU;3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SDP(&1A>7,\ M'0^ M)SDP(&1A>7,\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2P@3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS+#,T-BPQ,34\2!V86QU M871I;VX@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2!O9B!3:6=N:69I8V%N="!!8V-O=6YT M:6YG(%!O;&EC:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)S0@>65A2`H87,@82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q M,#5?83'0O:'1M M;#L@8VAA'0^)SQS M<&%N/CPOF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-CDR+#DR M-BD\2!A;F0@97%U:7!M96YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3,L,3'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q M.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA&EM=6T\8G(^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N(&]F(&QI8V5N3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DS+#`P M,#QS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'1E M;F1E9"!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M)S8P(&1A>7,\6%L='D@;V8@86=R965M96YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!F965S(')A;F=E('5N9&5R('1H92!L:6-E;G-E M(&%G'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%L M='D@'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@86YD($%C8W)U960@17AP96YS97,@*$1E=&%I;',I("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P M+B`S,"P@,C`Q-#QB6%B;&4@86YD($%C8W)U960@17AP M96YS97,\+W-T7)O;&P\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!P97)C96YT86=E(&]N(&YE M="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO2!P87EM96YT'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!P87EM96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)W%U M87)T97)L>3QS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@86UO=6YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6EN9R!A;6]U;G0\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q M.5\X,C$X7S0Q,#5?83'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E(')E;&%T960@ M=&\@;F]N=F5S=&5D(&%W87)D3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9F8R8V0Q.5\X,C$X7S0Q,#5? M83'0O:'1M;#L@ M8VAA&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`Q M,BP@,C`Q-#QB&EM M=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`Q,BP@ M,C`Q-#QB'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)S@@>65A'0^)SQS<&%N/CPO'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5D(')A=&4L(&]P=&EO;B`Q/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!P97)C M96YT86=E(&]N(&YE="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO2!H87,@=&AE(&]P=&EO M;B!T;R!P2!O9B!T:&4@87!P;&EC M86)L92!#;&]S:6YG($1A=&4\+W1D/@T*("`@("`@("`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htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable (Details 2) (Revenue Interest Purchase Agreement, USD $)
0 Months Ended 2 Months Ended 9 Months Ended

Oct. 05, 2012

Aug. 14, 2012

Oct. 05, 2012

Sep. 30, 2014

Debt Instrument

Royalty percentage on net revenue 9.95%

Royalty payments, frequency through September 2014 monthly

Royalty percentage on product revenue 9.95%

Royalty payments estimated range calculated from September 2014 through September 2020, frequency quarterly

Total debt $ 20,800,000

Minimum annual payment amounts

2014 1,250,805

2015 6,781,440

2016 9,232,642

2017 9,000,000

2018 9,000,000

2019 9,063,000

2020 6,939,000

Term 8 years

Funded amount 19,050,000 1,750,000 20,800,000

Internal rate of return on funded amount (as a percent) 20.00%

Minimum

Debt Instrument

Varying amount 1,300,000

Maximum

Debt Instrument

Varying amount $ 2,500,000

X

- Definition

Description of the frequency of calculation of the periodic payments (monthly, quarterly, annual) for the period from September 2014 through September 2020 as specified in the agreement.

+ References

No definition available.

+ Details

Name: axgn_DebtInstrumentFrequencyOfCalculationOfPeriodicPaymentsPeriodTwo

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the frequency of periodic payments (monthly, quarterly, annual) for the period from inception of the loan through September 2014 as specified in the agreement.

+ References

No definition available.

+ Details

Name: axgn_DebtInstrumentFrequencyOfPeriodicPaymentPeriodOne

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract.

+ References

No definition available.

+ Details

Name: axgn_DebtInstrumentPeriodicPaymentPrincipalAndInterest

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the remainder of the fiscal year following the latest fiscal year ended.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the fourth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the seventh fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearSeven

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the sixth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearSix

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the third fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the required periodic payments for principal and interest required under the contract in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: axgn_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The required internal rate of return on the funded amount (including any delinquent interest) which the reporting entity will be required to repay in the event of a material adverse event or other condition specified in the agreement.

+ References

No definition available.

+ Details

Name: axgn_PutOptionRequiredInternalRateOfReturnPercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the royalty as a percentage of net revenue.

+ References

No definition available.

+ Details

Name: axgn_RoyaltyPercentageOfNetRevenue

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Royalty Percentage Of Product Revenue.

+ References

No definition available.

+ Details

Name: axgn_RoyaltyPercentageOfProductRevenue

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongTermDebtByMaturityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Debt Instrument

Total Debt $ 28,173,877 $ 25,363,695

Long-term Notes Payable 28,173,877 25,363,695

Revenue Interest Purchase Agreement

Debt Instrument

Total Debt $ 28,173,877 $ 25,363,695

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable (Details 3) (Revenue Interest Purchase Agreement)

Sep. 30, 2014

Revenue Interest Purchase Agreement

Long-Term Debt

Internal rate of return on funded amount related to put option (as a percent) 20.00%

Internal rate of return on funded amount related to change of control (as a percent) 32.50%

X

- Definition

The required internal rate of return on the funded amount (including any delinquent interest) which the reporting entity will be required to repay in the event of a) a change of control or other condition specified in the agreement or b)the reporting entity chooses to exercise an option to redeem the debt.

+ References

No definition available.

+ Details

Name: axgn_CallOptionAndChangeInControlRequiredInternalRateOfReturnPercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The required internal rate of return on the funded amount (including any delinquent interest) which the reporting entity will be required to repay in the event of a material adverse event or other condition specified in the agreement.

+ References

No definition available.

+ Details

Name: axgn_PutOptionRequiredInternalRateOfReturnPercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Stock Options

Stock options granted under 2010 Stock Incentive Plan (in shares) 476,250

Stock-based compensation $ 227,553 $ 142,200 $ 701,697 $ 534,673

Total future stock compensation expense related to nonvested awards $ 1,508,000 $ 1,508,000

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3.Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenue from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $69,000 and $59,000 at September 30, 2014 and December 31, 2013, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

September 30,
2014

December 31,
2013

(unaudited)

Finished goods

$

2,116,046

$

2,131,336

Work in process

221,362

235,966

Raw materials

1,008,707

1,031,136

$

3,346,115

$

3,398,438

Inventories were net of reserve of approximately $383,000 and $383,000 at September 30, 2014 and December 31, 2013, respectively.

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2010 through 2013; there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable and accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company’s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:

Nine months ended September 30,

2014
(unaudited)

2013
(unaudited)

Expected term (in years)

4.0

4.0

Expected volatility

79.76
%

83.27
%

Risk free rate

1.23
%

0.71
%

Expected dividends

0.0
%

0.0
%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the nine months ended September 30, 2014 and 2013 as they were deemed insignificant.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The core principle of the ASU is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration, or payment, to which the company expects to be entitled in exchange for those goods or services. The ASU may also result in enhanced disclosures about revenue. For public entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Due to the recent date of issuance for this ASU, management is currently evaluating what impact, if any, the pronouncement will have on the Company’s disclosures, its financial position or results from operations.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details) (USD $)
0 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Oct. 05, 2012

Revenue Interest Purchase Agreement

Sep. 30, 2014

Revenue Interest Purchase Agreement

Nov. 12, 2014

Subsequent Event

Nov. 12, 2014

Three Peaks

Subsequent Event

Nov. 12, 2014

Three Peaks

Subsequent Event

Term Loan

Nov. 13, 2014

Three Peaks

Subsequent Event

Term Loan

Nov. 12, 2014

Three Peaks

Subsequent Event

Term Loan

Nov. 12, 2014

Three Peaks

Subsequent Event

Revenue Interest Purchase Agreement

Nov. 12, 2014

Three Peaks

Subsequent Event

Revenue Interest Purchase Agreement

Nov. 12, 2014

Three Peaks

Subsequent Event

Revenue Interest Purchase Agreement

Maximum

Nov. 12, 2014

Three Peaks

Subsequent Event

Revenue Interest Purchase Agreement

Maximum

Nov. 12, 2014

PDL

Subsequent Event

Subsequent Events

Face amount $ 20,800,000 $ 25,000,000

Term 8 years 6 years 10 years

Interest rate stated (as a percent) 9.00%

Basis spread on fixed rate, option 1 LIBOR

Basis spread on fixed rate, option 2 1.00%

Effective interest rate (as a percent) 10.00%

Optional future additional borrowing 7,000,000

Royalty percentage on net revenue 9.95% 3.75% 4.80%

Royalty revenue per year 30,000,000

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date 120.00%

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date 135.00%

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date 150.00%

Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date 16.25%

Upon certain events, the additional percentage of the originally advanced Term Loan amount owed 3.00%

Shares of common stock sold 17,466,381 17,339,561 1,375,969 643,382

Value of common stock sold 174,664 173,395 3,550,000 1,750,000

Public offering price (in dollars per share) $ 2.58 $ 2.72

Amount of capital used to repay the royalty contract $ 1,750,000

X

- Definition

Percentage points added to the fixed to compute the total rate on the debt instrument.

+ References

No definition available.

+ Details

Name: axgn_DebtInstrumentBasisSpreadOnFixedRateOption2

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents potential future additional borrowings on existing debt instruments if certain covenants are maintained.

+ References

No definition available.

+ Details

Name: axgn_DebtInstrumentOptionalAdditionalBorrowings

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the royalty as a percentage of net revenue.

+ References

No definition available.

+ Details

Name: axgn_RoyaltyPercentageOfNetRevenue

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the additional percentage of the originally advanced Term Loan amounts the lender has a right to demand upon a change of control, sale of the majority of the Company's assets or a material adverse change

+ References

No definition available.

+ Details

Name: axgn_UponCertainEventsAdditionalPercentageOfOriginallyAdvancedTermLoanOwed

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.

+ References

No definition available.

+ Details

Name: axgn_UponCertainEventsInternalRateOfReturnOfOutstandingTermLoanLenderHasRightToDemandAfterThirdAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.

+ References

No definition available.

+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterFirstAnniversaryButBeforeSecondAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.

+ References

No definition available.

+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterSecondAnniversaryButBeforeThirdAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.

+ References

No definition available.

+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandOnOrPriorToFirstAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of total capital as defined in the regulations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 948

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 505

-Section 50

-Paragraph 1H

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=7881181&loc=d3e65071-112826

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 505

-Section 50

-Paragraph 1H

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=7881181&loc=d3e65071-112826

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 948

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998

+ Details

Name: us-gaap_Capital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The effective interest rate at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateAtPeriodEnd

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of any adjustments made to the stated rate to determine the effective rate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (USD $)

Sep. 30, 2014

Dec. 31, 2013

Current assets:

Cash and cash equivalents $ 11,802,608 $ 20,069,750

Accounts receivable, net of allowance for doubtful accounts of approximately $69,000 and $59,000, respectively 2,743,041 1,893,699

Inventory 3,346,115 3,398,438

Prepaid expenses and other 100,923 296,719

Total current assets 17,992,687 25,658,606

Property and equipment, net 613,174 381,689

Intangible assets 576,382 570,396

Deferred financing costs 914,931 1,073,579

Total Assets 20,097,174 27,684,270

Current liabilities:

Accounts payable and accrued expenses 2,020,091 2,083,942

Current Deferred Revenue 14,118 14,118

Total current liabilities 2,034,209 2,098,060

Note Payable - Revenue Interest Purchase Agreement 28,173,877 25,363,695

Long Term Deferred Revenue 75,168 85,882

Total liabilities 30,283,254 27,547,637

Commitments and contingencies

Shareholders' equity (deficit):

Common stock, $.01 par value; 50,000,000 shares authorized; 17,466,381 and 17,339,561 shares issued and outstanding 174,664 173,395

Additional paid-in capital 73,264,241 72,369,016

Accumulated deficit (83,624,985) (72,405,778)

Total shareholders' equity (deficit) (10,186,080) 136,633

Total Liabilities and Shareholders' equity $ 20,097,174 $ 27,684,270

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Net amount of long-term deferred finance costs capitalized at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basis of Presentation
9 Months Ended

Sep. 30, 2014

Basis of Presentation

Basis of Presentation

1.Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of September 30, 2014 and December 31, 2013 and for the three month and nine month periods ended September 30, 2014 and 2013. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2013, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2013. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

X

- Definition

The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details 3)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Summary of Significant Accounting Policies

Expected term 4 years 4 years

Expected volatility (as a percent) 79.76% 83.27%

Risk free rate (as a percent) 1.23% 0.71%

Expected dividends (as a percent) 0.00% 0.00%

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 27 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details) (USD $)
3 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

License agreements

Dec. 31, 2013

License agreements

Sep. 30, 2014

License agreements

Minimum

Sep. 30, 2014

License agreements

Maximum

Sep. 30, 2014

Patents

Dec. 31, 2013

Patents

Intangible assets consist of:

Finite-lived intangible assets, gross $ 838,586 $ 816,300 $ 79,721 $ 62,553

Less: accumulated amortization (341,925) (341,925) (308,457)

Intangible assets, net 576,382 576,382 570,396

Amortization period of intangible assets 17 years 20 years 3 years

Non-amortizable pending costs 79,721

Amortization of intangible assets $ 11,000 $ 15,000 $ 33,468 $ 44,176

X

- Definition

Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross.

+ References

No definition available.

+ Details

Name: axgn_NonamortizablePendingPatentCosts

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 28 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 29 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Business
9 Months Ended

Sep. 30, 2014

Organization and Business

Organization and Business

2.Organization and Business

Business Summary

The Company is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

X

- Details

Name: axgn_OrganizationAndBusinessAbstract

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Condensed Consolidated Balance Sheets

Accounts receivable, allowance for doubtful accounts $ 69,000 $ 59,000

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 50,000,000 50,000,000

Common stock, shares issued 17,466,381 17,339,561

Common stock, shares outstanding 17,466,381 17,339,561

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment (Tables)
9 Months Ended

Sep. 30, 2014

Property and Equipment

Summary of Property and equipment

September 30,
2014

December 31,
2013

(unaudited)

Furniture and equipment

$

825,690

$

893,973

Leasehold improvements

285,698

53,864

Processing equipment

1,194,712

1,015,388

Less: accumulated depreciation and amortization

(1,692,926
)

(1,581,536
)

Property and equipment

$

613,174

$

381,689

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2014

Nov. 13, 2014

Document and Entity Information

Entity Registrant Name AxoGen, Inc.

Entity Central Index Key 0000805928

Document Type 10-Q

Document Period End Date Sep. 30, 2014

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 19,487,530

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

X

- Details

Name: axgn_DocumentAndEntityInformationAbstract

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Tables)
9 Months Ended

Sep. 30, 2014

Intangible Assets

Schedule of intangible assets

September 30,
2014

December 31,
2013

(unaudited)

License agreements

$

838,586

$

816,300

Patents

79,721

62,553

Less: accumulated amortization

(341,925
)

(308,457
)

Intangible assets, net

$

576,382

$

570,396

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Condensed Consolidated Statements of Operations

Revenues $ 4,671,340 $ 2,957,462 $ 12,023,789 $ 7,962,683

Cost of goods sold 896,178 650,212 2,485,299 1,843,748

Gross profit 3,775,162 2,307,250 9,538,490 6,118,935

Costs and expenses:

Sales and marketing 3,250,977 2,757,241 9,326,596 7,177,170

Research and development 681,230 593,643 2,049,603 1,498,904

General and administrative 1,645,859 1,233,360 5,254,082 4,237,738

Total costs and expenses 5,578,066 4,584,244 16,630,281 12,913,812

Loss from operations (1,802,904) (2,276,994) (7,091,791) (6,794,877)

Other income (expense):

Interest expense (1,380,470) (1,214,603) (3,963,885) (3,505,869)

Interest expense-deferred financing costs (55,217) (61,216) (158,648) (146,648)

Other income (expense) 417 32 (4,886) (696)

Total other income (expense) (1,435,270) (1,275,787) (4,127,419) (3,653,213)

Net loss $ (3,238,174) $ (3,552,781) $ (11,219,210) $ (10,448,090)

Weighted Average Common Shares outstanding - basic and diluted 17,466,097 14,320,113 17,437,373 12,205,863

Loss Per Common share - basic and diluted (in dollars per share) $ (0.19) $ (0.25) $ (0.64) $ (0.86)

X

- Definition

Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable
9 Months Ended

Sep. 30, 2014

Notes Payable

Notes Payable

7.Notes Payable

Notes Payable consists of the following:

September 30,
2014
(unaudited)

December 31,
2013

Revenue Interest Purchase Agreement with PDL BioPharma, Inc. (“PDL”) for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues through September 2014; and the greater of (i) 9.95% of product revenue or (ii) specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.

$

28,173,877

$

25,363,695

Long-term Notes Payable

$

28,173,877

$

25,363,695

Note Payable

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, as defined below, and extinguish AxoGen’s long-term debt obligations there under. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, currently anticipated to be operative, of approximately $1.3 to $2.5 million per quarter which begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), including $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated.

The Company records interest using its best estimate of the effective interest rate. Currently the Company is accruing interest using the specified internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.

Put Option

Under the Royalty Contract, on October 5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen’s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the “Put Price.” The Put Price is equal to the sum of (i) an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of 20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii) any “Delinquent Assigned Interest Payment” (as defined in the Royalty Contract) the Company owed to PDL.

Change of Control; Call Option

In addition, in the event of a “Change of Control” (as defined in the Royalty Contract), the Company must repurchase the assigned Interests from PDL for a repurchase price equal to the “Change of Control Price” on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i) an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii) any “Delinquent Assigned Interest Payment” (as defined in the Royalty Contract) the Company owed to PDL. In addition, at any time after October 5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the Change of Control Price.

Board Designee

Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of the Company (the “Board”). The PDL designee was elected at the Company’s 2013 Annual Meeting of Shareholders. At each annual meeting thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen’s proxy statement for each annual meeting thereafter, provided that the election of the PDL designee is subject to shareholders’ approval.

Should at any time there become a vacancy on the Board as a result of (i) the resignation, death or removal of the PDL designee or (ii) such PDL designee failing to obtain the requisite approval of the Company’s shareholders at any annual or special meeting of the Company’s shareholders and where no other individual is elected to such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board.

On August 20, 2014, John McLaughlin, the PDL designee who was serving on the Board, delivered to us notice of his resignation as a member of the Board of Directors (the “Board”) of AxoGen, Inc. (the “Company”) effective as of the date of the notice. The Board accepted Mr. McLaughlin’s notice of resignation. The Company notes that Mr. McLaughlin’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Mr. McLaughlin had served as a member of the Board since October 2012. PDL has informed the Company that it does not intend to appoint a replacement for Mr. McLaughlin at this time.

Preemptive Rights

Under the Royalty Contract, PDL has preemptive rights with respect to certain new issuances of AxoGen’s equity securities and securities convertible, exchangeable or exercisable into such equity securities.

Restriction on Dividends

Under the Royalty Contract, during the period from the October 5, 2012 to December 4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to December 4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or acquire any such shares of common or preferred stock of any such entity (collectively, “Restricted Payments”), except that: (i) each subsidiary may make direct or indirect Restricted Payments to the Company; and (ii) the Company and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of the Royalty Contract, “Equity Interests” of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other “equity security” (as such term is defined in Rule 3a11-1under the Securities Exchange Act of 1934, as amended).

Guarantee and Collateral Agreement

In connection with the Royalty Contract, on October 5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) with PDL, pursuant to which (i) AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the “Secured Obligations,” which include the Company’s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii) each of the Company and AC grants to PDL a security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable and Accrued Expenses
9 Months Ended

Sep. 30, 2014

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

6.Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses includes $182,880 and $203,380 for accrued payroll at September 30, 2014 and December 31, 2013, respectively, $512,774 and $417,825 for accrued commissions at September 30, 2014 and December 31, 2013, respectively and $154,252 and $31,176 for accrued bonuses at September 30, 2014 and December 31, 2013, respectively.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Property and equipment

Less: accumulated depreciation and amortization $ (1,692,926) $ (1,581,536)

Property and equipment 613,174 381,689

Furniture equipment

Property and equipment

Property and equipment, Gross 825,690 893,973

Leasehold improvements

Property and equipment

Property and equipment, Gross 285,698 53,864

Processing equipment

Property and equipment

Property and equipment, Gross $ 1,194,712 $ 1,015,388

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable (Tables)
9 Months Ended

Sep. 30, 2014

Notes Payable

Schedule of notes payable

September 30,
2014
(unaudited)

December 31,
2013

Revenue Interest Purchase Agreement with PDL BioPharma, Inc. (“PDL”) for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues through September 2014; and the greater of (i) 9.95% of product revenue or (ii) specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.

$

28,173,877

$

25,363,695

Long-term Notes Payable

$

28,173,877

$

25,363,695

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Revenue Recognition

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenue from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $69,000 and $59,000 at September 30, 2014 and December 31, 2013, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

September 30,
2014

December 31,
2013

(unaudited)

Finished goods

$

2,116,046

$

2,131,336

Work in process

221,362

235,966

Raw materials

1,008,707

1,031,136

$

3,346,115

$

3,398,438

Inventories were net of reserve of approximately $383,000 and $383,000 at September 30, 2014 and December 31, 2013, respectively.

Income Taxes

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2010 through 2013; there currently are no examinations in process.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable and accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company’s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:

Nine months ended September 30,

2014
(unaudited)

2013
(unaudited)

Expected term (in years)

4.0

4.0

Expected volatility

79.76
%

83.27
%

Risk free rate

1.23
%

0.71
%

Expected dividends

0.0
%

0.0
%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the nine months ended September 30, 2014 and 2013 as they were deemed insignificant.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The core principle of the ASU is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration, or payment, to which the company expects to be entitled in exchange for those goods or services. The ASU may also result in enhanced disclosures about revenue. For public entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Due to the recent date of issuance for this ASU, management is currently evaluating what impact, if any, the pronouncement will have on the Company’s disclosures, its financial position or results from operations.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155942

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5093-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5212-111524

+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options
9 Months Ended

Sep. 30, 2014

Stock Options

Stock Options

8.Stock Options

The Company granted 476,250 options to purchase shares of stock pursuant to its 2010 Stock Incentive Plan for the nine months ended September 30, 2014. Stock-based compensation expense was $227,553 and $142,200 for the three months ended September 30, 2014 and 2013, respectively and $701,697 and $534,673 for the nine months ended September 30, 2014 and 2013, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,508,000 at September 30, 2014.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Sep. 30, 2014

Subsequent Events

Subsequent Events

9. Subsequent Events

On November 12, 2014, (the “Signing Date”), AxoGen, Inc. (the “Company” or “AxoGen”), as borrower, and the Company’s wholly owned subsidiary AxoGen Corporation, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, the Company has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. The Company has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three peaks has a first perfected security interest in the assets of the Company.

As of the Signing Date, the Company also entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of the Company’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. The Company has to maintain certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, the Company has the option at any time to prepay the Term Loan in whole or in part, and the Royalty Interest Agreements by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of the Company, sale of the majority of the Company’s assets or a material adverse change to the Company or any portion being prepaid: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) ) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan; or any portion being prepaid (iv) ) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case the Company will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, the Company would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In addition, on the Initial Closing Date, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million in cash (“Three Peaks Equity Sale”) at a public offering price of $2.58 per share. The proceeds from the Initial Term Loan, the Three Peaks Equity Sale and $1.75 million of capital from the Company, were used to fully repay the Royalty Contract with PDL. The Company has no further obligations to PDL under the Royalty Contract.

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AxoGen Corporation (“AC”), entered into a Security Agreement (“the Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

Subsequent to the closing of the Term Loan, also on the Initial Closing Date, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a public offering price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL dated the Signing Date. The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

Schedule of inventories

September 30,
2014

December 31,
2013

(unaudited)

Finished goods

$

2,116,046

$

2,131,336

Work in process

221,362

235,966

Raw materials

1,008,707

1,031,136

$

3,346,115

$

3,398,438

Schedule of weighted-average assumptions for options granted

Nine months ended September 30,

2014
(unaudited)

2013
(unaudited)

Expected term (in years)

4.0

4.0

Expected volatility

79.76
%

83.27
%

Risk free rate

1.23
%

0.71
%

Expected dividends

0.0
%

0.0
%

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details 2) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Summary of Significant Accounting Policies

Finished goods $ 2,116,046 $ 2,131,336

Work in process 221,362 235,966

Raw materials 1,008,707 1,031,136

Inventory, Net 3,346,115 3,398,438

Inventory valuation reserves $ 383,000 $ 383,000

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 09

-Article 12

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details 3) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Selling and marketing expense

Intangible assets

Royalty fees included in sales and marketing expense $ 93,000 $ 64,000 $ 238,000 $ 169,000

License agreements

Intangible assets

License agreements extended period 60 days

Minimum royalty of agreements 12,500

Milestone fee upon receiving a Phase II Small Business Innovation Research $ 15,000

Number of products under development 0

License agreements | Minimum

Intangible assets

Royalty fees range under the license agreements (as a percent) 1.00%

License agreements | Maximum

Intangible assets

Royalty fees range under the license agreements (as a percent) 3.00%

Royalty stack cap for royalties paid to more than one licensor for sales of the same product (as a percent) 3.75%

X

- Definition

Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement.

+ References

No definition available.

+ Details

Name: axgn_MilestonePaymentContingentUponReceiptOfGrant

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements.

+ References

No definition available.

+ Details

Name: axgn_MinimumRoyaltyOfLicenseAgreement

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Notice period for termination of license agreements.

+ References

No definition available.

+ Details

Name: axgn_NoticePeriodForTerminationOfLicenseAgreements

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the number of products under development.

+ References

No definition available.

+ Details

Name: axgn_NumberOfProductsUnderDevelopment

Namespace Prefix: axgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.

+ References

No definition available.

+ Details

Name: axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Royalty fees percentage under license agreements.

+ References

No definition available.

+ Details

Name: axgn_RoyaltyFeesPercentageUnderLicenseAgreements

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Cash Flows (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Cash flows from operating activities:

Net loss $ (11,219,210) $ (10,448,090)

Adjustments to reconcile net loss to net cash used for operating activities:

Depreciation 111,390 60,869

Amortization of intangible assets 33,468 44,176

Amortization of deferred financing costs 158,648 146,648

Share-based compensation 701,697 534,673

Stock grants 60,125

Interest added to note 2,810,182 2,752,273

Change in assets and liabilities:

Accounts receivable (849,342) (690,127)

Inventory 52,323 (308,955)

Prepaid expenses and other 195,796 9,821

Accounts payable and accrued expenses (63,848) (162,631)

Deferred revenue (10,714)

Net cash used for operating activities (8,019,485) (8,061,343)

Cash flows from investing activities:

Purchase of property and equipment (342,875) (66,564)

Acquisition of intangible assets (39,454) (50,262)

Net cash used for investing activities (382,329) (116,826)

Cash flows from financing activities:

Proceeds from issuance of common stock 16,784,203

Proceeds from exercise of stock options 134,672 73,015

Net cash provided by financing activities 134,672 16,857,218

Net increase (decrease) in cash and cash equivalents (8,267,142) 8,679,049

Cash and cash equivalents, beginning of year 20,069,750 13,907,401

Cash and cash equivalents, end of period 11,802,608 22,586,450

Supplemental disclosures of cash flow activity:

Cash paid for interest $ 1,154,738 $ 749,857

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets
9 Months Ended

Sep. 30, 2014

Intangible Assets

Intangible Assets

5.Intangible Assets

The Company’s intangible assets consist of the following:

September 30,
2014

December 31,
2013

(unaudited)

License agreements

$

838,586

$

816,300

Patents

79,721

62,553

Less: accumulated amortization

(341,925
)

(308,457
)

Intangible assets, net

$

576,382

$

570,396

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of December 31, 2013, the patents were fully amortized, the remaining patents of $79,721 were pending patent costs and were not amortizable. Amortization expense was approximately $11,000 and $15,000 for the three months and was approximately $33,000 and $44,000 for the nine months ended September 30, 2014 and 2013, respectively. As of September 30, 2014, future amortization of license agreements is expected to be approximately $15,000 for the remainder of 2014 and $48,000 for 2015 through 2018.

License Agreements

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

·

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

·

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;

·

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

·

Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

Royalty fees were approximately $93,000 and $64,000 for the three months and were $238,000 and $169,000 for the nine months ended September 30, 2014 and 2013, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable and Accrued Expenses (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Accounts Payable and Accrued Expenses

Accrued payroll $ 182,880 $ 203,380

Accrued commissions 512,774 417,825

Accrued Bonuses $ 154,252 $ 31,176

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedBonusesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedSalesCommissionCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 52 160 1 false 15 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.axogeninc.com/role/DisclosureBasisOfPresentation Basis of Presentation false false R7.htm 10201 - Disclosure - Organization and Business Sheet http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness Organization and Business false false R8.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 10401 - Disclosure - Property and Equipment Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipment Property and Equipment false false R10.htm 10501 - Disclosure - Intangible Assets Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssets Intangible Assets false false R11.htm 10601 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R12.htm 10701 - Disclosure - Notes Payable Notes http://www.axogeninc.com/role/DisclosureNotesPayable Notes Payable false false R13.htm 10801 - Disclosure - Stock Options Sheet http://www.axogeninc.com/role/DisclosureStockOptions Stock Options false false R14.htm 10901 - Disclosure - Subsequent Events Sheet http://www.axogeninc.com/role/DisclosureSubsequentEvents Subsequent Events false false R15.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R16.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R17.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) false false R18.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) false false R19.htm 30703 - Disclosure - Notes Payable (Tables) Notes http://www.axogeninc.com/role/DisclosureNotesPayableTables Notes Payable (Tables) false false R20.htm 40301 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R21.htm 40302 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) false false R22.htm 40303 - Disclosure - Summary of Significant Accounting Policies (Details 3) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3 Summary of Significant Accounting Policies (Details 3) false false R23.htm 40401 - Disclosure - Property and Equipment (Details) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) false false R24.htm 40501 - Disclosure - Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) false false R25.htm 40502 - Disclosure - Intangible Assets (Details 2) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails2 Intangible Assets (Details 2) false false R26.htm 40503 - Disclosure - Intangible Assets (Details 3) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails3 Intangible Assets (Details 3) false false R27.htm 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R28.htm 40701 - Disclosure - Notes Payable (Details) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails Notes Payable (Details) false false R29.htm 40702 - Disclosure - Notes Payable (Details 2) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails2 Notes Payable (Details 2) false false R30.htm 40703 - Disclosure - Notes Payable (Details 3) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails3 Notes Payable (Details 3) false false R31.htm 40801 - Disclosure - Stock Options (Details) Sheet http://www.axogeninc.com/role/DisclosureStockOptionsDetails Stock Options (Details) false false R32.htm 40901 - Disclosure - Subsequent Events (Details) Sheet http://www.axogeninc.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element axgn_RoyaltyPercentageOfNetRevenue had a mix of decimals attribute values: 0 4. Element us-gaap_CommonStockValue had a mix of decimals attribute values: -4 0. Process Flow-Through: 00100 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00200 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 00300 - Statement - Condensed Consolidated Statements of Cash Flows axgn-20140930.xml axgn-20140930.xsd axgn-20140930_cal.xml axgn-20140930_def.xml axgn-20140930_lab.xml axgn-20140930_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details) (USD $)
9 Months Ended 9 Months Ended 9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Minimum

Sep. 30, 2014

61 - 90 days

Sep. 30, 2014

61 - 90 days

Minimum

Sep. 30, 2014

61 - 90 days

Maximum

Sep. 30, 2014

Over 90 days

Sep. 30, 2014

Over 90 days

Minimum

Accounts Receivable and Concentration of Credit Risk

Reserve for accounts deemed uncollectible (as a percent) 100.00%

Age of doubtful accounts 60 days 61 days 90 days 90 days

Reserve for doubtful accounts (as a percent) 5.00% 20.00%

Allowance for doubtful accounts reserve balance $ 69,000 $ 59,000

X

- Definition

Represents the age of specific types of trade accounts and notes receivable.

+ References

No definition available.

+ Details

Name: axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the valuation allowance for receivables due, that are expected to be uncollectible, expressed as a percentage.

+ References

No definition available.

+ Details

Name: axgn_AllowanceForDoubtfulAccountsReceivablePercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the reserve for accounts deemed uncollectible, expressed as a percentage.

+ References

No definition available.

+ Details

Name: axgn_ReserveForAccountsReceivableDeemedUncollectiblePercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

Intangible Assets (Details 2) (USD $)	Sep. 30, 2014
Future amortization of license and patent agreements
Remainder of 2014	$ 15,000
2015	48,000
2016	48,000
2017	48,000
2018	$ 48,000

Notes Payable (Details 2) (Revenue Interest Purchase Agreement, USD $)	0 Months Ended		2 Months Ended	9 Months Ended
	Oct. 05, 2012	Aug. 14, 2012	Oct. 05, 2012	Sep. 30, 2014
Debt Instrument
Royalty percentage on net revenue				9.95%
Royalty payments, frequency through September 2014				monthly
Royalty percentage on product revenue				9.95%
Royalty payments estimated range calculated from September 2014 through September 2020, frequency				quarterly
Total debt				$ 20,800,000
Minimum annual payment amounts
2014				1,250,805
2015				6,781,440
2016				9,232,642
2017				9,000,000
2018				9,000,000
2019				9,063,000
2020				6,939,000
Term	8 years
Funded amount	19,050,000	1,750,000	20,800,000
Internal rate of return on funded amount (as a percent)				20.00%
Minimum
Debt Instrument
Varying amount				1,300,000
Maximum
Debt Instrument
Varying amount				$ 2,500,000

Notes Payable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument
Total Debt	$ 28,173,877	$ 25,363,695
Long-term Notes Payable	28,173,877	25,363,695
Revenue Interest Purchase Agreement
Debt Instrument
Total Debt	$ 28,173,877	$ 25,363,695

Notes Payable (Details 3) (Revenue Interest Purchase Agreement)	Sep. 30, 2014
Revenue Interest Purchase Agreement
Long-Term Debt
Internal rate of return on funded amount related to put option (as a percent)	20.00%
Internal rate of return on funded amount related to change of control (as a percent)	32.50%

Stock Options (Details) (USD $)	3 Months Ended		9 Months Ended
Stock Options (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock Options
Stock options granted under 2010 Stock Incentive Plan (in shares)			476,250
Stock-based compensation	$ 227,553	$ 142,200	$ 701,697	$ 534,673
Total future stock compensation expense related to nonvested awards	$ 1,508,000		$ 1,508,000

Subsequent Events (Details) (USD $)			0 Months Ended				0 Months Ended			0 Months Ended		0 Months Ended
Subsequent Events (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Oct. 05, 2012 Revenue Interest Purchase Agreement	Sep. 30, 2014 Revenue Interest Purchase Agreement	Nov. 12, 2014 Subsequent Event	Nov. 12, 2014 Three Peaks Subsequent Event	Nov. 12, 2014 Three Peaks Subsequent Event Term Loan	Nov. 13, 2014 Three Peaks Subsequent Event Term Loan	Nov. 12, 2014 Three Peaks Subsequent Event Term Loan	Nov. 12, 2014 Three Peaks Subsequent Event Revenue Interest Purchase Agreement	Nov. 12, 2014 Three Peaks Subsequent Event Revenue Interest Purchase Agreement	Nov. 12, 2014 Three Peaks Subsequent Event Revenue Interest Purchase Agreement Maximum	Nov. 12, 2014 Three Peaks Subsequent Event Revenue Interest Purchase Agreement Maximum	Nov. 12, 2014 PDL Subsequent Event
Subsequent Events
Face amount				$ 20,800,000					$ 25,000,000
Term			8 years				6 years			10 years
Interest rate stated (as a percent)									9.00%
Basis spread on fixed rate, option 1							LIBOR
Basis spread on fixed rate, option 2							1.00%
Effective interest rate (as a percent)								10.00%
Optional future additional borrowing							7,000,000
Royalty percentage on net revenue				9.95%							3.75%		4.80%
Royalty revenue per year												30,000,000
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date									120.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date									135.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date									150.00%
Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date									16.25%
Upon certain events, the additional percentage of the originally advanced Term Loan amount owed									3.00%
Shares of common stock sold	17,466,381	17,339,561				1,375,969								643,382
Value of common stock sold	174,664	173,395				3,550,000								1,750,000
Public offering price (in dollars per share)						$ 2.58								$ 2.72
Amount of capital used to repay the royalty contract					$ 1,750,000

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 11,802,608	$ 20,069,750
Accounts receivable, net of allowance for doubtful accounts of approximately $69,000 and $59,000, respectively	2,743,041	1,893,699
Inventory	3,346,115	3,398,438
Prepaid expenses and other	100,923	296,719
Total current assets	17,992,687	25,658,606
Property and equipment, net	613,174	381,689
Intangible assets	576,382	570,396
Deferred financing costs	914,931	1,073,579
Total Assets	20,097,174	27,684,270
Current liabilities:
Accounts payable and accrued expenses	2,020,091	2,083,942
Current Deferred Revenue	14,118	14,118
Total current liabilities	2,034,209	2,098,060
Note Payable - Revenue Interest Purchase Agreement	28,173,877	25,363,695
Long Term Deferred Revenue	75,168	85,882
Total liabilities	30,283,254	27,547,637
Commitments and contingencies
Shareholders' equity (deficit):
Common stock, $.01 par value; 50,000,000 shares authorized; 17,466,381 and 17,339,561 shares issued and outstanding	174,664	173,395
Additional paid-in capital	73,264,241	72,369,016
Accumulated deficit	(83,624,985)	(72,405,778)
Total shareholders' equity (deficit)	(10,186,080)	136,633
Total Liabilities and Shareholders' equity	$ 20,097,174	$ 27,684,270

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2014
Basis of Presentation
Basis of Presentation	1.Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of September 30, 2014 and December 31, 2013 and for the three month and nine month periods ended September 30, 2014 and 2013. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2013, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2013. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounting Policies (Details 3)	9 Months Ended
Summary of Significant Accounting Policies (Details 3)	Sep. 30, 2014	Sep. 30, 2013
Summary of Significant Accounting Policies
Expected term	4 years	4 years
Expected volatility (as a percent)	79.76%	83.27%
Risk free rate (as a percent)	1.23%	0.71%
Expected dividends (as a percent)	0.00%	0.00%

Intangible Assets (Details) (USD $)	3 Months Ended		9 Months Ended					9 Months Ended			12 Months Ended
Intangible Assets (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 License agreements	Dec. 31, 2013 License agreements	Sep. 30, 2014 License agreements Minimum	Sep. 30, 2014 License agreements Maximum	Sep. 30, 2014 Patents	Dec. 31, 2013 Patents
Intangible assets consist of:
Finite-lived intangible assets, gross						$ 838,586	$ 816,300			$ 79,721	$ 62,553
Less: accumulated amortization	(341,925)		(341,925)		(308,457)
Intangible assets, net	576,382		576,382		570,396
Amortization period of intangible assets								17 years	20 years	3 years
Non-amortizable pending costs											79,721
Amortization of intangible assets	$ 11,000	$ 15,000	$ 33,468	$ 44,176

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2014
Organization and Business
Organization and Business	2.Organization and Business Business Summary The Company is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 69,000	$ 59,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,466,381	17,339,561
Common stock, shares outstanding	17,466,381	17,339,561

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 13, 2014
Document and Entity Information
Entity Registrant Name	AxoGen, Inc.
Entity Central Index Key	0000805928
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		19,487,530
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements of Operations
Revenues	$ 4,671,340	$ 2,957,462	$ 12,023,789	$ 7,962,683
Cost of goods sold	896,178	650,212	2,485,299	1,843,748
Gross profit	3,775,162	2,307,250	9,538,490	6,118,935
Costs and expenses:
Sales and marketing	3,250,977	2,757,241	9,326,596	7,177,170
Research and development	681,230	593,643	2,049,603	1,498,904
General and administrative	1,645,859	1,233,360	5,254,082	4,237,738
Total costs and expenses	5,578,066	4,584,244	16,630,281	12,913,812
Loss from operations	(1,802,904)	(2,276,994)	(7,091,791)	(6,794,877)
Other income (expense):
Interest expense	(1,380,470)	(1,214,603)	(3,963,885)	(3,505,869)
Interest expense-deferred financing costs	(55,217)	(61,216)	(158,648)	(146,648)
Other income (expense)	417	32	(4,886)	(696)
Total other income (expense)	(1,435,270)	(1,275,787)	(4,127,419)	(3,653,213)
Net loss	$ (3,238,174)	$ (3,552,781)	$ (11,219,210)	$ (10,448,090)
Weighted Average Common Shares outstanding - basic and diluted	17,466,097	14,320,113	17,437,373	12,205,863
Loss Per Common share - basic and diluted (in dollars per share)	$ (0.19)	$ (0.25)	$ (0.64)	$ (0.86)

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2014
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	6.Accounts Payable and Accrued Expenses Accounts payable and accrued expenses includes $182,880 and $203,380 for accrued payroll at September 30, 2014 and December 31, 2013, respectively, $512,774 and $417,825 for accrued commissions at September 30, 2014 and December 31, 2013, respectively and $154,252 and $31,176 for accrued bonuses at September 30, 2014 and December 31, 2013, respectively.

Property and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and equipment
Less: accumulated depreciation and amortization	$ (1,692,926)	$ (1,581,536)
Property and equipment	613,174	381,689
Furniture equipment
Property and equipment
Property and equipment, Gross	825,690	893,973
Leasehold improvements
Property and equipment
Property and equipment, Gross	285,698	53,864
Processing equipment
Property and equipment
Property and equipment, Gross	$ 1,194,712	$ 1,015,388

Summary of Significant Accounting Policies (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies
Finished goods	$ 2,116,046	$ 2,131,336
Work in process	221,362	235,966
Raw materials	1,008,707	1,031,136
Inventory, Net	3,346,115	3,398,438
Inventory valuation reserves	$ 383,000	$ 383,000

Intangible Assets (Details 3) (USD $)	3 Months Ended		9 Months Ended
Intangible Assets (Details 3) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Selling and marketing expense
Intangible assets
Royalty fees included in sales and marketing expense	$ 93,000	$ 64,000	$ 238,000	$ 169,000
License agreements
Intangible assets
License agreements extended period			60 days
Minimum royalty of agreements			12,500
Milestone fee upon receiving a Phase II Small Business Innovation Research			$ 15,000
Number of products under development			0
License agreements \| Minimum
Intangible assets
Royalty fees range under the license agreements (as a percent)			1.00%
License agreements \| Maximum
Intangible assets
Royalty fees range under the license agreements (as a percent)			3.00%
Royalty stack cap for royalties paid to more than one licensor for sales of the same product (as a percent)			3.75%

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (11,219,210)	$ (10,448,090)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	111,390	60,869
Amortization of intangible assets	33,468	44,176
Amortization of deferred financing costs	158,648	146,648
Share-based compensation	701,697	534,673
Stock grants	60,125
Interest added to note	2,810,182	2,752,273
Change in assets and liabilities:
Accounts receivable	(849,342)	(690,127)
Inventory	52,323	(308,955)
Prepaid expenses and other	195,796	9,821
Accounts payable and accrued expenses	(63,848)	(162,631)
Deferred revenue	(10,714)
Net cash used for operating activities	(8,019,485)	(8,061,343)
Cash flows from investing activities:
Purchase of property and equipment	(342,875)	(66,564)
Acquisition of intangible assets	(39,454)	(50,262)
Net cash used for investing activities	(382,329)	(116,826)
Cash flows from financing activities:
Proceeds from issuance of common stock		16,784,203
Proceeds from exercise of stock options	134,672	73,015
Net cash provided by financing activities	134,672	16,857,218
Net increase (decrease) in cash and cash equivalents	(8,267,142)	8,679,049
Cash and cash equivalents, beginning of year	20,069,750	13,907,401
Cash and cash equivalents, end of period	11,802,608	22,586,450
Supplemental disclosures of cash flow activity:
Cash paid for interest	$ 1,154,738	$ 749,857

Accounts Payable and Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts Payable and Accrued Expenses
Accrued payroll	$ 182,880	$ 203,380
Accrued commissions	512,774	417,825
Accrued Bonuses	$ 154,252	$ 31,176

Summary of Significant Accounting Policies (Details) (USD $)			9 Months Ended		9 Months Ended			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Minimum	Sep. 30, 2014 61 - 90 days	Sep. 30, 2014 61 - 90 days Minimum	Sep. 30, 2014 61 - 90 days Maximum	Sep. 30, 2014 Over 90 days	Sep. 30, 2014 Over 90 days Minimum
Accounts Receivable and Concentration of Credit Risk
Reserve for accounts deemed uncollectible (as a percent)	100.00%
Age of doubtful accounts			60 days		61 days	90 days		90 days
Reserve for doubtful accounts (as a percent)				5.00%			20.00%
Allowance for doubtful accounts reserve balance	$ 69,000	$ 59,000